EARNINGS UPDATE

Meta Platforms, Inc. NASDAQ: META

Before We Start

I have not published a full deep dive on Meta. It is on the list, and this quarter is a reasonable argument for moving it up. In the meantime, several readers have asked where I stand, so here is the thesis in a nutshell before we get to the numbers.

Meta is a wide-moat advertising business in the middle of a three-to-five-year AI infrastructure build that is temporarily inverting the relationship between its earnings and its cash. Capital expenditure runs at roughly half of revenue this year. Cash leaves now, but the depreciation on that spending does not reach the income statement for another two to six years. The result is that reported operating margin troughs years after the spending peaks, while free cash flow inflects years before earnings recover. That gap between when the cash leaves and when the earnings return is what I believe the market is mispricing.

Four things are worth stating plainly, because they shape everything that follows:

• This is a growth story with a capital expenditure kicker, not a normalization story. Once depreciation is properly coupled to capital spending, margin recovery contributes close to nothing. The return decomposes into revenue growth plus buybacks, less some multiple compression.

• The keystone variable is average price per ad. It is the reported number that converts AI capital spending into revenue, and it has to compound at mid-to-high single digits for a decade for the base case to hold.

• The load-bearing assumption is share. Our base case requires Meta’s advertising revenue to reach roughly 40% or more of global digital ad spend by 2036, from about 27% today. That is an extraordinary claim, but Meta’s advertising machine is an extraordinary business.

• Two parts of the thesis rest on the same judgment. That capital spending eventually normalizes, and that the resulting excess returns to shareholders in the form of high ROIC, are both bets on how one person allocates capital. I try to remember that is one judgment counted twice, not two independent supports.

The risks that break it are a capital program that becomes a treadmill rather than a build, price per ad decelerating while impressions accelerate, and a company that finds reasons to keep reinvesting indefinitely. This quarter spoke to all three, which is why the update runs long.

Summary

Meta grew revenue 28% and the stock fell roughly 10%. The advertising business performed in line with the thesis: price per ad rose 12% for a second consecutive quarter while impression growth decelerated, which is the mix shift required for AI capital spending to convert into revenue.

The rest of the income statement is where the quarter was decided. Operating margin fell from 43% to 31%, free cash flow fell from $8.5 billion to $784 million, and Meta declined for a second straight quarter to guide 2027 capital expenditures. Management issued $24.9 billion of long-term debt and repurchased no stock.

The central point of this update that I see folks missing: the margin compression investors saw this quarter is not the depreciation charge from the AI build. That charge has not started (yet). Margin compression was evident and has several resulting reasons, but not for the reasons people are assuming.

Guidance and the 2027 Question

The Q3 revenue range implies growth of roughly 22% at the midpoint, a deceleration from 28%, with foreign currency shifting from a tailwind to an approximate 1% headwind.

The expense guidance is more demanding than it appears. First-half expenses were $75.5 billion. A full-year range of $165–169 billion implies second-half expenses of $89.5–93.5 billion, or $44.8–46.8 billion per quarter against $42.0 billion in Q2. Against second-half revenue of approximately $135 billion, that produces operating income of roughly $41.5–45.5 billion, compared with $45.3 billion in the second half of 2025. The commitment to exceed 2025 operating income requires the low end of the expense range.

The number that was not given

Asked directly about 2027 capital expenditures, management declined to provide an outlook. This was the second consecutive quarter with that answer.

The surrounding commentary does not read as caution. Management described the company as demand-constrained, including within the core advertising business; stated a belief that industry capacity remains tight for the foreseeable future; and characterized 2028 planning as laying down data center, land, power and network foundations now so that server purchase decisions can be made later. Separately, Meta disclosed in the first quarter that new cloud contracts and infrastructure purchase agreements added approximately $107 billion to contractual commitments in that quarter alone.

That combination (no guidance, expansionary language, and large forward obligations already contracted) supports a single conclusion: the duration of this build is genuinely unknown, and the information required to resolve it has not been provided.

For context, peers have been more forthcoming. Alphabet has indicated 2027 capital expenditures will increase significantly from 2026 levels. Declining to guide while competitors guide upward, in a supply-constrained market, is not typically a signal of restraint.

Margin Compression Is Running in Two Waves

The most common reading of this quarter is that AI spending has finally reached the income statement. That reading is half right and half wrong.

Wave one: operating expense (in progress)

Research and development expense grew 67% year over year to $21.7 billion, and now represents more than 35% of revenue against 27% a year ago. Share-based compensation grew 58% to $7.7 billion, or 12.6% of revenue. Cost of revenue grew 33%, driven by data center operating costs and third-party AI token expense.

This is AI talent, model training and inference cost, but not the capital build. It is compressing margins today. Excluding one-time charges, the clean operating margin was approximately 35%, against a 40–48% range that prevailed from 2024 through 2025.

Wave two: depreciation (not yet started)

Depreciation and amortization in the first half of 2026 was $12.4 billion, roughly 10% of revenue, which is approximately where Meta has run historically. Second-quarter D&A was $6.4 billion, up only 6% sequentially.

Set that against capital expenditures of $130–145 billion. Net property and equipment rose from $176.4 billion to $225.7 billion in six months. A substantial portion of that increase is construction in progress. It is not depreciating, because it is not yet in service.

When those facilities come online, the charge begins and runs for the useful life of the assets inside them — five to six years for silicon, decades for shell and land. Applying a vintage depreciation roll to a plausible capital expenditure path produces D&A in the range of 19–21% of revenue by the early 2030s, roughly double the historical norm, and it does not revert, because silicon must be replaced on a rolling basis.

This is the substance behind the claim that Meta’s margins are structurally lower. It is not a statement about one expensive year. A permanently more capital-intensive business carries a permanently heavier depreciation charge, and the charge arising from the 2026–2028 build lands in 2029–2033.

The resulting timing mismatch

Cash departs during 2026 through 2028. The earnings consequence of that cash arrives during 2029 through 2033. Our base case has operating margin bottoming near 29% around 2029 (approximately four years after capital spending peaks) and not recovering to current levels until well into the 2030s.

The practical implication is that no single quarter between now and then will look clean. Investors will be asked to hold a business whose reported margins decline for several years after the spending that caused the decline has already stopped.

Return on the Spend Is Undisclosed

There is no segment reporting, no disclosure and no return metric that would allow an outside investor to calculate what a dollar of AI capital expenditure earns.

Management cited genuine evidence of effectiveness: an 8.3% increase in ad clicks and a 15.7% uplift in conversions on Facebook from new ranking models; over 9 million small businesses using at least one AI creative tool; Advantage+ end-to-end solutions at a $75 billion annual revenue run rate; more than one million businesses using business agents weekly; and the first billion-dollar quarter for Family of Apps other revenue, up 73%.

These are meaningful operating datapoints. However, none of them is a return on invested capital.

In our base case, approximately $750 billion of build capital expenditure through 2030 generates roughly $0.39 of annual revenue per dollar spent. That is broadly consistent with hyperscaler cloud economics. Meta’s advertising business has historically produced a multiple of that figure. The base case therefore embeds infrastructure-like returns on the incremental dollar while applying an advertising multiple to the consolidated entity. That tension is the central valuation question, and it is not resolvable with currently available disclosure.

Offsetting Considerations

Three items received little attention and are constructive.

Cash taxes. Meta paid $2.0 billion of cash income taxes in the first half against $40.5 billion of pre-tax income, an effective cash rate below 5%. Bonus depreciation against a build of this scale is a multi-year cash shield. Whenever capital spending tapers, distributable cash will emerge faster than reported tax rates imply.

Share count. Diluted shares declined year over year, to 2,566 million from 2,570 million, despite zero repurchases. Approximately $4.3 billion per quarter of tax payments related to net share settlement of equity awards is retiring stock through the financing line rather than the repurchase line.

Cost discipline. Headcount fell 3% sequentially following the reduction of approximately 8,000 positions, the first evidence that management will trim operating expense rather than defend it alongside capital expenditure.

Optionality

For me, this is the case for continuing to own the position and rests on the breadth of unmodeled revenue paths, none of which carry meaningful weight in the base case:

• Personal agents delivered to a base of 3.6 billion daily users

• Business agents, already used weekly by more than one million businesses

• A model API now opening to enterprise customers and third-party distribution

• Consumer subscriptions, with Meta One newly launched

• Direct sale of compute capacity, with management reporting offers at a premium to cost

• AI glasses, which management stated are exceeding sales expectations

Any individual path may produce nothing. Two of them working would change terminal value materially. Their exclusion from the base case is what makes it possible to underwrite a business whose near-term cash generation has gone to zero.

Items I’m Keeping My Eye On

Four items will determine whether the thesis holds in its current form, in order of importance:

1. The 2027 capital expenditure figure. Historically disclosed with fourth-quarter results in late January.

2. Contractual commitments in the quarterly filing. A forward capital expenditure signal disclosed in a footnote, updated quarterly, and available without any further guidance from management.

3. Average price per ad. The keystone variable that converts AI spending into revenue. Deceleration here alongside accelerating impressions would be a thesis problem independent of capital expenditure.

4. Share repurchases. Two consecutive quarters at zero, alongside $24.9 billion of new debt issuance and net cash reduced to $6.6 billion. The expectation that excess capital eventually returns to shareholders currently has no supporting evidence.

Conclusion: Clear as Mud

The thesis is on track. The advertising business is compounding at a rate that would justify the position on its own, price per ad — the keystone — is doing exactly what it needs to do, and the depreciation mismatch I described at the top is not a theory anymore. It is visible in the filings. Fifty billion dollars of property and equipment went onto the balance sheet in six months and almost none of it is depreciating yet.

And I want to be honest about the rest of it: the future here is clear as mud, as we say back home in eastern Kentucky.

I am showing you a model in this update, and I am doing it reluctantly. Not because I do not believe the work, but because the format implies more precision than the situation supports. A meaningful number of the inputs are not knowable from outside the company, like how long the build lasts or what the terminal capital intensity settles at? What a dollar of AI capital expenditure actually earns. Whether depreciation schedules hold as silicon cycles compress. Whether the excess ever comes back to shareholders. Those are not conservative-versus-aggressive judgments where I can defend a range. They are guesses wearing decimal places.

*From a trading price of ~$535 per share.

Some of this I am still learning, and some (if any) of it I will never be an expert in. I do not know what a gigawatt of purpose-built inference capacity is worth in 2031. I am not sure anyone does, including the people building it.

But that cuts both ways, and this is the part I keep coming back to. The same murkiness that makes the costs impossible to model makes the benefits impossible to model. If I cannot underwrite the downside of the spending with any precision, I also cannot underwrite the upside of what it buys. Personal agents at the scale of 3.6 billion daily users. Business agents already running commerce inside messaging threads. An enterprise API. Compute sold directly at a premium. Subscriptions. Glasses. Every one of those carries a zero in my base case, and they cannot all be zero.

That asymmetry is the whole reason to stay. A business with this much unmodeled optionality, attached to an advertising franchise still compounding in the high twenties, does not need my spreadsheet to be right. It needs my spreadsheet to not be catastrophically wrong.

So, the position comes down to the obvious optionality and trust in Zuckerberg. He has been early and eventually right on mobile, on Reels, and on rebuilding the ads stack, each time through a stretch where the spending looked indefensible and the market said so. I am willing to extend that credit again.

It isn’t conviction that I have the model right or that I’m used to having in a company I own. This is conviction that the range of outcomes is wide in both directions, and that the upper half of that range is not in the price.

I believe the questions resolve into fact (for good or bad) over three years at minimum, not three quarters. Until it does, the honest characterization is that the near-term financial path is unusually difficult to even guess at.

$META is a position in the portfolio and was added to following this print. Positions may be increased or reduced at any time without notice. This document is research and commentary, not investment advice, and does not account for any individual’s circumstances. Figures are drawn from company disclosure and are subject to revision. Do your own work.

EARNINGS UPDATE

CoStar Group, NASDAQ: CSGP Second Quarter 2026

Summary

CoStar reported second-quarter results on July 28. The operating side of the business came in ahead of expectations; the growth side came in behind them. Shares fell roughly 12% on the print.

Revenue grew 18% to $925M while operating expenses grew 2%. Adjusted EBITDA of $184M represented a 20% margin, roughly double the prior-year level. The Residential segment recorded positive adjusted EBITDA for the first time in its history.

Against that, full-year revenue guidance was reduced 1.7% to $3.735B while adjusted EBITDA and EPS guidance were affirmed, third-quarter revenue was guided below consensus, and annualized net new bookings declined 26% year over year. Renewal and cancellation metrics held or improved across every disclosed product.

Read-through: the cost and cash side of the story is running ahead of schedule; the organic growth input underneath it is running behind. Bookings over the next two to three quarters are the metric that resolves which of those dominates.

Second-quarter results

The expense line is the number worth sitting with. Operating expenses grew 2% against 18% revenue growth, and a residential segment that has consumed cash since inception produced positive adjusted EBITDA. Both are consistent with the end of an investment cycle rather than a single quarter of cost control. It’s not all perfect, residential is without question being carried by Apartments.com and the eventual success of homes.com is still yet to determined.

Guidance

• Third-quarter revenue guided to $940M, against consensus of roughly $968M.

• Full-year revenue reduced 1.7% to $3.735B.

• Full-year adjusted EBITDA and EPS affirmed.

• Commercial revenue growth guided down to 6-7% from 8% in the quarter.

The shape of the revision matters more than its size. Revenue came down while profitability was held. That is a company optimizing for margin over volume, the correct posture if the investment cycle is genuinely ending, and a defensive one if it is not.

One arithmetic note: first-quarter revenue was $897M and second-quarter revenue was $925M. With the third quarter guided to $940M, the $3.735B full-year figure implies fourth-quarter revenue of roughly $973M, a 3.5% sequential step, against the 1.6% step guided into Q3. The full-year guide is back-half weighted into a single quarter.

Retention and bookings

Moats break at the renewal line before they break at the bookings line. Bookings measure sales effort; renewals measure customer verdict. Nothing broke at the renewal line this quarter.

The Homes.com cancellation rate is the quiet figure in the release. Churn fell by roughly two-thirds year over year. Whatever is happening on the sales side, the product is not being rejected by the customers who bought it.

The bookings number, measured correctly

The 26% year-over-year decline in annualized net new bookings is the headline that moved the stock, and it is the wrong lens. Second-quarter 2025 bookings were a 65% sequential outlier, the hardest comparison in the trailing eight quarters.

• Trailing two quarters: down 8.7%, not 26%.

• First quarter 2026: $67M against $56M, up roughly 20%.

• Bookings per representative: down to approximately $34.9k, from approximately $50.8k a year ago.

Corrected for the comparison base, the deceleration is one quarter old. That is not enough to re-underwrite a multi-year growth rate. It is enough to require a specific test.

Management’s explanation, and how to test it

Management attributed the bookings weakness to three causes: short-term cyclicality, a shift in the sales force, and a restructuring at Ten-X. Each is plausible. Each is also the kind of explanation offered whether or not it is the operative one, which makes plausibility useless as a filter. Below, each is paired with a test specified in advance.

1. Cyclicality

Claim: commercial transaction activity and multifamily leasing are soft, and this passes through to new subscription sales.

Test: Zillow reports August 5. If the Apartments.com ARPU decline reflects a soft multifamily market, Zillow’s rentals revenue growth and advertised property count should show the same softness. If Zillow’s rentals accelerate while CoStar’s ARPU falls, the correct description is price competition, not cycle, and it belongs in the terminal margin rather than in a note about timing.

2. Sales force shift

Claim: representatives were reorganized or reassigned, and productivity dipped through the transition.

Test: bookings per representative. A genuine reassignment produces a trough followed by a recovery as territories settle and new representatives ramp. A demand problem produces a trough followed by a plateau. If the figure has not recovered meaningfully by the first quarter of 2027, the transition explanation has expired.

3. Ten-X restructuring

Claim: changes at the commercial auction platform weighed on the bookings figure.

Test: whether Ten-X materially belongs in the metric at all. CoStar defines net new bookings as the annualized change from new, changed and cancelled subscription-based contracts. Ten-X is an auction business generating transaction revenue. If its subscription contribution is small, a Ten-X restructuring cannot account for much of a subscription-bookings decline. This is the leg most in need of a dollar figure on the next call.

What to watch, and when

Bookings lead subscription revenue by roughly four quarters, which makes them the earliest honest read on organic growth and the easiest figure in the release to misuse. Two rules: never read a single quarter year over year and set the expectation before the print rather than after it.

For calibration, a bookings-to-growth conversion currently implies organic growth of roughly 7.6%, against management commentary of roughly 8.5-9% organic in the second half and an implied fourth-quarter exit rate near 8.1%. That gap is small enough to be measurement noise and large enough to matter when compounded, because organic growth is what any exit multiple is ultimately paying for.

Capital allocation and management

Repurchases were $505M in the first quarter, executed largely through an accelerated share repurchase at an average price near $44, and $82M in the second quarter with shares trading in the low $30s. Approximately 86% of the year’s repurchase spending was deployed at a price more than 50% above the current level.

For any thesis that depends on a shift from building to harvesting, capital allocation into a drawdown is the first observable test of that shift. Buying aggressively into strength and pausing into weakness is not what the harvest posture predicts. This is contrary evidence and should be called out as such.

Two additional items: the Chief Financial Officer departed for Allstate, with Robin Rossmann promoted internally, and the Zonda acquisition remains pending. Neither is thesis-altering on its own. Both are reminders that the harvest is a set of decisions being made continuously rather than a switch already flipped.

Thesis status

The original case rested on three one-time events sitting on top of a modest compounder: margin normalization, capex normalization, and a re-rating as the earnings power became visible. Two of the three are now in motion and no longer forecasts. The re-rating depends on the third variable (organic growth) which is exactly what this quarter called into question.

The base case never required Homes.com to succeed. It required the core to carry the business while Homes.com merely existed. The scenario that genuinely damages the case is a break in the core franchise, and the core renewed at 93% and 99% this quarter.

Conditions that would change the assessment:

• CoStar Suite renewal falling below roughly 90%.

• Trailing-2Q bookings still meaningfully negative into the first quarter of 2027.

• Apartments.com ARPU pressure confirmed as price competition rather than a soft market.

• Repurchase behavior continuing to buy into strength and pause into weakness.

None of the four tripped this quarter. Three of the four receive a fresh reading before the end of October.

Updated Base Case Model:

*From a trading price of $28.45

My personal assessment:

My honest position after this quarter is that the upside is narrower than I was underwriting. The bookings deceleration, the ARPU pressure, and a commercial growth rate guided down to 6–7% all argue that the compounder underneath the one-time events is more modest than my earlier work assumed, and I’d rather mark that down now than defend a number I penciled out before. What has not changed is the gap between price and outcome. Even on a fuller-priced set of assumptions, the stock is trading materially below the range of outcomes I’d call probable (not the bull case, the probable ones) and the downside is still floored by asset value I can point to on a balance sheet. That combination is why CSGP is my largest position and why I added into the drawdown rather than out of it. I like this business a great deal: a forty-year data asset with 93% and 99% renewal rates does not get rebuilt by a competitor with capital. But liking a company is not a thesis. This one is going to pay out slowly, through a set of one-time events I can name and a growth rate I have to keep verifying quarter by quarter, and it requires more patience and closer monitoring than anything else I own. I’m comfortable holding it that way. I’m not comfortable holding it passively.

$CSGP is a position in the portfolio and was added to following this print. Positions may be increased or reduced at any time without notice. This document is research and commentary, not investment advice, and does not account for any individual’s circumstances. Figures are drawn from company disclosure and are subject to revision. Do your own work.

BETWEEN THE DIVES MEMO · ISSUE 002

The most widely misread line item from Mercado Libre’s Q1 earnings is the 3.9 percentage point margin drag labeled “bad debt.” The confusion is widespread and the mechanics are worth explaining precisely.

Income from operations fell 20% year over year. Operating margin compressed 600 basis points and a single expense line (provisions for doubtful accounts) nearly doubled from $603 million to $1.244 billion. If you stopped reading there, you’d conclude the credit business is deteriorating, but it isn’t. The mechanics of how that number is generated explain almost everything.

THE ACCOUNTING MECHANICS FIRST

What IFRS 9 actually requires and why it matters here.

Under IFRS 9 (the international accounting standard governing Mercado Libre’s financial reporting), expected credit losses must be recognized at the moment a loan is originated. Not at the moment a borrower misses a payment. Not when a loan crosses 30, 60, or 90 days past due. At origination. Day one. Before the borrower has made a single payment.

This is a front-loaded framework by design. Its purpose is to force companies to recognize expected losses early. The practical consequence for a fast-growing lender is significant: in any quarter where origination volume is high, provision expense is high regardless of whether the underlying loans perform well or poorly.

Mercado Libre originated $13.2 billion in loans during Q1 alone. The full credit portfolio grew 87% year over year to $14.6 billion. Under IFRS 9, every dollar of that growth triggered an immediate day-one provision for its expected lifetime losses. Two thirds of the 390-basis point margin compression is a direct and mechanical consequence of that origination pace. The portfolio is growing at 87% while consolidated revenue is growing at 49%, that gap alone, under IFRS 9, guarantees provision expense outpaces revenue regardless of how the loans actually perform or how management believed they will perform.

This is the cost of growth. Not the cost of credit deterioration.

I categorize this as a customer acquisition cost (CAC), which should dwarf the Life Time Value (LTV) of the loan underwritten.

THE DURATION EXTENSION

The remaining third of the compression and what the transcript actually said.

The remaining third has a more specific origin. Management confirmed on the earnings call that they extended average personal loan duration from 5 months to 8 months (a 60% increase) while simultaneously expanding the personal loan product to borrower segments that had previously held but not utilized existing credit lines.

The accounting consequence is again mechanical. A longer duration loan carries a higher modeled lifetime probability of default simply because the exposure window is wider. IFRS 9 requires the full expected lifetime loss to be reserved at origination. An 8-month loan therefore requires proportionally more upfront provisioning than a 5-month loan even with an identical borrower and identical monthly default probability. The margin hit is front-loaded at origination. The interest income that offsets it accrues across the loan’s lifetime.

There’s one more dynamic here that I haven’t seen discussed anywhere. When asked about longer duration loans, management acknowledged that extending duration is producing more early repayments. Borrowers who receive longer terms are paying off ahead of schedule. The result: Mercado Libre provisions for an 8-month loan at origination and then collects interest on a shorter actual duration because the borrower exits early. The accounting cost is fixed at inception. The revenue it’s supposed to offset is partially surrendered.

Some portion of the margin compression is therefore a consequence of borrowers outperforming the conservative lifetime loss model. A revenue timing mismatch, not a credit loss.

THE STRATEGIC CONTEXT

Why they’re doing this and what it’s actually buying.

The duration extension and credit box expansion are not isolated decisions, they’re part of a coherent down-market strategy. Mercado Libre is deliberately targeting the consumer demographic that currently shops on Shopee (the biggest perceived competitor in Brazil) and uses informal credit sources. In Mexico more than half the population relies on informal credit. In Brazil the addressable population of underbanked consumers runs into the tens of millions.

The thesis is straightforward. A consumer who establishes their first formal credit relationship through Mercado Pago becomes a long-duration ecosystem participant. Purchase frequency on the marketplace increases. Daily transaction volume through Pago grows. Savings migrate toward Mercado Fondo. The credit product is functioning as a customer acquisition channel whose economics are measured in lifetime value, not quarterly spread.

MELI is absorbing accounting costs today against lifetime relationships their data suggests are worth acquiring at current prices. The margin drag is not a loss. It’s a reinvestment decision expressed through an accounting mechanism that makes it look worse than it is.

THE NUMBER THAT ACTUALLY MATTERS

NIMAL tells you what the income statement doesn’t.

If provisions are the wrong metric, the right one is NIMAL (Net Interest Margin After Losses). It represents credit revenues less provision for doubtful accounts less third-party funding costs, expressed as a percentage of average portfolio. It incorporates the provision expense directly and tells you what the credit business is actually earning after absorbing the cost of expected losses.

NIMAL in Q1 2026 was 17.8%. After the credit card mix shift. After the duration extension. After the down-market expansion. After $1.244 billion in provisions. The credit business is not a margin problem, but a highly profitable operation choosing to reinvest its economics into origination volume rather than harvest them as reported income.

For context, traditional consumer lenders in Brazil operate at NIMALs in the 8-12% range. Mercado Libre is running at more than double that after all of the deliberate compression. The compression trajectory (from 22.7% a year ago to 17.8% today) warrants monitoring, but the absolute level remains firmly in value-creative territory.

The 15-90 day non-performing loan ratio (the leading indicator of actual credit stress) held at 8.0% in Q1, flat year over year and broadly stable across the trailing five quarters. Provision coverage on a greater-than-15-day basis was maintained at 103%. These two data points together tell you the underwriting is holding. The provision expense is growing because the book is growing, not because the loans are going bad.

WHERE THE REAL RISK LIVES

Bull and bear. Always.

This is not an entirely clean story, and intellectual honesty requires acknowledging that.

The NIMAL compression trajectory is the primary variable to monitor. 17.8% clears cost of equity comfortably. According to my personal valuation, 15% begins to impair the investment thesis and 13-14% raises legitimate questions about whether equity capital being deployed into the credit book is generating adequate returns. The direction over the next four to six quarters matters as much as the absolute level.

Write-offs will also accelerate mechanically. The current annualized write-off rate reflects losses on a book that averaged $8-10 billion during the loss emergence period. The book now stands at $14.6 billion and growing. Write-offs will follow with a 6-18 month lag regardless of underwriting quality. The question is not whether they accelerate (they will) but whether NIMAL remains wide enough to absorb the acceleration.

The duration and credit box experiments introduce genuine uncertainty. The extended cohorts have less seasoning history. Management’s confidence is data-supported but the data is still early.

My plan is to watch NIMAL and 15-90 day NPL together every quarter. They tell the complete story. The provision line does not.

Until next time,

— Shane

The content in this publication is for informational and educational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. All information is provided in good faith but is not guaranteed to be accurate, complete, or current. Investing involves risk, including the potential loss of principal. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial professional before making any investment decisions. The author may hold positions in securities mentioned in this publication.

Subscribe now

NASDAQ: CSGP · ~$16B Market Cap · Analysis at $39.23 · At Publication: ~$35 · Rating: Buy · 18.22% Probability-Weighted IRR · Tier 1.5 Compounder

In This Issue

1. Thesis Summary

2. Business Overview and Revenue Architecture

3. Management and Capital Allocation — The Historical Pivot

4. Hard Gate Scorecard

5. The Proven Cash Machine — Moat Analysis

6. The Hidden Tailwinds

7. Homes.com Assessment

8. The Activist Situation

9. Institutional Holders

10. Financial Deep Dive and Two-Lens Valuation Model

11. Future Growth Opportunities

12. Risk Register

13. My Conviction Builder Summary

14. KPI Tracking Framework and Kill Triggers

15. Portfolio Role and Position Sizing

16. What Has to Go Right and What Could Go Wrong

17. Conclusion

18. 2026 Q1 Earnings Review and Update

⚠ This analysis applies the Holler to Tide Investment Constitution. Readers unfamiliar with the framework, including IRR hurdle rates, tier classifications, and scenario multipliers, may find it helpful to read the constitution first: Holler to Tide Investment Guide Investment Constitution Framework

1. THESIS SUMMARY

CoStar Group has spent 39 years building the dominant data infrastructure platform for the largest asset class in the world. All businesses minus Homes.com (CoStar Suite, LoopNet, Apartments.com, STR, Matterport, Domain, OnTheMarket, and a growing European commercial footprint) generate approximately $945 million in look-through free cash flow in 2026, compound at double digits, and have survived every real estate cycle, every competitive challenge, and every macro shock in their history (including minimal revenue contraction during the GFC) and have delivered 59 consecutive quarters of double-digit revenue growth. The market is pricing this business as if it grows at 3.4% annually for a decade. That is the entire thesis: the market is wrong about the growth rate, wrong about the permanence of the Homes.com drag, and wrong about the significance of what Florance is doing with capital right now.

The investment case does not require Homes.com to succeed. It does not require activist investors to win a proxy fight. It requires only that the commercial franchise continues compounding at a healthy rate while the broader platform maintains the durability reflected in CoStar’s 59 consecutive quarters of company-level double-digit revenue growth and that the market eventually prices what the underlying business actually earns rather than what it earns with $550 million of deliberate residential investment obscuring the P&L.

There are three things converging simultaneously in 2026 that the market has not fully priced. First, Florance has publicly committed to reducing net Homes.com investment by $300 million this year - the first structural pullback in the residential build after five years of escalating spend. Second, the $460 million Richmond campus is completing as CoStar’s broader new-campus capex (which totaled $307 million in 2025 per the 2025 10-K) begins phasing down, a double tailwind that removes a capex burden and creates a potential leaseback revenue stream simultaneously. Third, Andy Florance personally purchased 55,720 shares in the open market in early March 2026 at prices above today’s entry point — one of the clearest recent signals that the founder is willing to commit personal capital at depressed prices.

A catastrophic Homes.com failure is not a catastrophic investment outcome. The commercial franchise floor (CoStar Suite and Apartments.com alone at conservative multiples) sits above the current price. The market has confused a costly mistake inside a great business for a broken business. The distinction is worth approximately $30–40 per share.

What the Market Is Pricing In — Reverse DCF at $39.23

At $39.23 per share, CoStar requires only 3.4% annual look-through free cash flow growth to justify that price at a 25x exit P/FCF multiple, once the approximately 3% annual share count reduction from the buyback program is incorporated. The starting base is $945 million — the 2026 look-through FCF figure that strips approximately $550 million of deliberate Homes.com net investment. That 3.4% FCF growth rate implies a terminal free cash flow of approximately $1.32 billion in 2036: a CAGR of approximately 2.4% from 2025 actual revenue of $3.25 billion. The buyback program alone reduces the market-implied growth hurdle by approximately 270 basis points relative to a no-repurchase scenario. The future price target that delivers 10% from $39.23 is $101.75.

A structural note on the look-through base: the $945M figure is look-through today and will not match reported free cash flow until Homes.com investment normalizes toward breakeven by 2029. The FCF margin in the model ramps from 24.5% in 2026 to 27.5% by 2030 to capture this transition as the residential investment reduces annually, look-through and reported FCF converge and by 2030 they are essentially the same number. This is not an accounting adjustment. It is the honest starting point for evaluating a business where the gap between reported and underlying earnings is deliberately manufactured and publicly announced as temporary.

2. BUSINESS OVERVIEW AND REVENUE ARCHITECTURE

What CoStar Actually Does

CoStar Group is the dominant data, analytics, and marketplace infrastructure company for commercial real estate globally. Founded by Andy Florance in 1987, the company has spent 39 years building the most comprehensive database of commercial property information on earth covering more than 6 million commercial properties across 450 markets, tracked by 1,400 full-time researchers conducting primary source research daily. Before Homes.com entered the conversation, this was an undisputed institutional compounder. The market has temporarily forgotten that.

The business is best understood as three proven franchises plus one speculative bet. The proven franchises generate real cash, compound predictably, and have deep competitive moats. The speculative bet has consumed $3 billion in capital, generated $80 million in revenue, and remains unproven. The market is pricing the whole as if the speculative bet defines the proven franchises. It does not.

The Brand Portfolio — Proven vs. Speculative

• CoStar Suite — The flagship. The Bloomberg terminal of commercial real estate. 1,400 full-time researchers. 6M+ properties. 450 markets. 89% company-wide renewal rate. 93% CoStar Suite quarterly renewal. 94% for clients over five years. Embedded in CMBS underwriting at every major conduit lender, rating agency, and loan servicer. PROVEN.

• Apartments.com — The dominant U.S. multifamily marketplace. $1.25 billion in annual revenue. Approximately 50% EBITDA margins. 841 million renter visits in 2025. 99% monthly renewal rate. Returned 33% IRR / 11x invested capital. PROVEN.

• STR — The gold standard in global hospitality data benchmarking. 90,000 hotels. 11.8 million rooms. 190 countries. The institutional standard for hotel CMBS underwriting globally. PROVEN.

• LoopNet — The most trafficked commercial real estate marketplace. 13+ million monthly unique visitors. The listing platform where commercial space is marketed to tenants and buyers. Among the top 10,000 most valuable commercial properties in the United States, only 3.8% are enhanced listing clients — a penetration rate that is either a red flag or the entire bull case depending on your view of execution risk. PROVEN.

• Matterport — 3D spatial data company acquired for $1.6 billion. 152 million 3D tours in 2025. The technology layer differentiating Homes AI from Zillow AI after Zillow terminated the Matterport API in October 2025. PROVEN data asset, UNPROVEN residential application.

• Visual Lease / CoStar Real Estate Manager — Combined top-two enterprise lease accounting platforms. ASC 842 and IFRS 16 compliance. 1,500+ organizations. PROVEN.

• European Commercial (BureauxLocaux, Belbex, Business Immo, Thomas Daily) — Pan-European commercial data and marketplace franchise across France, Spain, and Germany. Invisible to U.S. analysts. No competitor has this four-country coverage combination. PROVEN and UNDERAPPRECIATED.

• Domain — Australia’s number two residential portal. $1.9B acquisition in 2025. Q4 2025 revenue $73M at 28% margins. Full-year run rate approximately $300M. Profitable at acquisition. PROVEN.

• OnTheMarket — UK residential challenger portal. 20 consecutive months of positive net new bookings. EARLY STAGE but profitable.

• Homes.com — The U.S. residential for-sale portal. $80M annual revenue after $3B invested. 31,000 paying agents. 56.4M Similarweb monthly visitors vs. Zillow’s 300.8M. THE SPECULATIVE BET.

Revenue Architecture — 2025 Actuals

3. MANAGEMENT AND CAPITAL ALLOCATION — THE HISTORICAL PIVOT

Andy Florance — 39 Years, Founder-Led, Performance-Aligned

Florance founded CoStar in 1987 at age 21 and has run it for 39 years. His 2024 compensation was $1 million base salary and $3 million performance bonus — modest for a CEO running a $16 billion market cap business — with the overwhelming majority of his total compensation delivered through performance-based RSUs vesting over multi-year periods. Florance directly owns approximately 1.59 million shares of CSGP as of early March 2026. At $39.23, that position is worth approximately $62 million. Every dollar of stock price recovery adds $1.59 million to his personal wealth. Every dollar of further decline costs him the same. That is not a compensation structure argument, but a concentrated founder bet that has been compounding since 1987 and is currently sitting at a 59% discount to where the stock traded eighteen months ago.

The Acquisition Track Record — Capital Allocation Before Homes.com

Context matters when evaluating capital allocation. Every major investment Florance made before Homes.com compounded shareholder capital at between 17% and 39% IRR. The following table is drawn directly from CoStar’s investor presentations:

The Historical Pivot — Three Signals at Once

For 39 years, Florance returned zero capital to shareholders through repurchases. He reinvested every dollar. He grew the database. He built the balance sheet to $1.7 billion in cash against $1.0 billion in debt, a net cash position of approximately $700 million after the Matterport and Domain acquisitions consumed the majority of the prior cash balance. Something has changed. In the past 90 days, three things have happened simultaneously that have never happened together before in this company’s 39-year history. The model assumes CoStar continues repurchasing shares beyond the current authorization, the decade-long ~3% annual share count reduction is a model assumption, not a company commitment. The current $1.5B authorization supports meaningful near-term shrink but sustained 3% annual reduction through 2036 requires continued repurchase activity as FCF expands.

SIGNAL 1 — HOMES.COM RAMP-DOWN: January 7, 2026 guidance press release. Florance publicly commits to reducing net Homes.com investment by $300M in 2026 and $100M+ annually thereafter, targeting breakeven by 2029. After five years of escalating residential spend, this is the first public acknowledgment that the investment level is not sustainable indefinitely.

SIGNAL 2 — ACCELERATED BUYBACK: $500M buyback program completed ahead of schedule. New $1.5B authorization announced simultaneously. The first buyback program in the company’s 39-year history. At $39.23 against a business generating $945M in look-through FCF, this is the company saying explicitly with its own cash that the stock is cheaper than every other available use of capital.

SIGNAL 3 — COORDINATED INSIDER PURCHASES: Four separate insiders bought CoStar stock in the open market in the same two-week window in early March 2026, all at prices above the current $39.23 entry point. CEO, operating president, board chair, and a director. All sourced from Form 4 filings with the SEC.

The Insider Purchase Picture = Four Buyers, Two Weeks

The insider picture is broader and more coordinated than a single CEO purchase. The following transactions are sourced directly from Form 4 filings with the SEC:

The CEO, operating president, board chair, and a director all bought CoStar stock in the open market simultaneously with every single purchase above the current entry price. These are not stock grants or compensation awards. These are personal capital commitments from four people with direct visibility into the business, made at a time when the stock was under maximum activist pressure and public criticism.

The historical context deepens the signal. D.E. Shaw and Third Point both publicly criticized the CoStar C-suite for being net sellers over the prior multi-year period when shareholders were losing money. The current coordinated purchasing represents a clear and documented reversal of that pattern. The scale and simultaneity make this analytically meaningful rather than coincidental.

Florance’s RSU grant on February 27, 2026 of 83,708 units vesting over three years adds a further layer. His new equity compensation directly aligns his 2027-2029 financial outcome with where the stock trades over that exact period. Interestingly this is the same window in which the Homes.com normalization, campus capex completion, and CRE volume recovery are all expected to flow through reported earnings. This shows he has both the confidence and the incentive to make these investments successful, especially Homes.com.

4. HARD GATE SCORECARD

All eight Perennial gates must clear before valuation work carries real weight. A weak business does not become attractive simply because the stock is cheaper.

5. THE PROVEN CASH MACHINE — MOAT ANALYSIS

Why 39 Years Without Displacement Matters

The most important analytical fact about CoStar’s commercial franchise is not the renewal rate or the EBITDA margin, it is that no competitor has displaced it at scale in the core institutional CRE workflow across 39 years. That is not a streak of luck. It is the output of a genuinely structural moat that compounds as the database gets deeper and as the professional real estate community builds workflows around it.

CoStar has 1,400 full-time researchers conducting primary source research on more than 6 million commercial properties across 450 markets. Those researchers call property managers to verify occupancy, visit construction sites to track new supply, pull permits, review lease abstracts, and update records continuously. That research infrastructure cannot be purchased off the shelf, replicated in two years, or approximated through web scraping. It represents 39 years of accumulated institutional knowledge that cannot be shortcut. A broker who has built 10 years of comparable sales analyses, underwriting models, and deal tracking inside CoStar does not switch, the proprietary data history, workflow integration, and professional standard all point to staying.

CoStar Suite — The Professional Standard

An 89% company-wide renewal rate rising to 93% for CoStar Suite specifically and 94% for clients over five years is not the behavior of a business with viable substitutes. CoStar is to commercial real estate data what Bloomberg is to fixed income: not merely the best option, but the standard the market has built itself around. Switching away requires convincing every counterparty in your transactions (lenders, brokers, institutional investors) that your alternative is acceptable. That coordination problem is why no one has solved it in 39 years.

Management has stated on earnings calls that the primary driver of CoStar Suite churn is not competitive displacement, but it is that client businesses fail entirely. Subscribers don’t leave CoStar for a competitor. They leave because they go out of business. That is not a data point about retention mechanics. It is the clearest possible statement that no credible alternative exists at the institutional level.

“The Relentless Protector”

CoStar’s 10-K proprietary rights section reads as boilerplate to most analysts. It is actually a competitive strategy statement. CoStar maintains over 100 issued patents, an internal antipiracy team with fraud detection technology, and a documented willingness to spend more than double the expected financial recovery to eliminate a competitor who threatens the data moat. Florance’s legal track record is not a legal department function. It is a 39-year moat-deepening campaign.

• 1999 — LoopNet. First copyright infringement lawsuit. Eventually acquired LoopNet in 2012 for $860M turning a legal target into a portfolio asset.

• 2015 — RealMassive. Settled for $1M. Florance: “RealMassive’s systematic theft had been conducted on, for lack of a better phrase, a real massive scale.”

• 2016-2019 — Xceligent. The defining case. Two teams of sheriffs descended on a Philippines research facility. FTC-appointed monitor found 38,489 improperly derived CoStar images. $500 million judgment, the largest ever copyrighted image case. Xceligent destroyed entirely. CoStar spent more than double what it recovered. Florance’s message to the market: we will spend whatever it takes.

• 2008-2018 — Password sharing campaigns. Nine lawsuits in 2008-2009. Seven in a single day in 2018. Florance stated publicly he believed 10,000+ people were illegally accessing CoStar.

• 2020-ongoing — CREXi. Most credible current commercial challenger. Active litigation. Growth suppressed for years.

• July 2025 — Zillow. 46,000+ copyrighted photographs from the Matterport acquisition. Florance filed within weeks of Zillow launching AI Mode using Matterport images CoStar now owns.

Florance on legal strategy: “There’s no sports team with a better track record than our legal track record. We overwhelmingly prevail in the things we go into. I am a fierce protector of our shareholders’ interests.”

Apartments.com — The Proof of Concept

Apartments.com deserves its own moat discussion because it is the clearest evidence of what the CoStar playbook produces when executed successfully. Acquired for $1.24B in 2014 with $132M of subsequent investment, total $1.37B. 2025 revenue: $1.25B. EBITDA margin: approximately 50%. IRR: 33%. Return multiple: 11x. That is not luck. It is the same data-plus-marketplace strategy applied in multifamily that Florance is now applying in residential for-sale.

Apartments.com also has the 99% monthly renewal rate, the highest in the entire CoStar portfolio. When landlords and property managers have embedded Apartments.com in their leasing workflow, they essentially never leave. That is the commercial franchise at its most mature and most valuable.

6. THE HIDDEN TAILWINDS

The Homes.com investment reduction is well documented in the activist letters and analyst coverage. Two other tailwinds converging in 2026 are almost entirely absent from the analyst narrative, and together they represent a step-change in free cash flow that the market has not modeled.

Tailwind 1 — The Richmond Campus Capex Cliff

CoStar has been building a $460 million, one million square foot global operations center along the James River in Richmond, Virginia since late 2022. The campus (a 26-story tower with capacity for 4,000 employees) completes in spring 2026, right now, as this article publishes. Campus-specific capital expenditure running at $307 million in 2025 (per the 2025 10-K, “Purchases of property, equipment, and other assets for new campuses: $307M”) annually phases in during 2026 as the remaining ~$155M of contractual obligations complete, falling to near-zero in 2027.

The direct cash flow improvement from campus capex normalization is approximately $307M at full run-rate, phasing in during 2026 as the remaining ~$155M of contractual obligations complete (~$150-175M benefit in 2026), then falling to near-zero in 2027. Unlike an operating cost reduction, capex savings improve free cash flow dollar-for-dollar, a number the market has not isolated from ongoing maintenance capex in the reported figures. This does not require a single dollar of revenue outperformance. It does not require Homes.com to succeed. It does not require D.E. Shaw to win a board seat. It requires only that a construction project that is already complete stops consuming cash, which it will.

Tailwind 2 — The Campus as an Unrecognized Asset

When CoStar completes the Richmond campus this spring, the market will continue treating the entire construction cost as sunk, capital consumed and gone. That framing misses what was actually built. CoStar did not spend this capital on rent. The Richmond campus expansion was described as a $460M project, while CoStar’s total new-campus capex across the broader buildout has been considerably larger — the 10-K’s “purchases of property, equipment, and other assets for new campuses” line item captured $307M in 2025 alone across all new campus activity. The result is a one million square foot, 26-story Class A tower on the James River that CoStar now owns outright, with no associated debt, no ongoing construction burden, and no landlord. The capex is done. The asset exists. The market appears to be giving little explicit credit to this owned real estate optionality.

The construction cost figure requires one important adjustment before drawing any conclusions about the net economic cost to shareholders. CoStar negotiated tax incentives with the Commonwealth of Virginia and the City of Richmond tied to job creation and capital expenditure targets running from 2022 to 2029. The 10-K estimates the value of those incentives (including the allowance to use market-based income apportionment for income taxes and partial reimbursements of property tax assessments) in the range of $275 to $285 million. The net economic cost of the campus to CoStar shareholders is therefore approximately $720-730 million after the estimated potential incentives, conditioned on CoStar meeting job creation and investment targets through 2029. Virginia and Richmond conditionally offered approximately $280 million in estimated incentives tied to job creation and capital expenditure targets running through 2029 because they believed CoStar was building a long-term economic anchor asset worth subsidizing. That institutional validation matters when assessing what the campus is actually worth.

The immediate value is operational and permanent. CoStar now houses a significant portion of its 6,600 U.S. employees in a world-class facility it owns rather than leases. There is no rent escalation exposure. There is no lease expiration risk. There is no landlord with competing priorities. The building is CoStar’s (permanently and without encumbrance) and that permanence has compounding value as the company scales its U.S. workforce over the next decade. Ownership of the physical infrastructure that houses your most important operational teams is a structural advantage that does not appear in any earnings metric but reduces long-term occupancy cost risk in a way that a tenant relationship never can.

The longer-term optionality is what the market is missing entirely. Florance has executed a headquarters sale-leaseback before. In 2011 CoStar purchased its Washington D.C. headquarters for $41.25 million and sold it eleven months later for $101 million, converting an illiquid real estate asset into deployable cash while retaining full occupancy on a long-term lease. He knows this playbook. He has run it with a CoStar headquarters. In a sale-leaseback CoStar would sell the Richmond building to an institutional buyer (a net lease REIT, a pension fund, a sovereign wealth fund as possibilities) sign a long-term lease to continue occupying the same space and convert the asset into capital that can be redeployed into buybacks, commercial investment, or balance sheet strength. CoStar retains the space. The institutional buyer gets a long-term creditworthy tenant on a trophy asset. Florance gets capital flexibility he does not currently have.

The lease-back theory is 100% speculative on my part, but what it represents is a strategic option that compounds in value as the office market normalizes, as CoStar’s earnings and credit profile expand through margin recovery, and as institutional appetite for long-duration net lease assets with creditworthy tenants returns. A company that owns its headquarters outright, fully paid for, debt-free, and with $280 million of government incentives attached to it has a degree of capital allocation optionality that a company paying rent does not. The Commonwealth of Virginia and the City of Richmond have already told you what they think this asset is worth by writing a $280 million check to attract it. That institutional validation has not translated into any explicit credit in the current stock price. At some point in the next decade, as office transaction markets recover and CoStar’s margin expansion takes the earnings story to a different place, the Richmond campus becomes a source of capital recycling that no analyst has modeled, no activist has demanded, and no institutional investor has priced. That is what genuine unrecognized optionality looks like.

Tailwind 3 — CRE Transaction Volume Recovery

Commercial real estate transaction volumes have been suppressed by elevated interest rates since 2022. The $900 billion+ of CMBS loan maturities in 2023-2025 and the ongoing refinancing backlog create a structural demand catalyst for CoStar’s analytics and marketplace products as rates normalize. The commercial franchise has endured through every prior CRE cycle including the 2009 Great Recession when revenue fell by only 1%. The recovery cycle is a tailwind, not a requirement.

7. HOMES.COM ASSESSMENT

This section is the most important in the article for a specific reason: the intellectual honesty here is what makes the investment thesis credible. If the bull case required Homes.com to succeed, this article would be much harder to write. It does not. But Homes.com is worth a serious assessment rather than a dismissal, because the strategic logic is more sophisticated than the financial results suggest and because there is a genuine path to value creation that does not require displacing Zillow.

Why Zillow Is So Hard to Beat

Zillow launched in 2006, built the Zestimate as a consumer brand anchor that gave homeowners a reason to visit even when not actively transacting, and spent 20 years building a behavioral habit that is now essentially automatic. 300.8 million monthly visitors (independently measured by Similarweb) is not a traffic number. It is 20 years of consumer conditioning. Zillow’s Premier Agent monetization model (charging agents $3,000+ annually for zip code lead exclusivity) creates real agent resentment because the seller’s listing agent loses buyer contacts to a competitor who paid Zillow for access. That resentment is the structural opening Homes.com is trying to exploit.

“Your Listing, Your Lead” — Why This Is Andy’s Big Bet

Florance’s Homes.com thesis deserves a genuine explanation before the criticism. The core insight: Zillow and Realtor.com profit by selling buyer leads generated by one agent’s listings to competing agents. The seller’s listing agent (who knows the home best) is sidelined. Homes.com inverts this. Every buyer inquiry goes exclusively to the listing agent at no charge. Always. Agents pay Homes.com only for enhanced visibility, priority placement, retargeting across 1,000+ websites, and Matterport 3D tours.

The global model validation is Florance’s strongest argument. Every dominant residential portal outside North America uses vendor-paid listings rather than buyer-lead monetization. REA Group in Australia. Rightmove in the UK. Hemnet in Sweden. Scout24 in Germany. Idealista in Spain. These are the world’s most sophisticated residential markets, and in every single one the vendor-paid model has achieved dominant market position. The United States is the anomaly, not the global standard. Florance is betting the U.S. market will eventually converge with the global standard.

The structural fragility of Zillow’s model has not gone unnoticed internally. Spencer Rascoff, Zillow’s co-founder, stated publicly in 2023 that a ban on commission sharing would be a gift from heaven for CoStar and put $1.5 billion of Zillow’s revenues at risk. When the founder of your primary competitor publicly identifies your model as the correct one for a changing regulatory environment, that is not a trivial data point. It is the clearest possible external validation of the your listing, your lead thesis from someone with direct knowledge of the competitive dynamics.

The Case Against — Why the Execution Has Been Poor

The financial results are indefensible on their own terms. $3 billion invested since 2020. $80 million in annual revenue. 31,000 paying agents out of 1.6 million licensed in the United States, only 1.9% penetration. Trustpilot: 1.2 stars. BBB: F rating. The gap between the strategic logic and the execution reality is enormous.

The agent-level evidence is more concerning than the traffic data. During this research cycle I informally surveyed approximately 30 realtors and brokers across markets. The overwhelming majority do not use Homes.com, do not see a need for it, and (the most damaging finding) do not understand the “your listing your lead” value proposition. They still think of Homes.com as a Zillow competitor where buyers go to search. Not a single agent mentioned Homes.com unprompted. When I explained the model - your leads go to you for free (you pay only for enhanced placement) the most common response was: “why would I pay for placement on a site where buyers aren’t going yet?” That response is the thesis problem in one sentence.

The Case For — Why the Gamble May Still Be Worth It

• Lower CAC, massive revenue per user runway. Homes.com charges agents approximately $800-$1,000 per year. Zillow Premier Agent charges $3,000+. CoStar’s cost per acquired agent is materially lower, and there is an enormous gap between the current $800-1,000 ARPU and Zillow’s $3,000+. If Homes.com achieves even 30-40% of Zillow’s monetization per agent on a meaningful fraction of the 1.6M addressable agents, the revenue math works without needing to surpass Zillow in traffic.

• The residential TAM dwarfs the commercial TAM. There are approximately 6 million commercial properties in the U.S. There are approximately 140 million residential units and $2 trillion in annual transaction value. If CoStar can carve out a durable number two position with meaningful monetization, the long-term revenue contribution could eventually match or exceed the commercial franchise.

• Matterport creates genuine product differentiation Zillow cannot replicate. Zillow terminated the Matterport API in October 2025 upon CoStar acquiring the company, and now cannot license it back. Every Homes.com member listing gets Matterport 3D tours. Homes AI runs on spatial data Zillow does not have.

• eXp Realty (March 18, 2026) — America’s largest brokerage by transaction sides chose Homes.com over Zillow for pre-market listing syndication, explicitly rejecting exclusivity. CEO Leo Pareja: “I just do not feel that exclusivity is the right choice.” The anti-Zillow coalition is real and growing.

• Apartments.com was once exactly here. In 2014, Apartments.com had single-digit unaided brand awareness and a challenger market position. By 2025 it had 50%+ EBITDA margins on $1.25B revenue and 99% monthly renewals. The playbook works. The question is timeline and capital efficiency, not strategic validity.

The behavioral data confirms the slow pace of change. A Redfin survey found that only 27% of recent home buyers negotiated or attempted to negotiate agent fees following the August 2024 NAR settlement — despite now having the explicit legal right to do so. Old habits are proving durable, which is why Zillow’s monetization model remains intact today. It also means the structural shift CoStar’s model is positioned for is real but on a longer timeline than the market’s patience. The path to relevance for Homes.com runs through behavioral change that is measurable in years, not quarters.

8. THE ACTIVIST SITUATION

The activist situation at CoStar is relevant context for the investment thesis, but not the thesis. This affects the near-term timeline for Homes.com normalization and the probability of accelerated board change. The commercial franchise compounds regardless of whether D.E. Shaw wins a board seat.

Third Point — Exited, April 10, 2026

Daniel Loeb’s Third Point sold its entire CSGP stake on April 10, 2026 and will not pursue a proxy fight. His letter to investors: “Despite our efforts, CEO Andy Florance has continued what can only be seen as a reckless drain on a majority of the company’s operating income into Homes.com. We no longer believe that our original thesis holds true today and have disposed of our position in its entirety.”

Third Point entered at approximately $66 per share in late 2025. They exited near $36-40. The loss was significant. The important distinction: Loeb’s complaint is about Homes.com continuing to burn capital, not about the commercial franchise being impaired. He abandoned an activist-catalyst thesis, win the proxy fight, force the Homes.com restructuring, capture the rapid re-rating. That thesis failed. The long-duration commercial compounding thesis is a different thesis that does not require winning a proxy fight.

D.E. Shaw — Still Engaged

D.E. Shaw, an $85 billion fund with successful activist campaigns at Lowe’s, Emerson Electric, and Air Products has made no announcement of exit. Their February 4 and March 10, 2026 letters remain on record. Without Third Point as a coalition partner, the June 2026 AGM becomes less confrontational, but D.E. Shaw’s continued engagement maintains pressure on management to demonstrate investment discipline and capital return progress.

9. INSTITUTIONAL HOLDERS

Two institutional holders provide independent analytical validation of the ex-Homes commercial franchise thesis. Both established meaningful positions at prices 45-50% above today’s entry point. Neither has exited. Neither mentions Homes.com in their public communications.

Akre Capital Management — 5.76% of Fund, ~$667M

Akre Capital added 4.3% to their CSGP position in Q4 2024, bringing it to 5.76% of their total fund, significant concentration for a firm that has compounded at 15.7% annually since 2009. Cost basis approximately $70-80. At $39.23 they are sitting 50% below their established cost and have not sold.

Their Q4 2025 letter on CoStar: “Valuation multiple compression due to concern that these software-oriented businesses will be degraded or disrupted by artificial intelligence. We believe this narrative to be overblown and that our businesses will be enormous beneficiaries of AI.”

No mention of Homes.com. No defense of the residential strategy. Anchored entirely on the commercial data franchise. Independent convergence with this article’s framework from a firm with years of ownership and deep due diligence.

Polen Capital — $465M Position, Initiated Q4 2024

Polen Capital initiated a $465 million position in Q4 2024 after the post-Q3 earnings pullback. Their description: a “leading provider of commercial real estate information, analytics, and online marketplaces.” No mention of Homes.com specifically. Cost basis approximately $70-80. Also 50% below entry with no announced exit.

10. FINANCIAL DEEP DIVE AND TWO-LENS VALUATION MODEL

Historical Revenue and Margin Architecture

The margin compression from 20.4% in 2022 to 8.8% in 2024 is entirely explained by Homes.com net investment ramping from approximately $300M to $900M annually. The commercial franchise margins have been consistent and expanding throughout. The suppression is deliberate, documented, and temporary.

Key Model Assumptions — Both Lenses

Lens 1 — Look-Through Price to Free Cash Flow Model

5-Year CAGR (to 2031): 29.06% | 10-Year CAGR (to 2036): 20.76%

Lens 2 — Reported EV to Adjusted EBITDA Model

5-Year CAGR (to 2031): 29.82% | 10-Year CAGR (to 2036): 21.06%

Model Validation — Convergence Check

Probability-Weighted Scenario Analysis

*IRRs calculated above via the two lens models are cut based on my personal investment constitution and framework. “IRR (Post-Cut)” referenced in the “Probability-Weighted Scenario Analysis” are based on the business quality tier classification of 1.5. To learn more about this framework please refer to: Holler to Tide Investment Guide Investment Constitution Framework

11. FUTURE GROWTH OPPORTUNITIES

The base case model captures only the organic growth of businesses CoStar already owns at current growth rates. The following optionality sits above that base case — none of it required for the thesis, all of it real.

AirDNA / STR — The Short-Term Rental Gap: STR covers traditional hotels exclusively. The Airbnb/VRBO short-term rental analytics market is dominated by AirDNA, a completely separate company tracking 10M+ rentals globally. CoStar does not own it and receives zero credit for this TAM in the model. An AirDNA acquisition or organic build would extend the hospitality data franchise into a growing segment STR does not touch.

Visual Lease / CoStar Real Estate Manager — IFRS 16 International: ASC 842 drove massive U.S. demand for lease accounting compliance software. IFRS 16 is the international equivalent adopted in 140+ countries. The international compliance software market remains underpenetrated. As the largest enterprise lease accounting platform by customer count after the Visual Lease merger, international IFRS 16 expansion represents organic revenue growth on a regulatory mandate. Not in the model.

European Commercial Expansion: BureauxLocaux (France), Belbex (Spain), Business Immo (French CRE news), Thomas Daily (Germany) — CoStar has assembled pan-European commercial data and marketplace infrastructure across three of the four largest continental CRE markets. Almost entirely invisible to U.S. analysts. Not modeled separately. No competitor has this four-country coverage combination.

Domain / OnTheMarket — Global Platform on Shared Infrastructure: Florance has confirmed Domain migrates onto the Homes.com software platform within 12-18 months, with OnTheMarket following in 2027. Three residential portal geographies on shared technology infrastructure materially reduces marginal cost as revenue scales. Domain’s $300M annualized run rate at improving margins becomes more valuable as shared infrastructure cost is amortized.

CMBS Volume Recovery: Every dollar of CRE transaction volume returning to trend is incremental revenue for CoStar Suite, LoopNet, and STR. The commercial franchise grew through the 2009 GFC with revenue -1%. The recovery from the 2022-2025 rate suppression period is a tailwind above the organic base.

12. RISK REGISTER

Artificial Intelligence — The Real Risk Is Not Where the Market Thinks

The market is pricing CoStar as if artificial intelligence is an existential threat to the business. It is not, but the distinction between where AI cannot touch CoStar and where it can matters for understanding the probability distribution of outcomes. The commercial data franchise (CoStar Suite, STR, the CMBS underwriting infrastructure) is structurally insulated from AI displacement in a way that most software businesses are not. The underlying database was built manually over 39 years by 1,400 boots-on-ground researchers conducting primary source verification that no language model can replicate or legally access. CoStar’s antipiracy infrastructure and litigation track record (Xceligent destroyed, CREXi suppressed, Zillow sued within weeks of the Matterport acquisition) ensures that proprietary data remains proprietary. An LLM cannot train on data it cannot access, and no competitor has legal access to CoStar’s database. The data moat is not AI-proof because CoStar has better technology. It is AI-proof because the data does not exist anywhere else and CoStar will spend whatever it takes to keep it that way.

The real AI risk is second order and concentrated in the marketplace businesses. LoopNet and Homes.com compete for attention in environments where AI-enhanced search, personalized recommendations, and generative property descriptions are increasingly table stakes. If Zillow or a well-capitalized new entrant deploys AI tooling that meaningfully narrows the user experience gap, Homes.com’s already difficult traffic deficit becomes harder to close, and LoopNet’s monetization timeline extends. This does not break the thesis. The base case assigns zero credit to Homes.com and the commercial franchise floor sits above the current entry price independent of any marketplace outcome. What AI competitive pressure does is compress the probability of the bull case materializing on schedule (shifting weight from the 21.8% IRR bull scenario toward the 19.2% base) without touching the underlying compounding engine that makes the investment work in every scenario above impairment. The market is conflating two separate risks: AI threatening the data infrastructure, which is not credible, and AI intensifying marketplace competition, which is real but already partially reflected in the bear case weighting. Separating them is what the current stock price does not do.

The risk register distinguishes between two categories: events that break the thesis entirely (Kill Triggers) and events that shift the probability distribution between scenarios without invalidating the underlying commercial franchise thesis (Probability Weight Adjusters). Only commercial franchise impairment constitutes a kill trigger. Everything else adjusts scenario weights.

13. MY CONVICTION BUILDER SUMMARY

• The commercial franchise floor (CoStar Suite + Apartments.com at 15x EV/EBITDA plus net cash) sits at approximately $47-48 per share. The stock trades at $39.23. You are buying below the standalone floor of two proven businesses before giving any credit to Domain, Matterport, European commercial, or the Homes.com option. Floor derivation: CoStar Suite estimated 2025 EBITDA of approximately $692M (revenue of $1,259M at approximately 55% margin) plus Apartments.com estimated 2025 EBITDA of approximately $591M (revenue of approximately $1,182M at approximately 50% margin) equals approximately $1,283M. At a conservative 15x EV/EBITDA (a meaningful discount to the market rate for data businesses of this quality) the enterprise value is approximately $19.2B. Adding net cash of approximately $700M and dividing by 421M diluted shares produces approximately $47 per share. LoopNet, STR, Domain, Matterport, the European commercial franchise, OnTheMarket, the Richmond campus asset, and the Homes.com option all contribute zero to this floor.

• Morningstar fair value: $76 per share (February 2026). That implies a 48% discount at the current price from one of the most conservative valuation frameworks available.

• 39 years of compounding through the dotcom bust, the GFC, COVID-19, and the 2022-2025 CRE rate suppression with 59 consecutive quarters of double-digit revenue growth. The commercial franchise has never shown sustained contraction, including a period of only minimal total revenue decline during the 2009 GFC.

• Three simultaneous normalization events in 2026: Homes.com investment reduction ($300M), Richmond campus capex normalization (~$150-175M FCF improvement in 2026, ~$307M at full 2027 run-rate), CRE volume recovery. Reported EBITDA nearly doubles from $442M to ~$770M (company guidance) without commercial revenue outperformance, the 2025 Commercial segment EBITDA was $672M per the 10-K, confirming the commercial franchise integrity.

• ~1.59M shares directly owned (~$62M at current price) by CEO. $1M base salary / $3M performance bonus, modest for a $16B market cap business. Performance RSUs vesting over three years. Four insiders bought open market in March 2026 simultaneously - Florance 55,720 shares at $44.52, Saint 20,000 at $45.33, Sams 1,000 at $48.36, Glaser 1,000 at $44.94. All sourced from Form 4 filings.

• First share buyback in the 39-year history ($500M accelerated completion followed immediately by new $1.5B authorization) simultaneous with Homes.com investment reduction. A founder publicly signaling the first philosophical shift from build to harvest.

• Akre Capital holds 5.76% of their fund at ~$70-80 cost basis, has not sold. Polen Capital holds $465M at similar cost, has not sold. Neither mentions Homes.com. Both anchor their thesis entirely on the commercial franchise. Independent convergence from two firms with decades of quality compounder track records.

• Acquisition track record: 17-39% IRR on every major decision before Homes.com. Real Estate Manager: 39% IRR / 53x. Apartments.com: 33% IRR / 11x. The market prices Homes.com as if it invalidates a 39-year track record of exceptional capital allocation.

• The CMBS moat — CoStar’s data is embedded at three independent layers of the $1.8 trillion commercial mortgage-backed securities market: conduit lender underwriting, rating agency verification, and loan servicer monitoring. No single regulatory actor can mandate a switch because the dependency was built through decades of distributed private market adoption across uncoordinated institutional participants. That is structurally more durable than FICO’s regulatory mandate, which was created by a GSE requirement and eroded by the same mechanism when FHFA approved VantageScore. CoStar’s CMBS moat has no equivalent lever.

• A catastrophic Homes.com failure is already in the price. The impairment scenario recovers 55 cents on the dollar. The bear case produces 11.6% post-cut IRR. The scenario work suggests the risk of permanent capital loss is lower than the market price implies but that conclusion depends on the commercial franchise remaining intact.

14. KPI TRACKING FRAMEWORK

This section identifies the specific metrics to monitor, their current state as of publication, and the direction they need to travel to confirm the thesis.

Commercial Franchise Health — Monitor Quarterly

Capital Allocation — Monitor Quarterly

Homes.com — Monitor Monthly and Quarterly

Institutional Holders — Monitor via 13F Filings

Activist / Governance — Event Driven

15. PORTFOLIO ROLE AND POSITION SIZING

CoStar at $39.23 is built for the core layer of a concentrated portfolio. The commercial data franchise moat is structural, and 39-year proven. The balance sheet has no financial distress. The entry price sits below the commercial franchise standalone floor. The capital allocation inflection (first buyback in 39 years, simultaneous Homes.com pullback, founder personal purchases) is a founder signaling with every available mechanism that the stock is mispriced.

Position Sizing — Constitution Framework

Initial position: 4-6% at current levels. The Tier 1.5 classification (rather than Tier 1) reflects the founder equity gate requiring slightly reduced initial sizing. The commercial franchise being priced below its standalone floor provides meaningful margin of safety that supports the higher end of the range.

Sizing should increase to 8-10% on thesis confirmation, not on price weakness alone.

Why CoStar at $39.23 Works as a Core Position

The best concentrated portfolios are built around businesses where the long-term outcome is highly probable even when the short-term path is uncertain. CoStar’s commercial franchise does not erode between quarters. The 89% renewal rate does not disappear if Homes.com gets wound down. The CMBS moat does not evaporate in an activist transition. The 39-year data infrastructure is not disrupted by a single product cycle.

A decade from now, the probability that CoStar is still the dominant platform for commercial real estate data globally is high. The probability that the market continues valuing these two businesses at less than 20x EBITDA (their current implied valuation without any Homes.com credit) approaches zero over a sufficiently long holding period.

16. WHAT HAS TO GO RIGHT AND WHAT COULD GO WRONG

This is not a position where everything works automatically. The following are the specific conditions that must be met for the bull and base case returns to materialize. Each is tied to a measurable, trackable outcome, not a hope.

What Has to Go Right

What Could Go Wrong — Specific Risk Linkage

Each risk below is mapped to the specific financial and thesis impact if it materializes, not merely flagged as a generic concern.

INVESTMENT VERDICT

Hurdle rate: 17.5% post-cut. At $39.23 entry, the probability-weighted expected return from a $5,000 position is approximately $26,660, implying an 18.22% IRR, clearing the hurdle by 72 basis points. CoStar is classified Tier 1.5. A Tier 1.5 bear case still produces a real return. The position is sized at 4–6% initially because the IRR clears the hurdle, not because it clears it comfortably. The discipline is to hold the entry price, monitor the kill triggers, and add only on thesis confirmation — not price weakness alone.

17. CONCLUSION

For 39 years, Andy Florance built the most important data infrastructure platform in commercial real estate and returned zero capital to shareholders. He reinvested every dollar. He grew the database. He acquired Apartments.com, LoopNet, STR, Matterport, and a dozen other businesses, each one returning 17-39% IRR. He drew a $1 million base salary and aligned the bulk of his compensation to multi-year share price outcomes through performance-based RSUs. That discipline built a strong balance sheet and decades of compounding and 59 consecutive quarters of double-digit revenue growth.

Then he made one costly mistake. He bet $3 billion on a U.S. residential portal that has generated $80 million in annual revenue, attracted 1.9% of licensed agents, and trailed Zillow’s traffic by 5.3x after five years of the largest portal marketing campaign in U.S. real estate history. The activists are right that the capital allocation on Homes.com has been indefensible. Third Point took a loss and walked away. D.E. Shaw is still fighting.

The market has responded by pricing the entire company (39 years of compounding commercial data infrastructure, the dominant U.S. multifamily marketplace, a profitable Australian portal, and a growing European commercial franchise) as if that one mistake defines what the business is. It does not. The commercial franchise floor alone, at 15x estimated 2026 EBITDA plus net cash, is approximately $47-48 per share. The stock trades at $39.23. Morningstar’s fair value estimate is $76.

Something has changed in the past 90 days that the market has not fully processed. The Homes.com investment is being cut. The Richmond campus capex cliff is arriving. Florance is buying stock with his own money. The company just completed its first-ever buyback program and authorized a new $1.5 billion one. These are not incremental events. They are a founder simultaneously pulling every available lever to signal (with his own money, not words) that the chapter of aggressive investment is transitioning to a chapter of capital return and margin expansion.

The dual-lens model converges at a 20.76% FCF CAGR and 21.06% EV/EBITDA CAGR over 10 years from $39.23. The 5-year CAGR in both models is in the 29-30% range as the Homes.com normalization flows through reported earnings. Neither requires multiple expansion. Neither requires Homes.com to succeed. Both require only that the commercial franchise keeps compounding at a fraction of its historical rate while the investment drag normalizes.

Akre Capital holds 5.76% of their fund at 50% below today’s price and has not sold. Polen Capital holds $465 million at the same cost basis and has not sold. Both anchor their thesis entirely on the commercial franchise. The thesis of the quality compounder investors and the thesis of this article is the same thesis.

At $39.23, the probability-weighted IRR of 18.22% clears the 17.5% post-cut hurdle by 72 basis points. The margin of safety is not in those 72 basis points. It is in a business where the bear case produces an 11.6% real return, the commercial franchise floor sits above the current price, and a catastrophic Homes.com failure is not a catastrophic investment outcome. That is what a Tier 1.5 holding looks like at a discount to intrinsic value.

The market has spent five years pricing Homes.com as the story. The story is the cash machine that has been quietly compounding underneath it the entire time.

18. 2026 Q1 EARNINGS: THESIS CONFIRMATION AT A LOWER PRICE

I am truly astonished that CoStar Group trades below $35 per share after the Q1 print. At that price you are paying approximately 15x look-through free cash flow and a reverse DCF implies essentially 0% revenue growth annually for a decade to justify a 10% return. The company just reported 23% revenue growth, doubled adjusted EBITDA year-over-year, guided its residential segment to profitability next quarter, and executed $505 million in buybacks in a single quarter. The market’s after-hours reaction to one of the clearest thesis-confirmation prints this business has ever produced is the mispricing this article was written around, made more extreme.

The $505 Million Buyback Signal — The Most Important Number

Start here. In Q1 2026 alone, CoStar repurchased $505 million of its own stock (11.4 million shares) the majority through an accelerated share repurchase plan. That is not a token gesture. That is the entire first buyback program, which was announced as a $500 million authorization, completed and exceeded in a single quarter at prices the company’s own CEO and three other insiders purchased in the open market just weeks earlier. Every one of those purchases is now 20–30% underwater and not one of them has sold.

CoStar then immediately announced a new $1.5 billion authorization. The company expects to deploy an additional $195 million in the remaining nine months of 2026, bringing total cash allocated to buybacks this year to $700 million. Against a market cap of approximately $14.3 billion at $35 per share, that is roughly 5% of the entire company being repurchased in a single year. This is a founder who for 39 years reinvested every dollar, made acquisitions, built the database, and returned zero capital to shareholders. Something has permanently changed in how Andy Florance is thinking about capital allocation, and the scale of this buyback is the clearest possible signal of what he thinks the stock is worth.

The math compounds the signal. The $505 million Q1 buyback retired 11.4 million shares. With 414 million diluted shares outstanding, that is a 2.7% reduction in share count in a single quarter. Annualized, the buyback program at this pace would retire more than 10% of shares outstanding per year. The article’s model assumes 3% annual share count reduction over a decade as a conservative baseline. The actual pace in Q1 2026 ran well above that. Every share retired at $35–40 against a commercial franchise floor of approximately $47–48 per share is genuinely accretive capital allocation, the same standard Florance has applied to every major investment in the company’s history, each of which returned 17–39% IRR.

The buyback also answers one of the most persistent bear criticisms directly. Third Point and D.E. Shaw both attacked the C-suite for being net sellers of CoStar stock over the prior multi-year period while shareholders lost money. The Q1 2026 record is a documented reversal: four insiders bought in the open market simultaneously in March, and the company then deployed $505 million in a single quarter to reduce share count. The prior pattern of net selling that activists cited no longer describes the current picture. The question going forward is whether the pace sustains.

What the Quarter Confirmed

This was CoStar’s 60th consecutive quarter of double-digit revenue growth. Adjusted EBITDA of $132 million doubled year-over-year and came in 26% above the midpoint of management’s own guidance. The outperformance was driven by genuine operating leverage (lower personnel costs from AI-driven efficiency initiatives) not one-time items. The commercial franchise generated $161 million in adjusted EBITDA at a 34% margin, above the high end of guidance. Net new bookings of $67 million were up 20% year-over-year.

The three simultaneous normalization events identified in this article as the re-rating thesis are all executing. Homes.com net investment is on pace to hit the guided $550 million for 2026, down from $850 million last year, the $300 million reduction is flowing through exactly as Florance committed. The Richmond campus capex line fell to $45 million in Q1 versus $54 million in Q1 2025, confirming the completion trajectory. And the buyback executed $505 million in a single quarter, with an additional $195 million planned for the remaining nine months. Every lever is pulling simultaneously.

The Homes.com Data — My Honest Assessment

I want to be transparent: I came into this earnings call skeptical of Homes.com and I remain partially skeptical. The traffic gap versus Zillow is still enormous. 35,000 paying agents out of 1.6 million licensed in the United States is 2.2% penetration. The sequential booking trend has declined for three consecutive quarters, which management attributes to Q1 seasonality and a rookie sales force - a reasonable explanation I want to see resolve in Q2 before upgrading conviction.

That said, Florance presented data tonight that I cannot dismiss. CoStar analyzed the first 11,400 Homes.com members and compared commission earnings in the 12 months before joining versus the 12 months after. The average member earned $36,400 more in commissions against an average annual subscription cost of $3,400, an 11x return on investment. Members saw commissions grow 16% while non-members saw commissions decline. Agents earning under $50,000 in the prior year saw average earnings jump from $26,000 to $82,000. Florance is raising prices on May 1 because of this data, and close rates at the top half of the sales force are reportedly north of 50%.

I still think the traffic gap is the thesis problem in one sentence. But an 11x ROI for members is not a weak product. It is a product with a monetization model that works and a distribution problem. Those are different things. The base case in this article assigns zero credit to Homes.com. That remains the right framework. But this data shifts my probability weight on the bull scenario higher than it was at publication.

The Numbers That Matter Most

Residential adjusted EBITDA improved by $56 million in a single quarter from ($85 million) in Q1 2025 to ($29 million) in Q1 2026. Q2 guidance is $0 to $10 million, essentially breakeven. Full year residential adjusted EBITDA is now guided to $110–$130 million, a swing from a massive drag to a meaningful contributor within a single fiscal year.

Zillow unique visitors were down 5% year-over-year for 15 consecutive months. Apartments.com unique visitors were up 3% in the same environment. CoStar Suite users grew 22% year-over-year to 317,000. Broker sales were up 29% and tenant sales up 27%. The quarterly renewal rate held at 92%. Five-year subscribers renewed at 95%, updated from 94% at publication. The commercial franchise is not just intact. It is accelerating.

The One Honest Bear Point

Sequential net new bookings declined for the third consecutive quarter. Q1 2026 at $67 million remains well below pre-Homes.com levels. Florance’s Q1 seasonality explanation is historically accurate and the year-over-year comparison is up 20%, but the pattern warrants watching. Two consecutive negative year-over-year quarters would be the kill trigger identified in the risk register. Tonight was not that quarter. But sequential booking momentum needs to rebuild through Q2 and Q3 before conviction upgrades to full position sizing.

The Entry Point Has Improved — Reverse DCF at $35.00

This article was written at $39.23. The stock trades near $35 after hours following a print that confirmed the core thesis on every primary metric. At $39.23 the analysis required 3.4% annual look-through FCF growth for a 10% return. At $35, the market requires approximately 1.5% annual FCF CAGR for a 10% return, which at a 32% terminal FCF margin implies revenue that is flat to slightly declining from the 2025 base, for a business that just delivered its 60th consecutive quarter of double-digit growth and raised full year EBITDA guidance by $30 million tonight.

What Happens Next

The next observable catalyst is the Q2 2026 earnings call, the first full quarter under reduced Homes.com investment with the Apartmentalize bookings cycle included. That print, more than anything said tonight, will confirm whether the sequential booking recovery is underway. The June 2026 AGM remains a data point to monitor, but it is no longer a binary risk to the thesis without Third Point as a coalition partner. The KPI tracker from Section 14 is now active. Pull the commercial franchise metrics first every quarter. They are the only numbers that can trigger an exit.

The market has spent five years pricing Homes.com as the story. Tonight’s print confirmed the cash machine underneath it is compounding faster than the model assumed, with the drag normalizing faster than anyone expected. At $35.00, the market is still pricing the problem. The article was right. The entry point is better.

Holler to Tide Investment Guide · hollertotideinvestmentguide.substack.com · This is not financial advice. All figures are estimates based on public filings and independent analysis. Do your own work.

Leave a comment

BETWEEN THE DIVES MEMO · ISSUE 001

Bessembinder’s research on U.S. equity market wealth creation from 1926 to 2016 produced a finding that should reframe how every long-term investor thinks about stock selection.

The remaining 96% collectively matched treasury bills. Not underperformed meaningfully. Matched risk-free cash in aggregate, across nine decades (Study Link).

The implication is uncomfortable. The default outcome of owning a diversified basket of equities is mediocrity. The extraordinary returns that justify the risk of equity ownership are concentrated in an extraordinarily small number of businesses. Finding them, sizing them correctly, and holding them long enough for the compounding to do the work is the entire point of this game we play on Wall Street

So, what does that 4% actually look like?

WHAT I SPEND MY TIME LOOKING FOR

The proven model. Enormous runway. Founder still running it.

The businesses that belong in that 4% share identifiable characteristics. Proof of concept behind them (the model works), the unit economics are demonstrated, the moat has held up under competitive pressure. But the opportunity in front of them is still enormous relative to current penetration. A founder still running the business with meaningful equity on the line. Reinvestment capacity that isn’t close to exhausted.

Intuitive Surgical, NASDAQ: ISRG is a clear illustration of this profile. Dominant surgical robotics platform with genuine network effects built into hospital infrastructure and surgeon training. Procedure penetration globally is still early, the runway in international markets, in new surgical categories, and in the data and services layer being built on top of the hardware platform is real and large. The business has compounded at an extraordinary rate for two decades and the competitive position has strengthened rather than weakened over time.

It is also nearly impossible to buy at a price that works (at least using my framework).

The market understands ISRG precisely. It has understood it for years. The multiple prices in the runway, the moat durability, and the compounding track record. A disciplined investor running an 18% probability weighted IRR hurdle cannot make the numbers work at current prices and probably hasn’t been able to for the better part of a decade. The business belongs in the 4%. The entry price puts it out of reach using my system.

THE RARE EXCEPTION

When the market misprices something it should understand.

Occasionally the market misprices a business that belongs in the 4% — not because the quality is ambiguous but because the complexity of underwriting it creates analytical friction that drives capital elsewhere.

MercadoLibre, NASDAQ: MELI is a current example. The e-commerce model across Latin America is proven. Mercado Pago’s unit economics are visible and compounding. The competitive position across the markets it operates in has strengthened consistently. The runway; financial services penetration across an underbanked continent, e-commerce adoption in markets still transitioning from informal retail, a fintech platform earlier in its development than the headline numbers suggest stretches further than the market typically prices in my opinion.

MELI has periodically traded at prices that clear a disciplined IRR hurdle because Latin American macro noise, currency volatility, and the complexity of underwriting a business operating across multiple regulatory and economic environments creates friction. Investors who require clean, simple narratives look elsewhere. That friction is the opportunity.

Right now, MELI is presenting both the profile and a reasonable entry point simultaneously. The ISRG-quality business at a price that works. Those moments are rare and they don’t persist. It is my largest position for exactly that reason.

The broader point stands though: businesses like this are the exception. For every MELI that becomes accessible, there are ten ISRG situations where the quality is undeniable and the price is permanently prohibitive.

THE SIGNAL MOST INVESTORS MISREAD

The buyback pivot as a second window.

When a historically reinvestment-oriented business initiates or accelerates a buyback program, the market’s default interpretation is maturation. Growth is slowing. The story is aging. The multiple compresses, growth investors rotate out, and the narrative shifts from category winner to maturing asset.

That instinct is frequently wrong, and the academic evidence says so directly.

Ikenberry, Lakonishok and Vermaelen, writing in the Journal of Financial Economics in 1995 (Study Link), studied open market repurchase announcements and found that initiating companies generated +12.1% abnormal returns over the subsequent four years. The signal was most powerful when the announcing company had historically prioritized reinvestment over capital return, precisely the profile of a business making its first meaningful pivot toward buybacks.

The mechanism is straightforward once you see it. Management has informational advantage over the market on exactly one question: whether the stock is trading below intrinsic value and whether internal reinvestment opportunities at hurdle rate are genuinely compressing. When a founder-led business with meaningful equity concentration initiates buybacks, both things are being communicated simultaneously. The stock is cheap relative to their view of intrinsic value, and the internal deployment pipeline cannot absorb all generated FCF at target returns. Both are bullish signals. The market reads maturation. The evidence says this is a possible second chance entry point to own an amazing business.

WHY THE PIVOT DOESN’T MEAN THE STORY IS OVER

Natural saturation is not deterioration.

There are two very different reasons a business pivots to buybacks and they have completely different implications.

1) Competitive or structural deterioration - the moat is narrowing, churn is rising, and management is returning capital because they have no credible reinvestment thesis, not because they’ve exhausted a good one. This version is genuinely bad. The buyback is a cover story.

2) Natural saturation - the business compounded correctly for long enough that penetration in the core market is rising toward a ceiling. The moat held. The customers stayed. The FCF is durable. However, the original reinvestment runway is compressing simply because the business won its market. This version is benign, often healthy, and the pivot to buybacks is the rational answer to a capital allocation problem created by success.

The market consistently struggles to distinguish between these two in real time. Both look like slowing growth from the outside. That’s the mispricing. NRR is the primary diagnostic - a business with decelerating topline and stable or expanding NRR is almost certainly showing natural saturation rather than competitive deterioration. If NRR is falling alongside revenue growth, the deceleration is telling you something different and the buyback is a warning rather than a signal.

THE HISTORICAL EVIDENCE

AutoZone and NVR as proof of concept.

AutoZone, NYSE: AZO is the clearest long-run illustration. Auto parts retail is not a hypergrowth market. Revenue growth ran mid-to-high single digits through most of the company’s modern history. But as domestic store saturation rose and new unit returns compressed, management pivoted to one of the most disciplined buyback programs in corporate history.

High ROIC on the operating business. Durable FCF from a sticky customer base. Systematic buybacks at prices management believed were below intrinsic value. Per-share intrinsic value compounded aggressively while headline revenue growth looked unimpressive. Investors anchored to topline consistently underpriced the per-share math and missed the return.

NVR Inc, NYSE: NVR follows a structurally similar arc. The homebuilder avoided the capital-intensive land ownership model that destroyed competitors in downturns by optioning land rather than owning it, generating exceptional FCF relative to its asset base. As organic deployment capacity compressed, buybacks began. Share count has been cut roughly in half since the early 2000s. The investors who ran the per-share compounding math outperformed those anchored to housing market volume as the primary thesis driver.

The return in both cases came from correctly reading the pivot signal and holding through a period when the market was still applying growth investor logic to businesses that had entered a different compounding regime.

WHERE THIS PLAYS OUT RIGHT NOW

Five names, four different positions on the curve.

*Read about VEEV here.

THE FAILURE MODE

Where I got it wrong and what it taught me.

Optionality is only valuable if the conditions required to exercise it remain available.

I owned Evolution Gaming OMXS: EVO.ST on a version of this thesis. Live casino software, dominant market position, exceptional unit economics, and what appeared to be significant optionality in regulated market expansion globally. The underlying platform quality was genuine.

What I underestimated was the regulatory fragility embedded in the revenue base. Evolution operated across a mix of fully regulated and grey market jurisdictions. When the business committed to a 100% white market model (the right long-term decision) a meaningful portion of the revenue base that was funding the growth trajectory effectively exited. The growth I was underwriting required access to markets that were legislated away. The moat didn’t fail. Competitors didn’t win. The addressable market got smaller and the optionality I had given value to couldn’t be exercised.

That distinction between optionality within the business’s own control and optionality dependent on external conditions is now a specific part of how I evaluate every setup.

The 4% finding tells you the stakes. The pivot signal tells you where to look when the ideal is out of reach.

That’s the lens I’m bringing to the next deep dive on CoStar Group, NASDAQ: CSGP which will be published the week of 4/19/2026.

Until next time,

— Shane

The content in this publication is for informational and educational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. All information is provided in good faith but is not guaranteed to be accurate, complete, or current. Investing involves risk, including the potential loss of principal. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial professional before making any investment decisions. The author may hold positions in securities mentioned in this publication.

In This Issue:

1. Thesis Summary

2. Business Overview and Revenue Architecture

3. Management, Ownership, and Capital Allocation Philosophy

4. Hard Gate Scorecard

5. Moat Analysis

6. The Vault CRM Transition and eCTD 4.0 Convergence

7. Capital Return Pivot

8. Financial Deep Dive and Two-Lens Valuation Model

9. Future Growth Opportunities

10. Competitive Landscape

11. Risk Register

12. My Conviction Builder Summary

13. KPI Tracking Framework and Kill Triggers

14. Portfolio Role and Position Sizing Framework

15. What Has to Go Right and What Could Go Wrong

16. Conclusion

* This analysis applies the Holler to Tide Investment Constitution. Readers unfamiliar with the framework, including IRR hurdle rates, tier classifications, and scenario multipliers, may find it helpful to read the constitution first: Holler to Tide Investment Guide Investment Constitution Framework

1. THESIS SUMMARY

Veeva Systems is the dominant software platform for the global pharmaceutical industry, the system that runs drug trials, manages regulatory submissions to the FDA, and increasingly, the commercial operations of every major biopharma company on earth. The market has spent two years punishing the stock over a CRM transition that represents less than half of subscription revenue, while the business that matters compounds quietly in the background. The entry price implies Veeva will grow slower than GDP for a decade. That is not a bet the evidence supports.

Veeva’s competitive advantage of switching costs are not enforced by preference or integration complexity, they are structurally reinforced by 21 CFR Part 11, EU Annex 11, and related compliance obligations. The cost of switching is borne not by adopting a competitor, but by the act of migration itself. Every pharmaceutical company running Veeva’s platform has spent thousands of organizational hours executing Good Practice (GxP) validation in their own environment, approved by their own quality assurance function, signed off by their own Change Control Board - work that cannot be transferred, inherited, or abbreviated when changing vendors. That organizational cost, multiplied across five or more validated systems running clinical, regulatory, quality, and safety workflows, makes displacement not just expensive but operationally reckless for any company with a Food and Drug Administration (FDA) relationship to protect. The market understands none of this. It has spent two years repricing a customer relationship management transition, a known, time bounded disruption in the commercial layer representing approximately 46% (and shrinking) of subscription revenue, while the Research and Development and Quality cloud compounded at 21% year-over-year for seven consecutive quarters without interruption. At the same time, a founder-Chief Executive Officer who returned zero capital to shareholders for 18 years has announced a $2 billion buyback against a $6.6 billion net cash balance: a deliberate capital allocator stating publicly, with his reputation on the line, that his own stock is cheap. The entry price assumes Veeva broke a promise it never made. The regulatory moat is getting stronger. The business that matters is compounding. And the man who built it is buying.

The FDA pipe insight deepens the thesis further. Veeva’s Vault Submissions infrastructure is not merely a document management system, it functions as a live operational gateway between pharmaceutical sponsors and the FDA’s electronic submission infrastructure. That integration is active today, validated today, and trusted today by the agencies whose regulatory relationships our customers exist to protect. Adding eCTD 4.0, a mandatory electronic submission format change that the FDA requires by 2029 creates a second forced buying event entirely independent of the Customer Relationship Management transition. The Customer Relationship Management sunset creates urgency on the commercial side. eCTD 4.0 creates urgency on the regulatory and submissions side. Both deadlines converge in the same two-to-three year window, and Veeva sits at the center of both.

The financial architecture reinforces the compounding case. The Salesforce royalty wind-down contributes approximately 200 basis points of structural margin improvement by fiscal year 2030 with no offsetting cost increase. Sales and marketing leverage adds further as the install base matures and net revenue retention compounds. This is not a business that needs the market to re-rate it. It needs only to execute, and the margin expansion happens as a byproduct of existing commitments already made.

What the Market Is Pricing In — Reverse DCF at $180

At $180 per share independently confirmed as the exact fair value entry for a 10% annual return over ten years, Veeva requires only 4.81% annual free cash flow growth to justify that price at a 28x exit multiple, once the 2.25% annual buyback yield is incorporated. Starting from FY26 actual free cash flow of $1.386 billion with a 47% mature free cash flow margin assumption, that 4.81% FCF growth rate implies a terminal revenue base of $4.72 billion,a compound annual growth rate of just 3.98% from FY26 actual revenue of $3.2 billion. The buyback program alone reduces the market-implied growth hurdle by approximately 240 basis points relative to a no-repurchase scenario. The future price target that delivers 10% from $180 is $467.

At $180, the probability-weighted IRR of 17.63% clears the 17.5% post-cut hurdle by 13 basis points. That margin is not the source of conviction; the quality of the business is. A Tier 1 classification means the bear case still produces a real return, and the impairment scenario recovers 72 cents on the dollar. Those are the numbers that matter. The 13 basis points is the output of a disciplined model applied honestly. The margin of safety is in what the business is, not in how far above the line the math lands. The full scenario framework, probability-weighted expected value, and dual-lens valuation appear in Section 8. The complete kill trigger map appears in Section 16.

Subscribe now

2. BUSINESS OVERVIEW AND REVENUE ARCHITECTURE

What Veeva Actually Does

Veeva provides cloud software, data, and related services that help life sciences companies develop drugs, run clinical trials, manage regulatory submissions, maintain quality systems, and commercialize products more effectively. In plain English, Veeva sells the digital systems that pharmaceutical, biotech, and medical device companies use to keep critical work organized, compliant, and moving.

Founded in 2007 by Peter Gassner, a former Salesforce executive, Veeva was built on the idea that life sciences needed purpose-built software rather than generic horizontal enterprise tools. Over time, that focus allowed the company to become deeply embedded in day-to-day workflows across research, clinical development, quality, regulatory affairs, medical, and commercial operations.

The business is easiest to understand in two broad solution families with different growth profiles and competitive dynamics. Commercial Solutions includes customer relationship management, content, medical engagement, and data products that help customers market and support their products. Research and Development Solutions includes the systems used to run studies, manage submissions, maintainquality documentation, and support safety processes. One side helps customers sell and support medicines. The other helps them develop, approve, and manage those products inside a highly regulated environment.

The key architectural point is that these are not simply two unrelated product lines under one roof. At larger customers, Veeva increasingly functions as a connected operating layer across the life sciences value chain. A company may choose a different customer relationship management front end, but replacing validated systems tied to clinical, regulatory, quality, or safety workflows is a very different decision from swapping a standard sales tool. That distinction matters because it means the customer relationship management headline noise does not capture the full durability of the franchise.

The Vault Platform — The Common Foundation

Revenue Architecture

For financial reporting purposes, Veeva organizes revenue into two segments. Research and Development Solutions, comprising the Development Cloud and Quality Cloud, represented approximately 53% of fiscal year 2026 subscription revenue ($1,427M) and grew 21% year-over-year. Commercial Solutions, comprising the Commercial Cloud and Data Cloud, represented approximately 47% of fiscal year 2026 subscription revenue ($1,258M) and grew 14% year-over-year. The Research and Development segment is most of the business and is growing at a materially faster rate than Commercial, yet it is almost entirely absent from the customer relationship management transition narrative that dominates analyst coverage.

Product Architecture

• Veeva Clinical Platform

  Connects patients, research sites, Contract Research Organizations (CROs), and sponsors in a single ecosystem for clinical trial execution. Manages trial documents, data flow, and site collaboration across what can be hundreds of locations in dozens of countries simultaneously. The platform that replaced boxes of paper and spreadsheet trackers. (Electronic Trial Master File · Clinical Trial Management System · Electronic Data Capture)

• Veeva Clinical Data Management

  Tools for trial design and execution including Veeva Electronic Data Capture for capturing patient data directly at the point of care, Veeva Clinical Database for aggregating, cleaning, and transforming clinical data, and electronic patient consent and assessment solutions. The systems that turn raw trial data collected at individual research sites into a validated, submission-ready package. (Electronic Data Capture · Clinical Database · Electronic Consent)

• Veeva Safety

  Manages adverse event intake, processing, and submission to regulators after a drug reaches the market. The pharmacovigilance infrastructure that every pharmaceutical company is legally required to maintainfor every approved product indefinitely. A pharmaceutical company cannot decommission its safety system without replacing it and any gap during a migration creates regulatory liability. (Pharmacovigilance · Adverse Event Reporting · Post-Market Safety)

• Veeva Regulatory Information Management

  End-to-end management of global product registrations, submission content planning, authoring, publishing, and direct electronic transmission to the United States Food and Drug Administration and the European Medicines Agency via direct gateway integration. A pharmaceutical company’s drug application flows from Vault directly to the Food and Drug Administration’s Electronic Submissions Gateway. The acknowledgment flows back. The entire exchange is logged inside the platform. Veeva is not adjacent tothe regulatory submission process. It is the submission process. (Food and Drug Administration Gateway · Electronic Common Technical Document · Global Registrations)

• Veeva Quality Management System

  Manages integrated quality processes across the full product lifecycle from development through manufacturing. The system of record for every corrective action, every deviation, every change control event in a Good Manufacturing Practice-regulated facility. In a pharmaceutical manufacturing environment, this system cannot go dark for a day without creating a compliance gap. (Quality Processes · Good Manufacturing Practice · Corrective and Preventive Actions)

• Veeva Quality Docs

  Validated repository for Standard Operating Procedures, batch records, and product specifications throughout their full lifecycle. Every regulated document has an approved version, an audit trail, and a controlled distribution record. The moment a company migrates this content to a new system, every document’s validation history must be verified to have transferred intact, a qualification project in its own right. (Controlled Documents · Standard Operating Procedures · Batch Records)

• Lab Solutions

  Enables quality control laboratories to optimize batch release testing, stability study management, and environmental monitoring. The systems that determine whether a manufactured batch of drug product meets specification before it is released to patients. (Laboratory Information Management · Batch Release · Stability Studies)

• Training Solutions

  Personnel qualification tracking and training compliance documentation. In a Good Practice regulated environment, every person who touches a validated process must have documented evidence of training on that process. This is a regulatory requirement that auditors check on every inspection, not optional record-keeping. (Training Compliance · Personnel Qualifications · Inspection Readiness)

• Vault Customer Relationship Management Suite

  Next-generation customer relationship management built natively on Vault, replacing the legacy Veeva Customer Relationship Management product that was built on Salesforce infrastructure. The legacy product is supported until December 2029, a date Veeva moved forward from September 2030 in March 2026. Vault Customer Relationship Management unifies sales, marketing, medical affairs, and service teams in a single Vault database. This is what the entire analyst debate is about. It represents one product family in one of four cloud categories. (Healthcare Professional Engagement · Field Force · Multichannel)

• Veeva Medical

  Single validated source of medical content across channels and geographies for medical affairs teams. Centralizes medical inquiries and content for medical science liaisons and medical affairs professionals engaging with healthcare professionals. (Medical Affairs · Medical Science Liaisons · Medical Inquiries)

• Veeva PromoMats

  End-to-end content and digital asset management for commercial teams; collaboration, medical/legal/regulatory review, distribution, and lifecycle management of promotional materials. Manages the review process that every pharmaceutical advertisement and sales aid must pass through before it can be used in the field. (Digital Asset Management· Medical Legal Regulatory Review · Content)

• Veeva Crossix

  Analytics platform using real-world patient claims data to measure pharmaceutical media investment effectiveness and marketing return on investment. Built on pharmacy claims and medical claims data licensed from insurance companies and pharmacy benefit managers. The data network compounds with each new commercial customer making it more valuable to all customers simultaneously and creating a switching cost that goes beyond software validation into commercial analytics capability. (Claims Data· Media Analytics· Marketing Return on Investment)

• Veeva OpenData

  Customer reference data; demographic information, license status, specialty, and affiliation information on healthcare professionals and organizations globally. The foundational dataset for commercial targeting and regulatory compliance. (Healthcare Professional Master Data · Reference Data · Global Coverage)

• Veeva Link

  Deep data platform combining intelligent software automation with human curation. Covers key opinion leaders, key accounts, publications, conferences, medical insights, and digital engagement patterns. The intelligence layer on top of the reference data. (Key Opinion Leader Data · Medical Insights · Digital Engagement)

• Veeva Compass

  De-identified United States longitudinal patient, prescriber, and national data for commercial planning, forecasting, patient journey analytics, segmentation and targeting, and incentive compensation design. The dataset that tells a pharmaceutical company how many patients with a given diagnosis are actually being treated with their drug versus a competitor’s. (Patient Data · Prescriber Analytics · Longitudinal Data)

• Veeva Customer Relationship Management Pulse

  Multichannel engagement metrics on healthcare professionals used by commercial teams for segmentation, targeting, and field force planning. The feedback loop that tells sales operations whether their promotional efforts are reaching the right prescribers. (Engagement Metrics · Segmentation · Targeting)

Professional Services — Implementation, Deployment, and Managed Services ~16% of Fiscal Year 2026 Total Revenue · $511 million

Veeva offers professional services to help customers implement and maximize the value of its solutions. Service teams possess industry expertise, project management capabilities, and deep technical knowledge organized by specific expertise across research and development and commercial functions. Services include implementation and deployment planning, requirements analysis, solution design and configuration, systems environment management, data migration and systems integration consulting, business process transformation, training, and ongoing managed services including outsourced systems administration. Veeva also operates a partner network of global systems integrators and market specialty firms.

Veeva Business Consulting — Strategic Consulting

Veeva Business Consulting is a separate organization from the standard professional services team. Where professional services help customers implement and deploy Veeva software, business consulting provides strategic advisory services informed by Veeva’s unique position serving over 1,000 life sciences companies simultaneously. That cross-industry perspective; knowing how hundreds of pharmaceutical companies run their commercial and research and development operations, is a consulting asset no independent firm can replicate.

• Commercial Business Consulting — Helps pharmaceutical companies redesign how they engage healthcare professionals, not just which software tools they use. Focuses on digital engagement strategy, commercial content management, field force optimization, and commercial insights and analytics.

• Research and Development Business Consulting — Enables continuous innovation across the drug development value chain including process efficiency improvements, time-to-market acceleration, and optimized operating model and governance design. Helps life sciences companies rethink how their clinical, regulatory, quality, and safety organizations work, not just the systems those organizations run on.

What the Architecture Tells You

The Research and Development and Quality clouds contain every product with Good Practice validation requirements, Food and Drug Administration gateway integration, and the structural switching costs that define the moat. The Commercial Cloud contains the customer relationship management product at the center of the transition narrative. Those are not the same business. They share a platform and a balance sheet. The market is pricing one as if it were the other.

The Vault platform is the thread that connects everything. Not because it creates lock-in through integration complexity, any enterprise software vendor can claim integration complexity. Because it means every Vault application a pharmaceutical company deploys adds to the same validated compliance infrastructure. Each new application is not a separate switching cost. It is an extension of the one that already exists. That compounding of validation burden across an expanding platform footprint is what makes Veeva’s moat genuinely structural and genuinely difficult to model from the outside.

3. MANAGEMENT, OWNERSHIP, AND CAPITAL ALLOCATION PHILOSOPHY

Veeva is a founder-led business. That is not a decorative description. It is the single most important governance fact in the investment thesis. Bain and Company states that founder-led business led to 3.1x total shareholder returns vs companies that are not (source). Peter Gassner has run Veeva since founding it in 2007, 19 years as of this writing with no material acquisitions, no dilutive equity raises, no guidance misses of consequence, and a capital allocation philosophy so conservative it bordered on obstinate until the January 2026 buyback authorization. Understanding who runs this business, what they own, and how they think about capital is not a soft analytical exercise. It is the foundation of the thesis.

Peter Gassner — Founder and Chief Executive Officer

Gassner, 60, built his career along every major transition in enterprise software. He wrote DB2 at IBM’s Silicon Valley Lab, served as Chief Architect and General Manager of PeopleTools at PeopleSoft for nine years, and was Senior Vice President of Technology at Salesforce during the company’s rise as the dominant cloud platform. That progression (mainframe, client-server, cloud) gave him a framework for recognizing inflection points that most enterprise software executives never develop. When he left Salesforce in 2007, he had watched one major platform transition unfold from the inside. He decided to run the next one himself.

The founding insight was vertical specificity. Generic horizontal software could not solve the compliance and workflow problems specific to life sciences. Pharmaceutical companies needed software built around their regulatory environment, not adapted to it. Gassner co-founded Veeva with Matt Wallach, Doug Ostler, and Mitch Wallace on $4 million of external capital, an amount so small relative to the eventual scale of the business that it became a defining artifact of the capital efficiency culture he built. Veeva went from zero to $500 million in annual recurring revenue largely without consuming that initial capital.

Ownership and Alignment

Gassner owns approximately 12.2 million shares of VEEV as of late 2025, representing roughly 7.6% of shares outstanding and a market value of approximately $3.5 billion at prevailing prices. He is the second-largest shareholder behind Vanguard. His net worth by Bloomberg’s estimate is approximately $5.25 billion with the overwhelming majority of which is a single concentrated position in the company he built.

The ownership context transforms the meaning of the January 2026 buyback authorization. A CEO who holds $3.5 billion of stock and authorizes a $2 billion repurchase program is not making a routine capital allocation decision. He is making a personal credibility commitment that the stock is cheap. If the buyback does not produce returns, it is his net worth that suffers most alongside every other shareholder. No founder with that level of personal alignment makes that commitment lightly. There have been no insider sales since the February 2023 block sale and no sales since the buyback authorization which is consistent with a CEO who believes he is buying the stock from a position of genuine conviction rather than managing perception.

His compensation structure reinforces the alignment. This is my personal favorite part of this thesis. Base salary is $475,000 annually, modest for a CEO of a $30 billion market cap business. No annual cash bonus exists. Compensation is delivered entirely through long-term, premium-priced stock options with market-based vesting conditions and a mandatory two year post exercise holding period. The options only vest if the stock price sustains performance hurdles over time. The structure makes it structurally impossible for Gassner to benefit in the near term unless shareholders benefit over the long term.

Capital Allocation Philosophy

For 18 years, Veeva generated substantial free cash flow and returned none of it to shareholders. That was not a failure of discipline, it was the discipline. Gassner has been explicit in interviews that he views the balance sheet as a strategic asset: a permanent buffer against macro uncertainty, a source of product investment flexibility, and a signal to customers and employees that the company has no financial fragility. The result is a $6.6 billion net cash position with zero financial debt; a balance sheet that most software companies of this scale can only wish for.

The philosophical shift in January 2026 is therefore more significant than the dollar amount suggests. Gassner did not change his view about balance sheet strength, that stays. What changed is that the stock, in his assessment, has become sufficiently cheap that deploying capital into repurchases is now the highest-return use of incremental cash. That is a value investor’s framework applied by a founder who has spent 18 years watching his own stock. The implication for forward capital allocation is that repurchases will expand further as cash generation grows, but the balance sheet will not be depleted recklessly. The discipline is in the superpower.

The Management Bench

Gassner’s succession risk is real and is acknowledged in the Risk Register. However, the bench around him is stronger than the founder-dependency narrative implies. Three executives are worth understanding:

Tom Schwenger, President and Chief Customer Officer, joined Veeva in September 2019 after more than 25 years at Accenture where he led the North American Life Sciences Practice. His background is in technology transformation for pharmaceutical and biotech clients; the exact customer base Veeva serves. He oversees all sales and customer-facing organizations and is the executive most responsible for the Vault CRM migration execution. His Accenture background is strategically relevant: he understands how pharmaceutical IT decisions are made from the buyer’s perspective, which is a meaningful advantage in a migration cycle where the sales motion is as much organizational change management as product selling.

Brian Van Wagener, CFO since September 2024, spent seven years inside Veeva before assuming the CFO role, including as Chief of Staff to Gassner and Vice President of Global Sales Operations. The internal progression matters, he understands the business at a granular level and was already embedded in the CEO’s decision-making process before taking the finance chair. He was already Gasner’s “right hand man”. His prior work at Monitor Deloitte in healthcare and life sciences and at BetterUp rounds out a profile that combines deep institutional knowledge with broader enterprise finance experience.

Tim Cabral, who served as CFO from 2010 to 2020 and guided Veeva through its IPO and from $10 million to over $1 billion in revenue, now sits on the board. That continuity; a former CFO who knows the business from its earliest scale as a board member provides an institutional memory anchor that is uncommon and valuable. Cabral stepped back in as Interim CFO during the transition period in 2024, demonstrating the depth of his ongoing engagement with the business.

4. HARD GATE SCORECARD

All eight Perennial gates must clear before valuation work carries real weight. A weak business does not become attractive simply because the stock is cheaper.

5. MOAT ANALYSIS

Why Switching Is Hard

Most Veeva writeups stop at the phrase switching costs. That is true, but it is not enough. The more useful question is why switching is so hard in the first place. In regulated life sciences workflows, software is not just another application sitting on a desktop. It is embedded in processes that touch documentation, approvals, audits, training, change control, and records that must be preserved and reviewed over long periods of time.

That means a replacement decision usually brings more than a new contract and an implementation plan. Customers often have to re-map processes, migrate data, retrain users, document new controls, and re-establish confidence that the system behaves as intended inside a regulated workflow. In practice, this can mean thousands of hours of internal work and outside support, especially when multiple systems are connected. The friction is economic, operational, and compliance-related all at once.

It is also important to be precise about the source of the moat. Veeva is not protected by regulation in a literal sense, as though customers are legally required to use Veeva. The moat is stronger than that simplistic formulation but also more nuanced: regulation raises the cost of change, and Veeva benefits because its products are already embedded in the processes customers must document, monitor, and defend.

The Regulatory Compliance Mandate — Veeva’s Reason for Existing

Veeva itself states this plainly in its 10-K. Its cloud software offerings are subject to Good Practice regulations for the life sciences industry and must meet requirements for robust audit trail tracking, compliant electronic signature capture, data encryption, and secure access controls. That is not a marketing claim. It is a description of the regulatory environment that Veeva’s customers operate in and the reason those customers cannot simply swap Veeva out for a generic enterprise software alternative.

The following is the list of specific global regulations that Veeva’s systems must comply with, drawn directly from Veeva’s 10-K Quality and Compliance Program disclosure. Each regulation represents a legal mandate that applies to Veeva’s customers’ use of the software and therefore to any vendor that wants to replace Veeva:

The Food and Drug Administration’s 2025 Computer Software Assurance Guidance

Recent Food and Drug Administration guidance around risk-based Computer Software Assurance is sometimes described as a simplification that could make validated systems easier to replace. That overstates the case. The direction of travel is toward better-structured, risk-based assurance rather than the removal of assurance obligations. For customers running quality and manufacturing systems, that still points to careful validation, testing, documentation, and governance.

The counterintuitive implication: Computer Software Assurance creates a new barrier to switching that did not exist under the old framework. Under the prescriptive Installation Qualification/Operational Qualification/Performance Qualification approach (IQ/OQ/PQ), validation was prescriptive, a competitor could show a pharmaceutical company a detailed validation package and say here is exactly what we will do. Under Computer Software Assurance, the company must perform its own risk assessment, design its own assurance framework, and defend that framework to regulators. A pharmaceutical company that has spent two years building a Computer Software Assurance-compliant assurance framework around Veeva’s platform cannot simply transfer that framework to a competitor. They must rebuild it from scratch.

The Data Layer

There is also a data layer on top of the workflow moat. Products like Crossix make Veeva more than a workflow vendor by giving customers data and analytics that become more useful as adoption deepens. That does not replace the core moat, but it strengthens it. The more Veeva sits at the center of commercial execution and measurement, the harder it is for customers to view the company as just another application vendor.

The Moat Stack

Taken together, the moat is best described as a stack: workflow entrenchment, compliance friction, process connectivity, and data. Each layer matters on its own. In combination, they make Veeva unusually difficult to displace in the parts of life sciences where the cost of disruption is highest.

6. THE VAULT CRM TRANSITION AND eCTD 4.0 CONVERGENCE

The debate around Veeva’s commercial future has been framed almost entirely around one question: will the Vault CRM migration succeed? That framing misses half the story. There are two independent forced buying events converging on the same 2029 window; one on the commercial side, one on the regulatory side and Veeva sits at the center of both.

The Vault CRM Migration

As of March 2026, more than 125 pharmaceutical companies are live on Vault CRM worldwide. Ten of the top-20 global biopharma companies have committed to Vault CRM as their enterprise commercial standard, a count that has doubled in the past twelve months. Veeva moved the legacy CRM end-of-support date forward from September 2030 to December 2029, tightening the migration window and effectively converting a choice into a deadline. The transition that has dominated two years of analyst debate is, as of this writing, executing ahead of the most pessimistic expectations.

The architectural framing matters more than the quarter-to-quarter migration count. Veeva’s legacy CRM was built on Salesforce infrastructure. Vault CRM is built entirely on Veeva’s own Vault platform, the same foundation that runs clinical, regulatory, quality, and safety workflows. That convergence is what separates Vault CRM from a simple product refresh. When a pharmaceutical company migrates its commercial organization to Vault CRM, it is not swapping one sales tool for another. It is unifying its commercial team onto the same platform that already manages its regulatory submissions, quality documentation, and clinical trial data. That cross-platform integration opportunity is not available to any competitor. Salesforce cannot offer it because Salesforce does not own the regulated workflow layer.

Salesforce Life Sciences Cloud (the primary competitive alternative) is still under active development. Customer commitments to Salesforce are based largely on a roadmap and promised capabilities rather than a fully delivered, GxP-validated system proven at scale in a pharmaceutical commercial environment. Every pharmaceutical company must independently validate that any software touching regulated commercial workflows meets the requirements of 21 CFR Part 11. A system that has not been validated at scale at a major pharmaceutical account does not yet have a reference base that compliance teams can point to when making a platform decision. Salesforce may eventually deliver. As of March 2026, the evidence base for that delivery remains thin.

The Royalty Wind-Down, A Margin Catalyst Hidden in Plain Sight

There is a margin expansion story embedded in the CRM migration that almost no analyst models explicitly. Veeva’s legacy CRM was built on Salesforce infrastructure, which means Veeva has been paying Salesforce a royalty on every dollar of legacy CRM subscription revenue for years. As customers migrate to Vault CRM built entirely on Veeva’s own Vault platform, that royalty obligation disappears. There is no replacement cost. There is no new vendor. The revenue that previously flowed through to Salesforce stays inside Veeva’s P&L. Management has guided to approximately 200 basis points of structural non-GAAP operating margin improvement from the royalty wind-down alone by fiscal year 2030, with no offsetting cost increase required to capture it. This is not operating leverage from scaling, but it is a contractual margin gift that arrives automatically as the migration completes. A business growing revenue at double digits while simultaneously shedding a royalty obligation on its largest product line does not need multiple expansion to deliver expanding margins. The math does it mechanically. That is precisely the kind of structural improvement that gets lost when analysts focus on the headline CRM transition risk rather than what the P&L looks like on the other side of it.

*More to come in the Financial Deep Dive section #8

The eCTD 4.0 Transition

The electronic Common Technical Document (eCTD) is the standardized format through which pharmaceutical companies submit drug applications to regulatory agencies worldwide. Every new drug approval, every labeling change, every safety update flows through this format. Version 4.0 is a mandatory structural upgrade requiring pharmaceutical companies to rebuild their submission infrastructure to meet new technical specifications. The FDA has set a mandatory adoption deadline of 2029. Japan’s PMDA mandated adoption from April 2026. The European Medicines Agency began accepting version 4.0 submissions in December 2025.

Veeva’s Vault Submissions platform is the infrastructure through which pharmaceutical companies build, publish, and transmit eCTD submissions directly to the FDA’s Electronic Submissions Gateway. Veeva is not a tool that supports the submission process, but it is the submission process. The eCTD 4.0 transition generates a mandatory professional services engagement for every Vault Submissions customer, a natural subscription uplift opportunity, and a forcing event that runs entirely independently of the CRM migration deadline.

The Convergence

The December 2029 legacy CRM end-of-support date creates commercial urgency. The FDA’s mandatory eCTD 4.0 deadline (also 2029) creates regulatory urgency. Both require active vendor engagement, implementation resources, and platform decisions. Both favor Veeva’s integrated position. A pharmaceutical company navigating a simultaneous CRM migration and eCTD 4.0 upgrade has every incentive to consolidate platform decisions rather than manage parallel implementations across competing vendors.

The professional services implication is underappreciated. A customer migrating from legacy CRM to Vault CRM and simultaneously upgrading regulatory infrastructure for eCTD 4.0 represents a multi-year professional services engagement. Veeva’s professional services segment, often dismissed as a low-quality revenue stream, becomes a leading indicator of the depth of platform engagement in the migration cycle.

7. CAPITAL RETURN PIVOT

For eighteen years, Veeva generated substantial free cash flow and did not return a dollar of it to shareholders through repurchases. Peter Gassner treated the balance sheet as a strategic asset, a permanent buffer against macro uncertainty, product investment needs, and the optionality to move fast on M&A if the right opportunity appeared. That discipline built a $6.6 billion net cash position with zero financial debt. It also meant that 100% of per-share value creation came from earnings growth, not capital return. Shareholders were entirely dependent on the business compounding its way to higher valuations.

The January 2026 authorization of a $2 billion share repurchase program is the first chapter of a different story. The signal is not the $2 billion itself, that is approximately 6.5% of the current market cap and roughly 1.5 years of free cash flow at current generation rates. The signal is that a founder who demonstrated 18 years of capital restraint chose this moment, at this price, to make his first public statement that the stock is cheap. That is not a routine capital allocation decision. It is a personal credibility commitment from the person with the most information about the business and the most to lose if the judgment is wrong.

How the Buyback Sits Inside the Return

Share count reduction is not a return on top of the 17.63% probability-weighted IRR, it is one of the three engines that compose it. The valuation model runs from 167 million diluted shares today to approximately 133 million by FY36, a net reduction of approximately 20% over ten years funded by the $6.6 billion balance sheet and ongoing free cash flow generation. That reduction drives a meaningful portion of the per-share price appreciation in both valuation lenses. Without it, the price targets fall and the IRR narrows. With it, the model is internally consistent and the return is achievable at conservative revenue growth assumptions.

The three engines are revenue compounding, margin expansion, and share count reduction - they are not independent. Revenue growth funds free cash flow, which funds repurchases, which reduce the denominator against which that growing free cash flow is measured per share. The Salesforce royalty wind-down contributes approximately 200 basis points of margin improvement by FY30, expanding the free cash flow available for repurchase without requiring revenue outperformance. The 17.63% IRR is the output of all three engines running simultaneously. Describing it as anything else overstates the return. More valuation details in section 8.

The balance sheet deployment question is more important than the repurchase mechanics. Veeva holds $6.6 billion in net cash against a business generating approximately $1.35 billion in annual free cash flow. That cash must eventually be deployed. The optionality it represents includes accelerated repurchases when the stock remains depressed, strategic bolt-on acquisitions in adjacent life sciences data or workflow categories, and a permanent capital buffer that allows management to invest through down cycles without needing external financing. None of these require the balance sheet to be fully liquidated. The discipline is in the deployment sequence, and the $2 billion authorization is the first step in a multi-chapter capital allocation story.

8. FINANCIAL DEEP DIVE AND TWO-LENS MODEL

Historical Revenue by Segment

Historical Margin Architecture

The last five years show a business whose center of gravity has shifted. Commercial has slowed as the Customer Relationship Management transition has weighed on growth, while Research and Development and Quality have taken a larger share of subscription revenue and become the more important engine of expansion. That mix shift is strategically constructive because the faster-growing side of the company is also the side with the deepest workflow entrenchment. Margins tell a similar story. Veeva has continued to scale with relatively modest capital intensity, strong gross margins, and high free cash flow conversion.

One FY26 note: operating cash flow of $1.415 billion includes a benefit from the One Big Beautiful Bill Act (OBBBA), which restored immediate expensing of domestic R&D expenditures that had been required to amortize over five years under TCJA, and permittedacceleration of previously capitalized amounts. The OBBBA creates a multi-year OCF tailwind but FY26 includes some catch-up deduction; the valuation model uses a normalized FCF anchor.

Two-lens Valuation Model

Veeva is valued through two independent valuation lenses: Price to Free Cash Flow and Enterprise Value to non-Generally Accepted Accounting Principles (GAAP) Operating Income. Both models use identical revenue, margin, and share count assumptions. The purpose of running two methodologies is not to find precision, it is to test whether fundamentally different valuation approaches converge on the same result. When they do, the model is internally consistent and the output is more trustworthy than either approach alone.

The critical validation: both lenses produce a 10-year price target within $70 of each other and a CAGR within 0.7 percentage points of each other. That convergence, across two completely independent methodologies using different metrics and different exit multiples confirms the model is internally consistent. The output is not a prediction. It is a framework for understanding what the business needs to deliver to justify the entry price.

Entry price for both models is $180 average cost basis. Both models are bull-leaning. They assume above-consensus revenue growth, margin expansion from the Salesforce royalty wind-down and operating leverage, and a net share count reduction program funded by the $6.6 billion cash balance and ongoing free cash flow generation. Neither model requires multiple expansion to produce above-hurdle returns.

Key Model Assumptions — Both Lenses

Lens 1 — Price to Free Cash Flow Model

Lens 2 — Enterprise Value to Non-GAAP Operating Income Model

Model Validation — Convergence Check

Probability-Weighted Scenario Analysis

The probability-weighted return of 17.63% is calculated by weighting each scenario’s expected terminal value by its probability on a hypothetical $5,000 investment: Bull $33,136 at 29%, Base $25,957 at 52%, Bear $14,784 at 14%, and Impairment at 5% recovering $3,600 arrives at a probability-weighted terminal value of $25,357. The 17.63% is the single annual growth rate that takes $5,000 to $25,357 over ten years. The framework model is built around scenario ending values, not independently computed annual cash flows. It clears the 17.5% hurdle rate by 13 basis points.

Expected Value Framework Summary Table — $5,000 Position from $180

9. FUTURE GROWTH OPPORTUNITIES

The investment case for Veeva is often framed as a defense of an existing moat against a known competitive threat. That framing is incomplete. Veeva is simultaneously defending what it has built and expanding into growth vectors that are not yet fully reflected in the model. The following opportunities represent the white space above the base case, each meaningful on its own, collectively capable of extending the Research and Development cloud’s growth trajectory well beyond what the current consensus implies.

The Contract Research Organization Channel — A New Distribution Engine

The traditional Veeva sales model targets pharmaceutical companies directly. A large top-20 pharmaceutical company is a defined account with a defined buying process. The long tail of emerging biotechs: companies running one or two clinical trials with ten to fifty employees has historically been expensive to reach through that same model.

Veeva is now building a second distribution channel through Contract Research Organizations. The logic is straightforward. As pharmaceutical companies have outsourced more of their research and development activity to Contract Research Organizations, specifically large pharma now outsourcing approximately 45% of internal research and development, CROs have become the technology decision-makers for an increasingly large share of clinical trial activity. A Contract Research Organization that runs on Vault Clinical, Vault Electronic Data Capture, and Vault Randomization and Trial Supply Management can bundle those tools as part of its service offering to emerging biotech customers that could never afford a direct Veeva enterprise relationship.

Gassner addressed this directly on the most recent earnings call, detailing a new focus on leveraging Contract Research Organizations as a channel for study-by-study deals, particularly for Electronic Data Capture, Randomization and Trial Supply Management, and electronic Clinical Outcome Assessment products. The emerging biotech segment, companies in the $50 million to $500 million revenue range running their first Phase II or Phase III trials represents a customer cohort that is currently underpenetrated and is growing faster than the top-20 pharmaceutical accounts that dominate Veeva’s current revenue base.

Contract Research Organization Technology Displacement

The second Contract Research Organization opportunity is separate and potentially larger. Traditional Contract Research Organizations like IQVIA, Covance, and Parexel built their own proprietary technology stacks for managing trial data, electronic trial master files, and clinical trial management. Those legacy platforms are losing ground to Vault as pharmaceutical company sponsors increasingly require their Contract Research Organizations to operate on Vault rather than on the Contract Research Organization’s own systems.

This creates a displacement dynamic that benefits Veeva in two directions simultaneously. First, pharmaceutical sponsors standardizing on Vault require their Contract Research Organizations to use Vault, expanding Vault’s installed base into the Contract Research Organization tier. Second, Contract Research Organizations that have already adopted Vault become distribution partners for new pharmaceutical customer wins — reinforcing the channel strategy described above. Veeva is becoming the technology standard that the Contract Research Organization industry must comply with rather than a vendor competing against it.

Artificial Intelligence Agents — Token-Based Revenue Layer

Veeva launched its first Artificial Intelligence Agents in December 2025 across Vault Customer Relationship Management and PromoMats, with regulatory-specific agents including a Health Authority Interactions Agent and Safety agents scheduled for 2026. These are not chatbot features added to the interface. They are domain-specific agents built on large language models from Anthropic and Amazon Web Services Bedrock, trained on life sciences regulatory workflows, and priced on a token consumption basis rather than included in the base subscription.

The token-based pricing model is structurally important. It means Artificial Intelligence adoption drives revenue expansion from the existing installed base without requiring new seat additions or new product purchases. A pharmaceutical regulatory affairs team that uses the Health Authority Interactions Agent to draft submission responses is consuming tokens on every interaction. As agent adoption scales across the 1,500-plus customer base, a new revenue layer compounds on top of the existing subscription base.

The financial contribution from Artificial Intelligence agents is expected to be modest in fiscal year 2027. Management has been deliberate about framing this as a multi-year adoption curve rather than an immediate revenue driver. The opportunity is real, the infrastructure is built, and the pricing model is in place. The question is adoption pace — which will be tracked through token consumption metrics once Veeva begins disclosing them.

eCTD 4.0 — The Mandatory Infrastructure Upgrade Cycle

As detailed in the moat analysis, the global transition to electronic Common Technical Document version 4.0 represents a forced infrastructure upgrade cycle for every pharmaceutical company managing regulatory submissions. The United States Food and Drug Administration has set a mandatory adoption deadline of 2029. Japan’s Pharmaceuticals and Medical Devices Agency mandated adoption from April 2026. The European Medicines Agency began accepting version 4.0 submissions in December 2025.

Veeva is already building the compliant version of its Vault Regulatory Information Management suite for electronic Common Technical Document 4.0. This is not an optional product enhancement, it is a regulatory mandate that every Vault Regulatory Information Management customer must adopt. That mandatory upgrade cycle generates professional services revenue for implementation, potential uplift in subscription pricing for the new capabilities, and creates a natural moment for pharmaceutical companies to evaluate whether their entire regulatory submission workflow should be modernized simultaneously.

The electronic Common Technical Document 4.0 cycle also creates an opportunity for Veeva to displace legacy regulatory information management installations at companies that have not yet standardized on Vault. A pharmaceutical company facing a mandatory submission format upgrade at a legacy Oracle or in-house system faces a decision: invest in upgrading a legacy platform or migrate to the industry standard. The regulatory deadline makes that decision urgent rather than deferrable.

Emerging Biotech — The Fastest Growing Customer Cohort

Veeva finished fiscal year 2026 with 1,552 total customers, including 1,196 in Research and Development and Quality Solutions. The emerging biotech cohort (companies with fewer than 500 employees running their first regulated clinical programs) is the fastest growing segment of the customer base and the segment with the lowest current penetration relative to the total addressable market.

The biotech funding cycle of 2020 through 2022 created a generation of well-capitalized emerging biotech companies that are now entering Phase II and Phase III clinical development. Each one of those companies needs a validated clinical data management system, a trial master file application, a regulatory information management platform, and eventually quality documentation infrastructure. The Veeva Basics platform, a simplified, lower-cost entry point for smaller companies is designed specifically to capture this cohort before they grow into full enterprise customers. The Basics entry point is strategically important because it creates customer relationships early in the company lifecycle, when switching costs are lower, with the expectation that those customers become full-platform users as they scale.

Adjacent Verticals — Consumer Products and Beyond

Veeva’s Quality Cloud has been extended beyond life sciences into adjacent regulated industries including consumer packaged goods, foodand beverage, and chemicals, all industries with Good Manufacturing Practice-adjacent quality management requirements. These verticals are not the primary growth driver in the near term, but they represent optionality above the base case.

The strategic logic is sound. The regulatory complexity is lower than pharmaceutical, the switching costs are the same, and the Quality Cloud product requires minimal modification to serve these adjacent markets. Veeva’s quality management and documentation products are being positioned as the standard for any regulated manufacturing environment not just pharmaceutical. The total addressable market expansion from adjacent verticals is not modeled in the base case and represents upside optionality rather than a required assumption.

The $6 Billion Revenue Run Rate Target

Management has guided to a $6 billion revenue run rate by 2030, approximately double the current $3.2 billion revenue base. Achieving that target requires roughly 13% compound annual revenue growth from fiscal year 2026 through fiscal year 2030 across all segments. The growth vectors described above: Contract Research Organization channel, Artificial Intelligence agent token revenue, electronic Common Technical Document 4.0 upgrade cycle, emerging biotech penetration, and adjacent verticals collectively represent the pathway to that target above and beyond organic growth in the existing installed base.

10. COMPETITIVE LANDSCAPE

Commercial Solutions faces the most visible competition, especially from Salesforce. That deserves attention, but it should not be confused with broad platform-level competition across Veeva’s full product set. In Research and Development and Quality, the more relevant comparison is with older incumbents such as Medidata and Oracle Health Sciences. That part of the market still looks more like a share-gain opportunity for Veeva than a market where a new entrant is taking the lead.

Commercial Solutions Competitors

Research and Development and Quality Competitors

11. RISK REGISTER

12. MY CONVICTION BUILDER SUMMARY

• Founder-led culture and a long record of focused execution. Peter Gassner has led Veeva since 2007 with no dilutive transformative acquisitions and no guidance misses of consequence.

• Research and Development and Quality have become the more important growth engine while carrying stronger workflow entrenchment than Customer Relationship Management. Seven consecutive quarters of 21% year-over-year growth through the Customer Relationship Management transition noise.

• The first share repurchase authorization after 18 years of zero capital return is a meaningful change in capital allocation philosophy. A founder with a track record of deliberate capital allocation stating that the stock is cheap.

• The balance sheet remains exceptionally strong ($6.6 billion net cash, zero financial debt) giving management flexibility without needing external capital. That cash balance must be deployed.

• Vault Customer Relationship Management migration is executing ahead of expectations. As of January 31, 2026, 125+ customers are live on Vault CRM, 10 of the top-20 global pharmaceutical companies have committed, and the December 2029 end-of-support deadline creates a non-deferrable migration clock. The transition story is not purely defensive, it is converting.

• The Food and Drug Administration’s 2025 Computer Software Assurance guidance appears to deepen the moat on the Quality Cloud side of the stack, shifting validation from a product certification exercise to an organizational capability exercise that is specific to each customer’s implemented environment. Nonbinding guidance, but directionally constructive for validated workflow switching costs.

• Salesforce Life Sciences Cloud (the primary Customer Relationship Management competitive threat) is still under active development. Customer commitments to Salesforce are largely based on a product roadmap and promises rather than a fully delivered, GxP-validated system proven at scale in a pharmaceutical commercial environment. The competitive threat is real but materially less advanced than the bear narrative implies.

• Veeva Artificial Intelligence Agents launched December 2025 with regulatory-specific agents including a Health Authority Interactions Agent scheduled for August 2026. Token-based pricing confirmed for fiscal year 2027. The 10-K confirms Veeva’s AI Agents run on large language models from Anthropic and Amazon Bedrock are embedded in production workflows, not a roadmap item. This is option value above the base case.

• The IQVIA litigation (previously the largest binary legal risk in this register) was fully resolved on August 13, 2025. Neither party paid damages. All claims and counterclaims were dismissed with prejudice. Veeva paid approximately $31M in contingency fees to its own law firms, recorded as a one-time G&A charge. The legal overhang that obscured the risk-reward for two years is gone.

• The Ostro acquisition (March 10, 2026, ~$100M cash plus equity retention) is Veeva’s first disclosed M&A in 2026. Ostro provides an AI-driven patient and physician engagement chat platform for life sciences. The acquisition signals that Gassner is willing to deploy the balance sheet on more bolt-on capability to expand the Vault CRM Patient CRM module with a validated, AI-native engagement layer. Watch for integration into Vault CRM Suite as the primary use case.

13. KPI TRACKING FRAMEWORK AND KILL TRIGGERS

Confirmation Signals — What Must Continue

• Vault Customer Relationship Management top-20 committed count advancing toward approximately 14 by end of calendar year 2026. Current: 10.

• Research and Development and Quality subscription revenue growth sustaining 18% or above for four consecutive quarters.

• Net diluted share count turning negative: two consecutive quarters of net reduction validates buyback execution thesis.

• Non-GAAP operating margin recovering toward 43 to 44% by fiscal year 2028 as Research and Development tax deduction lapping fades.

• Fiscal year 2028 revenue guidance at the fiscal year 2027 earnings call at or above 15%.

• Buyback pace consistent with 18-month completion timeline for the $2 billion program.

Kill Triggers — Thesis Invalidation

• Salesforce Life Sciences Cloud confirmed wins among top-20 biopharma exceeding six. Any count above six triggers bear probability revision upward.

• Research and Development and Quality subscription revenue growth decelerating below 17% for two consecutive quarters. This is a business deterioration signal, not a valuation trigger.

• Net diluted share count increasing for three consecutive quarters despite the $2 billion authorization.

• Fiscal year 2028 revenue guidance below 13% at the fiscal year 2027 earnings call.

• Peter Gassner departure or significant equity reduction beyond normal estate planning diversification.

• Food and Drug Administration enforcement action or material guidance change to 21 Code of Federal Regulations Part 11 that reduces validation requirements in a way that structurally lowers switching costs.

14. PORTFOLIO ROLE AND POSITION SIZING FRAMEWORK

Veeva is built for the center of a concentrated portfolio. The combination of regulatory moat depth, revenue visibility, founder-led governance, and a balance sheet with $6.6 billion in net cash checks every box a long-duration compounder requires. This is not a speculative position. It is not a turnaround. It is a high-quality business temporarily mispriced because the market is focused on a bounded, well-understood transition in one revenue layer while ignoring what the rest of the platform is doing.

In a concentrated portfolio of 10 to 15 positions, a business like Veeva earns an anchor allocation. The characteristics that define an anchor holding are straightforward: durable moat, high free cash flow conversion, founder or mission-aligned management, a balance sheet that does not require external capital, and a valuation that does not require aggressive assumptions to generate an acceptable return. Veeva meets all five. At a price that implies 4% annual revenue growth for a decade against a business compounding Research and Development and Quality revenue at 21%, the entry does not require the bull case to work. It requires only that the business does not stagnate.

Position Sizing Principles

The right initial position in a business of this quality and at this valuation is meaningful, large enough to matter to overall portfolio returns, not so large that short-term volatility around the Customer Relationship Management transition forces a decision. For a 12-position concentrated portfolio, a 10 to 12% allocation at entry is appropriate given the risk-reward: the hurdle rate is cleared at $180, the bear case still produces a real return, and the impairment scenario (where 72 cents on the dollar is recovered) is structurally better than most businesses in genuine distress.

Sizing should increase on confirmation, not on price weakness alone. The confirmation signals are specific and trackable: Vault Customer Relationship Management top-20 committed count advancing, Research and Development and Quality subscription growth sustaining 17% or above, and net diluted share count turning negative. If those arrive together, the case for adding toward a full anchor allocation strengthens on fundamentals rather than on conviction alone.

Entry Discipline

The reverse DCF establishes $180 as the price at which a 10% annual return requires only 4% revenue CAGR over ten years. That is the floor entry price where even modest execution delivers an acceptable return. The probability-weighted post-cut IRR of 17.63% (clearing my 17.5% hurdle by 13 basis points) is derived from that entry. Above $200, the margin between the market-implied growth rate and the bear case narrows and the risk-reward deteriorates. The entry price is the discipline, not the thesis.

Investors with a higher hurdle rate or a shorter holding period may find the margin thinner than they require. The 13 basis point clearance is not a comfort margin, it is the honest output of the model at the stated entry price. The justification for holding is Tier 1 quality classification, not mathematical headroom. A business where the bear case returns capital and the impairment scenario recovers 72 cents requires less mathematical margin than a lower-quality business where the same scenarios produce permanent loss of capital.

Why Veeva Works as a Core Anchor

The best concentrated portfolios are built around a small number of businesses where the long-term outcome is highly probable even if the short-term path is uncertain. Veeva fits that description precisely. The validated workflow moat does not erode between quarters. The Research and Development and Quality cloud does not disappear if the Customer Relationship Management transition takes longer than expected. The $6.6 billion net cash balance does not evaporate. The founder is still running the business and has put his capital allocation reputation on the line with a $2 billion buyback commitment.

A decade from now, the probability that Veeva is still the dominant platform for life sciences research, development, quality, and regulatory workflows is high. The probability that it has been displaced by a horizontal competitor that could not clear the Good Practice validation requirements is low. The probability that the pharmaceutical industry stopped needing software to manage drug development is essentially zero. Those three observations, combined, are why Veeva earns a position at the center of a concentrated portfolio rather than at the periphery.

15. WHAT HAS TO GO RIGHT — AND WHAT COULD GO WRONG

What Has to Go Right

This is not a position where everything works automatically. The following are the specific conditions that must be met for the bull and base case returns to materialize. Each is tied to a measurable, trackable outcome, not a hope.

What Could Go Wrong — Specific Risk Linkage

Each risk below is mapped to the specific financial and thesis impact if it materializes — not merely flagged as a generic concern. Probability and severity assessments appear in the Risk Register in Section 12. Color coding in the Thesis Impact and Kill Trigger columns: amber indicates thesis impaired but investment remains viable; red indicates thesis-breaking or immediate review required.

16. CONCLUSION

The reverse DCF is the cleanest summary of where we are. At $180, the market is pricing Veeva as if revenue grows at 4% annually for a decade. That is slower than nominal GDP. It is slower than pharmaceutical industry spending growth. It is less than one-third of the rate at which the Research and Development and Quality cloud compounded in fiscal year 2026. The market has taken a known, bounded commercial transition, one product layer, one platform migration, one defined deadline and used it to price the entire business as if the franchise is structurally impaired. It is not.

The moat in the regulated workflow stack is not weakening. It is deepening. Every customer that completes a Vault CRM migration unifies their commercial platform with their Research and Development infrastructure, increasing cross-platform switching costs above what they were under legacy architecture. Every customer that implements eCTD 4.0 regulatory workflows builds another organizational capability that cannot be transferred to a competitor. Every pharmaceutical company that adopts FDA Computer Software Assurance-native quality processes on Vault becomes harder to displace, not easier. The market has spent two years pricing a transition. The transition is executing, the deadline is hardening, and the underlying platform is compounding.

Two deadlines converge in 2029. The legacy CRM end-of-support in December 2029 forces commercial migration decisions. The FDA mandatory eCTD 4.0 deadline in 2029 forces regulatory infrastructure decisions. Both require platform choices. Both favor Veeva’s integrated position. Both generate professional services revenue regardless of which CRM platform a customer ultimately selects. The window of uncertainty does not extend indefinitely, it has a closing date. Investors who are willing to hold through the window own the outcome on the other side.

Peter Gassner’s $2 billion repurchase authorization after 18 years of zero capital return is not a routine capital allocation signal. It is a founder with perfect information about his business making a personal credibility commitment that the stock is undervalued at the current price. The balance sheet that funded that commitment ($6.6 billion in net cash with zero debt) is a permanent structural advantage that most software businesses can only simulate. Combined with $1.35 billion in annual free cash flow and a margin profile that expands structurally as the Salesforce royalty wind-down takes effect, the capital compounding story is just beginning.

Veeva at $180 does not require the bull case. It requires only that the business does not stagnate. That is a low bar for a platform with this regulatory entrenchment, this management team, this balance sheet, and two mandatory infrastructure deadlines arriving simultaneously in the next three years. The margin of safety is not in the 13 basis points by which the probability-weighted IRR clears the hurdle. It is in the quality of the business that makes the bear case still produce a real return and the impairment scenario recover 72 cents on the dollar. This is what a core anchor holding looks like.

Nothing in this publication is investment advice. All of this reflects my personal views and is for informational and educational purposes only. Past performance does not guarantee future results.

I didn’t build this system overnight. And honestly, I didn’t build it because I’m some kind of investing genius. I built it because I lost money the hard way and got tired of not knowing why.

My background is accounting. I’ve always been wired to think in systems and processes. But for a long time, that didn’t translate to my investing. I’d find a company I liked, do some reading, convince myself the price made sense, and buy. No real process. No checklist. No way to know if a bad result came from a bad decision or just bad luck. When you can’t tell the difference between those two things, you can’t actually get better.

2020 broke that wide open. I made the worst investing decision of my life that year and lost over a third of my portfolio. I’ve written about exactly what happened — you can read it here if you want the full story. But the short version is this: I had no framework, no risk management, and no written process. I was just winging it and calling it investing.

So, I stopped winging it. I spent the next few years reading everything I could find, studying the investors I respected most, testing ideas with real money, and building something I could actually hold myself accountable to. The journal entries from that period run to hundreds of pages. The framework got rewritten every time the market showed me a gap in my thinking.

What came out the other side is what I call my Investment Constitution. It’s the set of rules, gates, and frameworks that governs every position I own, every analysis I publish, and every exception I even consider making. This piece lays the whole thing out, because every deep dive I publish going forward will reference it, and I want you to be able to hold my work to the same standard I hold myself.

Subscribe now

My Past Performance

I’m going to share my numbers straight. That means including the years that hurt.

* 2020 was the worst investing decision of my life and the reason this framework exists. Read the full story here: “The Most Expensive Lesson I Ever Learned About Investing”

I’m including 2020 because leaving it out would be dishonest, and also because it’s the most important year in the table. Losing 36% in a single year isn’t bad luck. That’s what happens when you invest without a process. No quality filters, no position sizing discipline, no written thesis, nothing. I just owned things and hoped.

Once the system was in place, the results changed. From 2021 through 2025, the portfolio compounded at roughly 29% per year across five full years. That included a -11.7% year in 2022, which I’ll get to in a second. The cumulative return including 2020 is +109.4%, which means $100 grew to $209 across the full period.

2022 was painful, but it was a useful kind of painful. Quality growth stocks got crushed across the board when interest rates spiked. Concentration in high-multiple businesses was exactly the wrong place to be that year. The framework didn’t protect me from the losses. What it did was keep me from making them permanent. Every business I owned still passed its quality gates. The underlying theses were intact. So I held. That decision is what made 2023, 2024, and 2025 look the way they did.

2026 is currently running at -8.4% YTD. Same situation. Prices are down. The businesses aren’t broken. Those are two completely different things, and knowing the difference is most of what this framework is actually for.

My Core Conviction

The whole framework is built on one belief: owning a small number of exceptional businesses, and holding them through volatility, builds more wealth than spreading money across dozens of average ones.

Diversification feels safe. It isn’t. It just means your winners can’t move the needle because they’re too small a piece of the portfolio. Concentration is how conviction actually gets rewarded.

I run 10 to 12 positions. Each one with varying allocation percentages based on my conviction. If a position drifts below 2%, it either gets built back up or it gets sold. I call anything below 2% a zombie position, it’s too small to matter if it works and too easy to ignore if something goes wrong. That’s a dangerous combination. Zombie positions are a lazy habit I’ve written out of my process entirely.

My Investable Universe

The portfolio runs two separate mandates. Different universes, different names, but the same return hurdle and the same quality standard.

The Perennials are named after the flowers that come back year after year no matter what season you’re in. These are the proven compounders, businesses that have already demonstrated everything you’d want to see. Wide moats. High returns on capital. A track record long enough to take seriously. Think Visa, Constellation Software, or FICO. The question with a Perennial is never whether the business is great. It’s whether the price makes sense right now.

The Seedlings are my favorite part of this whole thing. A Seedling is a business that has everything a future Perennial has: the founder with skin in the game, the niche dominance, the switching costs, the margins, the reinvestment runway, but the market hasn’t figured it out yet. These are usually founder-led businesses in the $100M–$2B market cap range that most institutional investors won’t touch because they’re too small to move the needle on a multi-billion dollar fund. That’s not a problem. That’s the opportunity. The mandate is simple: find the next Berkshire Hathaway before it becomes Berkshire Hathaway.

Both mandates get held to the exact same return standard. A Seedling doesn’t get a free pass because it’s small and exciting. Being small and overlooked is only an edge if the business is genuinely excellent. If it’s not, small and overlooked is just small and bad.

My Hard Gates

Before I touch a single valuation number, every company has to clear a set of binary gates. Not guidelines. Not preferences. Hard requirements. One failure and I move on, no matter how interesting the valuation looks.

Perennial Gates:

Gate 1 — Management and Ownership Alignment Founder-led preferred. Acceptable alternatives, any one of which clears the gate:

• An operator with 5+ years of tenure, ≥3% equity ownership, and a verifiable track record of per-share value creation

• Backing from a named, long-term concentrated investor with a documented track record of backing compounders — concentration and holding horizon matter, index-weight institutional ownership does not qualify

• A founding family retaining meaningful board influence and equity ownership even if no longer in the operating role

Gate 2 — Shareholder Value Creation Total shareholder value creation ≥ 15% annually, composed of any combination of organic revenue growth, acquisition-driven growth, net buyback yield, and dividend yield, with the following archetype-specific conditions:

• Serial acquirers: inorganic growth counts in full provided ROIIC on deployed acquisition capital exceeds 15% on a trailing basis — the discipline of the capital deployment is the gate, not the source of growth

• Organic compounders: organic revenue growth must contribute at least 8% of the composite — capital return supplements but does not replace genuine business growth

• Mature capital returners: buyback yield counts in full provided the business generates genuine free cash flow and is not funding returns through leverage

In all cases, inorganic growth or buybacks funded primarily by net new debt do not count toward the composite.

Gate 3 — Customer Retention Quality Demonstrable customer retention quality appropriate to the business model:

• Subscription businesses: NRR ≥ 90%

• Transactional models: gross revenue retention ≥ 85%

• Service businesses: contract renewal rate ≥ 85%

Gate 4 — Margin Quality Gross margins in the top quartile of direct peers. The absolute number is less important than competitive positioning — a business with structurally superior margins relative to its peer set has demonstrated pricing power and operational efficiency that matters regardless of the industry baseline.

Gate 5 — Balance Sheet Quality Net cash on the balance sheet, or free cash flow that covers all debt within 2 years.

Gate 6 — Reinvestment Runway Demonstrable reinvestment runway of at least 10 years — new geographies, products, verticals, or acquisition targets that can absorb capital at returns above cost of capital. A business with a dominant market position still clears this gate if it can demonstrate adjacent reinvestment opportunities that extend the compounding horizon.

Gate 7 — Customer Concentration No single customer representing more than 25% of revenue.

Gate 8 — Governance No active regulatory investigation of the company or its leadership, no material related-party transactions, no dual-class structure that removes shareholder accountability entirely.

Seedling Gates:

Gate 1 — Market Cap Between $100M and $2B at the time of initiation.

Gate 2 — Liquidity Average daily trading volume sufficient to build a full 3% position within 10 trading days.

Gate 3 — Management and Ownership Alignment Founder, founding family, or a long-tenured operator with ≥5% equity ownership and demonstrated owner-operator capital allocation behavior. Alternatively, a named long-term concentrated investor with a meaningful position and a documented track record. Insider buying on the open market by any of the above is a strong confirming signal regardless of which version clears the gate.

Gate 4 — Shareholder Value Creation Total shareholder value creation ≥ 15% annually on the same composite basis as the Perennial gate, with the same archetype-specific conditions. For early-stage Seedlings with limited acquisition history, organic growth is expected to carry the majority of the composite — capital return is a supplement, not a substitute.

Gate 5 — Margin Quality Gross margins in the top quartile of direct peers.

Gate 6 — Customer Retention Quality Demonstrable customer retention quality appropriate to the business model:

• Subscription businesses: NRR ≥ 90%

• Transactional models: gross revenue retention ≥ 85%

• Service businesses: contract renewal rate ≥ 85%

Gate 7 — Balance Sheet Quality Net cash on the balance sheet, or a documented path to FCF-positive within 2 fiscal years.

Gate 8 — Acquisition Discipline No single acquisition representing more than 35% of trailing 12-month revenue in the prior 24 months.

Gate 9 — Customer Concentration No single customer representing more than 25% of revenue.

The reason these are binary is simple: a cheap price doesn’t fix a broken business. If something fails a gate, the answer is to pass, not to talk yourself into it with a lower entry multiple. That’s exactly the kind of motivated reasoning that blows up portfolios.

Not Deal Breakers, but Preferred (Conviction Builders)

Management and Alignment

• Insider buying on the open market in the last 12 months: not options, not scheduled plan purchases, open market buying with personal capital

• Founder still active in product or strategy even if no longer in the CEO role

• Management compensation tied to per-share value creation rather than revenue growth or headcount milestones

• Long-tenured executive team with key leaders with 5+ years in their current roles

• A consistent history of underpromising and overdelivering on guidance

Business Quality

• NRR above 110% - customers are spending more each year without being asked

• Recurring revenue above 80% of total revenue

• Rule of 40 above 40 for SaaS businesses; ROIIC above 20% for serial acquirers

• Negative working capital, customers pay before costs are incurred

• Pricing power demonstrated through multiple rate increases without meaningful churn

• Operating leverage visible in the historical numbers: margins expanding as revenue grows

• Capital-light model where incremental revenue requires minimal incremental cost

Market Position

• TAM growing faster than GDP with no signs of structural deceleration

• Fragmented competitive landscape the company is systematically consolidating

• A dominant local or vertical position that would take a competitor years and significant capital to replicate

• Network effects: the product becomes more valuable as more customers use it

Capital Allocation

• Share count flat or declining: buybacks offsetting dilution at minimum

• SBC below 5% of revenue and trending down as a percentage over time

• Disciplined M&A history: no transformative bets, no obvious overpaying, earn outs that reflect pricing discipline

• No large dividend: capital should compound inside the business before being distributed

• ROIC on acquisitions demonstrably above cost of capital within 3 years of closing

Valuation and Return Profile

• Entry P/FCF below 20x for Perennials, below 18x for Seedlings

• Probability-weighted IRR clearing the hurdle by at least 300 basis points, not just squeaking over

• Bear case IRR above 8%, downside is slower compounding, not permanent impairment

• Reverse DCF implies the market is pricing in meaningfully less growth than the business has historically delivered

On exceptions: I’m not so rigid that I’ll ignore a legitimate edge case. Sometimes a gate miss is genuinely temporary or not as bad as the raw number makes it look. But here’s the rule: every exception gets a written journal entry before I act. I have to explain exactly what gate I’m passing on, why that doesn’t break the thesis, how long I’m giving it to resolve, and what would force an exit if I’m wrong. If I can’t write that entry clearly, the exception doesn’t happen. The journal is what keeps me honest when the market is making something feel more urgent than it is.

My IRR Framework

Every position runs through the same valuation process. I build four scenarios: bull, base, bear, and impairment, then assign a probability to each and calculate a blended expected return. That return then gets discounted through a tier multiplier system I’ll explain in the next section. What comes out the other end must clear a minimum hurdle of 17.5% expected IRR.

That 17.5% figure isn’t arbitrary. It’s calibrated to produce a 15% post-tax, real-world return after accounting for capital gains taxes, execution friction, and cash drag. A flat 14% cut gets applied to the blended IRR. 17.5% × 0.86 = 15.1%. That’s the target.

How I assign scenario probabilities:

• Bull (optimistic but genuinely achievable): 20–35%

• Base (most likely outcome): 40–55%

• Bear (things go wrong): 14–25%

• Impairment (permanent thesis break, near-zero recovery): 4–10%

These ranges aren’t arbitrary either. They reflect realistic base rates for quality businesses over long holding periods. I have to document the rationale for every weighting. And if I ever want to push the bull case above 35%, I need a written justification for why. The easiest way for a framework to quietly fall apart is letting optimism creep into the probability weights.

Here’s a concrete example. Say I’m looking at a high-quality SaaS business. My bull-case IRR is 31%, my base-case IRR is 23%, my bear-case IRR is 10%, and my impairment case is -50%. I weight those outcomes at 30%, 45%, 18%, and 7%, respectively. That produces a raw blended IRR of 18.0% before any additional conservatism. I then apply tier-based haircut multipliers to the operating scenarios — 0.95x to the bull case, 0.86x to the base case, and 0.55x to the bear case — before blending again. The post-haircut blended return falls to 15.2%. The raw math may suggest the price is fair. The haircut framework helps show that fair is not the same as compelling.

The model isn’t the point. The process of building it honestly is.

The Business Model Tier Multiplier System: My defense against biased optimism (and stupidity)

Not every quality business carries the same risk, and the multiplier system prices that in. Every position gets assigned a tier based on durability of the revenue, unit economics, competitive advantage, management quality, margins, balance sheet, governance, and so on. The better the tier, the less severe the discount. A weaker business has to show a much higher raw IRR to clear the same 17.5% threshold. The system is self-correcting that way.

Tier 2 Core and Tier 1TT carry the same multipliers on purpose. The “TT” label tells you about the size and liquidity universe, not the quality level. What it does affect is position sizing, which I cover below. And to be clear about what the multipliers mean in practice: a Tier 3TT business needs a raw bull case IRR well above 25% just to clear the same hurdle a Tier 1 Perennial clears with a 22% bull. That gap is the whole point.

Tier assignments get reviewed every year and any time something material changes. A Seedling that hits its milestones and proves out its margins can move up. A Perennial that loses its founder or triggers a governance issue gets looked at immediately.

My Rules That Prevent Spreadsheet Fiction (and my ignorance)

The single easiest place to cheat in a long-duration model is the exit multiple. Most people anchor their terminal multiple to whatever the stock trades at today and then compound that assumption forward for ten years. The math looks fine. The logic is flawed.

I’ve spent more time on the multiple governance rules than anything else in the constitution, because this is where it’s hardest to stay honest with yourself. Four rules govern every model I build:

1. Starting multiples reflect fair value, not market price. What the stock trades at today is an input to position sizing. It is not the anchor for what the business is worth. If the market is pricing a business wrong, that’s the opportunity. Letting the market price set my starting multiple assumes the market is right, which defeats the entire purpose.

2. Terminal multiples must compress by at least 20%. A business growing free cash flow at 10% in year ten doesn’t deserve the same multiple it commanded when it was growing at 25%. Assuming flat multiples across a decade isn’t being optimistic. It’s making a modeling error.

3. Business type sets the range; quality sets the placement. I keep a reference table of permissible multiple ranges by business type — SaaS, payments, serial acquirer, industrial compounder, and so on. Where a business lands within that range depends on its specific quality evidence: NRR, return on incremental invested capital, margin trajectory. Seedlings start at the low end of the range by default.

4. Both models have to agree. Every position gets built two ways, typically a P/FCF model and an EV/EBITDA model. If the two IRR outputs diverge by more than 300 basis points, I don’t average them. I go back and find the calibration error. Divergence that wide means something in the inputs is wrong.

Position Sizing and When to Sell

These rules aren’t flexible. They’re what keeps the portfolio from drifting into something I didn’t intend to build.

Allocation Sizing

Tier 1 or Tier 1.5 Perennial are not capped. If a Tier 1 or Tier 1.5 business compounds beyond that weight, I let it run. Watering the flowers is the entire point of identifying them correctly in the first place.

Tier 2 Perennials are capped at 8%. They have not earned the right to run uncapped, and the cap exists to enforce that distinction.

Seedlings of any tier are capped at 8% until they earn reclassification as a Perennial. A Seedling that has outgrown its tier should be formally reviewed against the Perennial gates and if it passes, it graduates and the run rules apply. If it does not pass, the cap holds regardless of how much I like the business.

Nothing stays below 2%. A sub-2% position is either a mistake I have not cleaned up or a conviction I have not committed to. I have 30 days from the point a position drops below 2% to either build it or exit it. The only exception is a deliberate tracker position in a business I am still researching, which requires a defined decision deadline.

At all times a minimum of 5% of the portfolio is held in cash or a liquid Tier 1/1.5 position that can be sold within one trading day. This is not an investment decision; it is an operating constraint that keeps me solvent through volatility and able to act when dislocations appear.

Margin

Margin is a tool I use rarely and only in two specific circumstances: averaging down into a high-conviction Tier 1 or Tier 1.5 position during a dislocation or bridging a short-term tax-loss harvest where I intend to reenter within 30 days. In both cases the use is temporary, defined, and has a clear exit plan before I deploy it. Margin is never used to fund a new position I could not otherwise afford, to chase a move, or to avoid making a hard capital allocation decision. Excess liquidity must be at least 25% of total portfolio value, no exceptions.

When I sell:

I follow a Philip Fisher-style sell discipline. Price is not a reason to sell a great business. IRR compression from appreciation is not a reason to sell a great business. Position size is not a reason to sell a great business. The business has to have changed, or I have to have been wrong about it from the start.

There are three legitimate reasons to sell:

One: I was wrong. The original analysis contained a material error. The moat I thought existed does not, the management quality I underwrote is not there, the competitive position is weaker than I believed. This is not the business deteriorating, this is me discovering I bought the wrong thing. The honest version of this trigger requires separating new information from price noise. A bad quarter is not proof I was wrong. Evidence that the core thesis was built on a flawed premise is.

Two: The business has genuinely deteriorated. The company no longer meets the criteria that made it worth owning. A hard gate has been violated and not remediated within one fiscal year. The moat is narrowing. The management team that drove the original thesis has left and not been replaced in kind. The reinvestment runway has closed. This is different from a difficult period — every great business has difficult periods. The question is whether the difficulty is cyclical or structural. I sell when I conclude it is structural and irreversible.

Three: A dramatically better opportunity exists and this is my lowest conviction holding. Capital is finite. If a new business clears the gates by a wide margin and my portfolio is fully allocated, something has to move. The position that goes is always my lowest conviction holding at that moment, not my smallest position, not my most recent addition, but the one I would be least comfortable holding for the next decade if I could never add to it again.

Everything else: valuation, price movement, macro fear, market sentiment, IRR compression from appreciation alone, is noise. I do not act on noise.

My Investment Journal

Every meaningful decision I make gets written down before I make it. Not after. Before.

The journal does three things for me. First, it forces me to actually understand what I’m buying. If I can’t write the thesis clearly, I don’t understand the business well enough to own it. Second, it gives me something to read during a drawdown. When a position is down 30%, the journal entry from initiation is what tells me whether the thesis is broken or whether I’m just uncomfortable. Those are not the same thing, and in the moment they can feel identical.

Third, it’s how I manage exceptions. Any time I want to pass on a gate, change a tier, or size differently than the rules say, I have to write it down. What rule am I overriding, why, how long I’m giving it to resolve, and what forces an exit if I turn out to be wrong. If I can’t write a convincing entry, the exception doesn’t happen.

I’ve found that the act of writing it is usually enough to know whether it’s a good idea or not. Good decisions are easy to articulate. Motivated reasoning tends to fall apart on paper.

What’s Coming Next

The next piece will be the first deep dive: a full analysis of a specific business run through everything you just read. That’s where the framework becomes real.

Then, I’ll be publishing approximately one deep dive per month, assuming time allows and I have a good idea to share. My goal is to give you quality, not quantity.

Every piece will follow the same structure: a verdict up front, a plain-English breakdown of the business, a moat analysis, a hard gate scorecard, a financial quality review, a reverse DCF to show what the current price implies and why I think it’s wrong, a full scenario model with the post-haircut IRR, and the specific KPIs I’ll be watching to know if the thesis is playing out.

The Seedlings coverage is what I’m most excited about. The whole point is to build a research record that documents the thesis at formation, not after the fact. Anyone can write about Constellation Software now. The interesting question is what Constellation Software looked like in 2005, before it was obvious. That’s what I’m trying to do with every Seedling I cover.

If you’re reading this early, you’re in at the beginning. I’d rather build a small audience that actually engages with the work than a large one that just wants a stock tip.

First deep dive is next month. Let’s go.

Nothing in this publication is investment advice. All of this reflects my personal views and is for informational and educational purposes only. Past performance does not guarantee future results.

It did not start with a philosophy. It did not start with discipline. It started with a mistake.

In 2020, during the peak of the COVID frenzy, I took just about every spare dollar I had, ~$30,000 and put it into a tiny biotech stock chasing a “Healight” treatment. If this sounds familiar, it may be because President Trump talked about this in a public press conference as a potential corona virus treatment (read about it here: Trump Muses About Light as Remedy, but Also Disinfectant, Which Is Dangerous - The New York Times)

It felt like my chance to finally get ahead. People online were hyped, the stock was exploding, and after years of feeling like I was spinning my wheels, I convinced myself this was the moment everything changed. Bear in mind, I was in my late 20’s with a wife, two children, and stuck in a dead-end job – this money was substantial to me and my family at the time.

Several months later, 95% of that “investment” evaporated. And while the money hurt, what hurt more was realizing it wasn’t thirty thousand dollars I lost. It was years of work. Years of saving and grinding and trying to build something real. Not to mention, my wife was none too happy with me but still supported me anyways.

It took the wind out of me. It was embarrassing. For a long time, I just didn’t talk about it, I pretended it didn’t happen, but internally this was fuel that lit an all-consuming fire.

That loss ended up doing something important. It forced me to stop chasing shortcuts and start building an actual foundation. I knew the only way I could make that money back was to get it the same way I lost it – in the market. This pushed me to what eventually led me to create my Investing Constitution, define how I make decisions, understand risk in a real way, and figure out what kind of investor I wanted to become. It was painful tuition, but tuition all the same. Looking back, the crazy part is that it led me to something I genuinely love - studying businesses, writing, learning, and being part of the market every single day.

Ironically this was one of the best things to ever happen to me.

The Search for Understanding

When the world was locked down and the pace of life slowed, I made a decision. If I couldn’t get my money back (with the hope that I eventually would), I would gain something more valuable - knowledge.

My office became a study hall. My late nights, once spent scrolling on Facebook or stressing about COVID-19, became deep dives into investing, accounting, valuation, and business analysis. After brushing up on the “basics” from business school, I decided to learn how the best investors in the world do it and how they sustain their success.

I read and listened to everything I could get my hands and ears on. Here is a list of some of my favorites in case someone reading this finds themselves ready to go through what I call “the investment boot camp”

- Warren Buffett’s annual letters

- Benjamin Graham’s “The Intelligent Investor” and “Security Analysis”

- Everything Howard Marks has ever written – all his books and memos

- Joel Greenblatt’s “The Little Book That Still Beats the Markets”

- Morgan Housel’s “Psychology of Money”

- Lawrence Cunningham’s “Quality Investing: Owning the best companies for the long term” and “The Essays of Warren Buffet”

- Chuck Akre’s philosophy, the “three-legged stool”

- Monish Pabrai’s “Dhando Investor”

- “The Joys of Compounding”, Gautam Baid

- Richer, Wiser, Happier: How the World’s Greatest Investors Win in Markets and Life” by William Green

- Guy Speir Interviews

- Seth Klarman’s wisdom he gave in many public interviews

- The Investor’s Podcast – “We Study Billionaires”

- Business Breakdowns Podcast (Colossus)

- The Acquirers Podcast – Tobias Carlisle

- Founder’s Podcast

- Peter Lynch’s famous “One Up On Wall Street: How To Use What You Already Know To Make Money In the Market”

- “What I Learned About Investing from Darwin”, Pulak Prasad

- Terry Smith’s “Investing for Growth: How to make money by only buying the best companies in the world”

- “The Nomad Letters”, Nik Sleep

- “The Millionaire Next Door”, Thomas Stanley and William Danko

- Charlie Munger’s mental models

- Bruce Flatt’s Steady Compounder Philosophy

- Every interview given this century by all famous “Super Investors” that are on YouTube (I don’t think this is an exaggeration).

- And believe it or not, many, many more.

These weren’t books by day traders or gurus selling shortcuts. They weren’t written by people chasing excitement or trying to turn investing into entertainment. They were written by thinkers, the architects behind systems, philosophies, and disciplines that held up for decades. People who approached markets with clarity, patience, and an understanding of human behavior that went far deeper than “buy low, sell high.” What struck me most was how long-term their mindset was. They thought in decades, not days. They cared about durability, not drama. They focused on understanding businesses, not predicting stock prices. And as I worked through their idea’s day after day, something finally clicked. For the first time, I saw how unprepared I had been. I wasn’t missing “hot picks.” I was missing a foundation. A process. A philosophy. A way of thinking that could survive more than a lucky month in a bull market. Learning from these investors didn’t just teach me how to pick stocks, it taught me how to think. It showed me what good judgment looks like, what real risk is, and why discipline matters so much more than excitement. It became the turning point that shifted me from hoping to get lucky… to actually understanding what it takes to grow wealth over a lifetime.

The Moment I Finally Understood Compounding

The deeper I went into the writings of the great investors, the more I began noticing the same quiet truth running through all their philosophies. It wasn’t flashy. It wasn’t exciting. It wasn’t something you could use to impress people at a dinner party.

It was simple, almost painfully so:

Time is the most powerful force in investing, and the rarest one people actually use.

Buffett became Buffett because he never interrupted compounding. Munger built wealth by avoiding catastrophic mistakes, not by timing markets. Howard Marks obsesses over risk, not forecasts. Terry Smith focuses on cash flow, not GAAP earnings manipulated by accounting noise. Nick Sleep thought in decades, not days. Bruce Flatt built Brookfield on discipline, predictability, and “boring” excellence and became one of the most effective allocators alive in the process.

They all shared a disdain for hype. They all preferred companies with real cash flows, real moats, and real durability. They all trusted time more than timing.
And they all insisted on skin in the game - leaders who owned their decisions through ownership, not slogans.

As I studied their work, something clicked: these investors weren’t trying to be clever. They were trying to stay alive, stay rational, and stay invested long enough for compounding to do the heavy lifting.

And it finally hit me: my biggest mistake back in 2020 wasn’t bad luck,
it was choosing a terrible business.

No moat.
No durable economics.
No reinvestment runway.
No competitive advantage.

It was never built to survive, let alone compound.

The greats never touch businesses like that.

The Slow Realization: The Greats Were Playing a Different Game

The more I compared how they operated to how I used to think, the more obvious the gap became.

I chased excitement.
They chased durability.

I looked for stories.
They looked for cash flow.

I bought hype.
They bought competitive advantage.

I watched stock prices.
They watched businesses.

I sized positions emotionally.
They sized based on probability and permanence.

Most importantly, I tried to predict the next year.
They tried to own the next twenty.

Every great investor I studied had the same quiet bias for intention:
If you wouldn’t hold it for a decade, don’t buy it.

At first, I thought that was an exaggeration. Then I realized it was a survival strategy.

Most returns come from not selling.
Most losses come from selling for the wrong reason.
And the single best way to avoid both is to only buy companies you’d be proud to own for an extremely long time.

Companies with moats that widen.
Companies with leaders who have skin in the game.
Companies that reinvest intelligently.
Companies that reduce share counts instead of diluting shareholders into oblivion.
Companies whose cash flow tells you more than their GAAP earnings ever will.

It took me years and a painful lesson to understand that.

My Mistakes Weren’t About Stock Picking, They Were About Process

When I reflected honestly on the $30,000 loss, I finally saw it for what it was: the natural outcome of not having a system, not having a framework, and not having a philosophy.

I wasn’t investing, I was improvising.

I timed markets.
I trusted narratives.
I ignored evidence.
I sized hope like certainty.
I bought companies with no durable moat.
I never once asked whether the business had the ability to compound for a decade.
I was seduced by stories, charts, and hype cycles that evaporate the moment reality returns.

Meanwhile, the greats all followed the same script:

· Respect cash flow

· Ignore noise

· Favor insider ownership

· Avoid dilution

· Don’t time the market

· Don’t chase excitement

· Don’t interrupt compounding

· Own competitive advantage, not speculation

· And trust time, not adrenaline

Once I accepted that, my entire worldview began to reorganize.

The Turning Point: From Collecting Ideas to Building a System

I spent so much time reading that, eventually, the patterns became impossible to ignore.

Akre’s “three-legged stool” (management, financial strength, reinvestment runway).
Lynch’s “use what you know.”
Sleep’s “scale economies shared.”
Greenblatt’s logic around ROIC and earnings yield.
Terry Smith’s obsession with cash flow and simplicity.
Marks’ framework for risk management.
Buffett’s “don’t interrupt compounding.”
Flatt’s discipline around quality and permanent capital.

The principles were always there, but I wasn’t connecting them.

Then, slowly, I began weaving them together. And what emerged wasn’t a list of investment tips, it was a completely different way of thinking about money, business, time, and decision-making.

It became the philosophy I wish I’d had in 2020.
The one that would’ve saved me years.
The one that would’ve protected my capital.
The one that would’ve given me clarity in chaos.

And at the center of that philosophy was one idea:

Your portfolio should reflect durability, not hope and excitement.

The Discipline That Protected Me from Myself

If there is one breakthrough that changed me more than anything else, it was this:

Position sizing is where your beliefs become real.
Everything else is just talk.

For years, I sized positions based on the wrong things:

· Excitement

· Potential

· Price action

· Social media sentiment

· The “what if this becomes huge?” fantasy

I treated unproven companies like elite compounders.
I treated hope like evidence.
I treated volatility like opportunity instead of risk.

And the result was predictable:
I sized my biggest uncertainties the largest and it cost me dearly.

But as I kept studying and journaling, I started noticing the same truth appear over and over in the work of the greats:

**You size durability big, you size risk small, and you let winners, not hopes, earn their weight**

That became my defining turning point.

I realized that a risky stock sized at 2% can become 10% through compounding.
But a risky stock sized at 10% can destroy your portfolio before it ever compounds.

So, I changed and rewired my process from the ground up.

Today:

· Tier 1 compounders: the MELIs, Amazons, ASMLs, Ubers, Fortinets, Brookfields — earn large positions because they have earned trust through durability, cash flow, competitive advantage, and leadership with skin in the game.

· Tier 2 businesses sit in the middle - high quality, meaningful positions, but balanced sizing.

· Tiny Titans start small, always. They must prove their way into significance.

· Hype stocks don’t get bought at all. Boring is beautiful. Boring pays.

And above all:

I never interrupt compounding.
I never sell winners because of boredom.
And I never size hope above evidence again.

The Constitution: Where The Journey Led Me

There came a point in this journey where I realized something the greats understood long before I did:

A philosophy isn’t real until it’s written.
A rule isn’t real until it’s enforced.
And a system isn’t real until it guides you under pressure.

So, I built exactly that, the document I should’ve had a decade ago.
The guardrails that protect me from myself.
The philosophy that integrates everything I’ve learned.
The rules I intend to follow for the rest of my investing life.

My Investing Constitution.

It is the clearest expression of who I am now as an investor.
And the clearest departure from who I used to be.

Without further ado, I present to you the Shane Williamson Investment Constitution:

Purpose

Build a concentrated portfolio of elite compounders, supported by a selective allocation to asymmetric opportunities, targeting 15%+ long-term annualized returns while avoiding permanent capital impairment.

· Portfolio Structure

· 80% allocated to durable, high-quality compounders (Tier 1 & Tier 2).

· 20% allocated to asymmetric “Tiny Titans” with significant upside potential and controlled risk.

· Core Compounders

Definition:
Founder-led or founder-DNA businesses with:

· High and expanding ROIC

· Wide, durable, and widening moats

· Mission-critical products

· Long reinvestment runways

· High operating leverage

· Secular tailwinds

· Low blow-up or catastrophic risk

· Tiny Titans

Definition:
Early stage, misunderstood, or temporarily impaired businesses with asymmetric upside and higher variance.

· Position Sizing

Tier 1 Compounders:
8% to unlimited; highest-conviction, long-duration compounding machines.

Tier 2 Compounders:
5–8% positions; high-quality but more valuation- or execution-sensitive.

Tiny Titans:
3–4% positions at cost; add only during true dislocations; never exceed 5% at cost. Allow winners to grow into meaningful weight over time.

Lottery Tickets:
0.5–2% positions, only when asymmetry is extreme and accounting is clean. Very rare.

· Buying Discipline

· Buy only when the base-case 10-year IRR is 15%+.

· “Back-the-Truck” buying occurs only when IRR exceeds 20% and fundamentals remain intact despite market fear.

· Avoid adding when IRR falls below 15%, valuation is stretched, or risk outweighs return.

· Selling Discipline

Core Compounders:
Never sell unless:

· Fraud

· Permanent impairment

· Structural deterioration

Tiny Titans:
Sell when:

· Thesis breaks

· Unit economics weaken

· Accounting quality declines

· Management credibility fades

· Position size balloons without fundamental justification

· Risk Framework

Avoid:

· Structurally declining industries

· High leverage without stable cash flow

· Opaque or questionable accounting

· Terminally poor unit economics

· Fragile business models vulnerable to catastrophic downside

· Valuation Framework

· Never buy elite companies with <15% IRR expected returns.

· Great businesses still require great entry points.

· Avoid paying for perfection.

· Crash Playbook

During fear-driven selloffs:

· Deploy capital aggressively into high-quality compounders.

· Favor businesses where fundamentals remain strong while prices disconnect.

· Historically, these moments produce the highest long-term returns.

· Compounding Principles

· Favor predictable, long-duration compounding over short-term excitement.

· Stay fully invested, with dry powder optionality for dislocations.

· Never interrupt compounding without a fundamental reason.

· Decision Framework

· When choosing among quality businesses, prioritize the highest risk-adjusted IRR.

· Let evidence—not emotion—drive conviction.

· Trading Discipline

· Do not overtrade.

· Review holdings quarterly or when fundamentals materially change—not based on daily volatility.

· Emotional Discipline

· Avoid momentum-chasing and narrative-driven decisions.

· Anchor to IRR models, cash flows, competitive advantages, and long-term fundamentals.

· Optimization Goal

Maximize long-term compounding while minimizing portfolio fragility.

Attributes I Value Most in a Business

· High Insider Ownership: Prefer founders/operators with real skin in the game.

· Expanding ROIC: A core requirement for long-term value creation.

· Attractive Valuation: Buy only when long-term IRR is 15%+.

· Huge, Expanding TAM: Multi-decade structural growth opportunity.

· Market Share Expansion: evidence of durable advantage and execution.

· Widening Moats: Network effects, switching costs, regulatory advantages, mission-critical software.

· High Operating Leverage: Scalable models where incremental margins rise over time.

· Strong Secular Tailwinds: E-commerce, Cloud, payments, AI, fintech, VMS, cybersecurity, digital transformation, etc.

· Large Reinvestment Runways: New geographies, products, verticals, or bolt-on M&A.

· Long-Term Scalability: Growth that doesn’t require proportionate cost increases.

· High-Quality Management: Disciplined, transparent, rational capital allocators.

· Low Blow-Up Risk: Avoid businesses with catastrophic or unfixable downside.

· Multi-Decade Potential: Prefer businesses that can be held 10–20 years.

· Favorable Risk-Adjusted IRR: Prioritize durability over variance.

· Asymmetric 20% Bucket: Allocate 20% to early-stage, misunderstood opportunities with 5–15x potential.

Conclusion: The Investor I Became Because of the Investor I Was

When I look back at the last few years, it’s strange to think that the worst financial decision of my life is what led me to the best version of myself as an investor.

I didn’t become who I am today through winning streaks or lucky trades.
I became that person through loss, humility, reflection, and relentless curiosity.
Through the willingness to sit with reality instead of fighting it.
Through learning from people far wiser than me.
Through understanding that time, discipline, and structure matter far more than excitement or intuition.

The great investors didn’t hand me stock picks.
They handed me a worldview.

They taught me to look past headlines and hype and focus instead on:
moats, cash flows, incentives, reinvestment, durability, insider ownership, and the quiet compounding that happens when nothing dramatic appears to be happening at all.

They taught me that boring is beautiful.
That patience is a superpower.
That competitive advantage is the only thing that truly sustains high returns.
That position sizing is where beliefs become real.
That market timing is a tax on long-term wealth.
That dilution is the enemy of compounding.
That cash flow tells the truth even when GAAP earnings try to confuse you.
And that the only way to benefit from compounding is to stop interrupting it.

Above all, they taught me to think like a business owner, not a trader — to hold companies with the intention of keeping them for a decade, not a season.

And so the Constitution came naturally.
I didn’t write it because it sounded good.
I wrote it because, without it, I would drift back into the very behaviors that cost me $30,000 and years of progress.

It is the document that keeps me aligned with the investor I am trying to be — the investor who thinks clearly, sizes thoughtfully, acts patiently, and treats compounding with the respect it deserves.

If I could talk to my younger self — the one who clicked “buy” on a terrible business because it felt like the answer — I wouldn’t scold him. I would simply say:

This mistake will shape you.
This loss will refine you.
And someday, you’ll be grateful for what it forced you to learn.

Because in the end, I didn’t just recover the money.
I built the foundation that will compound for the rest of my life.

And that, more than anything in my brokerage account, is the real return on that painful tuition.

Disclaimer

This article is for informational purposes only and does not constitute financial advice. Always consult a qualified financial advisor before making any investment decisions.

Our move has been a success in every sense. I’ve started my new Finance Manager role with Grand Forest Inc., and both of our girls are thriving in their new surroundings. Adelaide has found her groove with her new softball team, full of energy and confidence, while Emmeline has made a great circle of friends and already turned our home into the go-to spot for weekend sleepovers. Jordan has been busy bringing her eye for design to life, decorating the new house and adding touches that make it feel like home.

A few months ago, I shared a picture of the mid-construction of our new home and now I am excited to show you the final product:

Now, let’s get to business. Through all these changes, I’ve found myself thinking about consistency, risk, what endures, and what compounds. Even as our daily life shifted, one constant remained: my fascination with studying great businesses, the people behind them, the value they create, and writing about them.

Among all the companies I follow, Brookfield Corporation remains my favorite business in the world. So, I figured that it would be a good topic to tackle and get me back into a solid writing routine. I’ve been a shareholder for five years, and my admiration only deepens with time. The combination of world-class management, long-term thinking, and alignment with shareholders makes it the kind of business I can own for decades.

The Quiet Giant Behind Global Capital Flows

In a market obsessed with quarterly results and headline narratives, Brookfield Corporation (NYSE: BN / TSX: BN) operates in a completely different rhythm. While others chase the next hot theme, Brookfield quietly builds and compounds value through tangible, income-generating assets. Its reach spans infrastructure, renewables, property, and credit, creating one of the most enduring wealth engines of the modern era.

For over three decades, CEO Bruce Flatt and his partners have executed a disciplined playbook: buy quality assets when others are forced to sell, improve them operationally, finance them conservatively, and recycle capital into the next major opportunity. That consistency has transformed Brookfield from a Canadian utility operator into a global investment platform managing more than $1 TRILLION in assets and producing over $6 billion a year in distributable earnings.

Brookfield is not about hype; it is about permanence. In an age defined by volatility, the firm stands directly in the path of long-term capital flows toward real assets and essential services.

The Brookfield Blueprint: How the Machine Works

To understand Brookfield, it helps to see the company as a complete ecosystem built around three closely connected segments: Asset Management, Wealth Solutions, and Operating Businesses. Each serves a unique purpose, yet all work together to form a powerful, self-sustaining engine of compounding that grows stronger with scale and time.

1. Asset Management: The Compounding Core

At the heart of Brookfield is its global Asset Management business, Brookfield Asset Management (BAM). This is the fee-generating foundation of the entire enterprise. The company manages capital for some of the world’s largest institutional investors, including pension funds, sovereign wealth funds, and insurance clients.
It oversees strategies across infrastructure, renewable energy, real estate, and private credit, all built around long-term, inflation-protected cash flows.

This segment produces high-margin, recurring fee-related earnings that expand steadily as assets under management increase. It is the most stable and predictable part of Brookfield’s business model, providing durable cash flow and consistent distributable earnings growth. With more than five hundred billion dollars of fee-bearing capital and a growing base of performance fees, the Asset Management segment remains the cornerstone of Brookfield’s compounding engine.

2. Wealth Solutions: The Next Growth Engine

The Wealth Solutions segment represents Brookfield’s bridge between institutional and individual investors, and it includes Brookfield Reinsurance (BNRE), which is the company’s fastest growing subsidiary.
This division gathers long-term, permanent capital from insurance and wealth management clients and invests that capital in Brookfield-managed strategies such as private credit, infrastructure debt, and real estate-backed lending.

Management has emphasized that Wealth Solutions will be the primary driver of Brookfield’s growth over the next five years. The company expects this segment to add several billion dollars in annual distributable earnings as insurance float and wealth inflows continue to scale.
BNRE now manages tens of billions in assets and is expanding quickly through new annuity and reinsurance partnerships.

As insurers and retirement funds search for stable, yield-oriented investments, Brookfield provides a natural home for that capital. Every new dollar of permanent insurance capital increases the firm’s management fees, expands its investment reach, and strengthens its recurring earnings base.

In effect, Wealth Solutions extends Brookfield’s model beyond institutional investors and into the broader wealth and retirement markets. It has the potential to become the largest source of growth for the company in the coming decade.

3. Operating Businesses: The Foundation Beneath It All

Beneath the Asset Management and Wealth Solutions platforms are Brookfield’s Operating Businesses, which include major holdings in Brookfield Renewable (BEP), Brookfield Infrastructure (BIP), and Brookfield Property Partners.
These entities own and operate essential real assets across energy, utilities, logistics, data centers, and commercial property. They generate the tangible cash flows that underpin the entire organization.

The Operating Businesses provide stability and optionality. Brookfield can recycle capital by selling mature assets, reinvesting in higher-yield opportunities, or using proceeds to fund share buybacks. This structure allows the company to compound value through multiple levers including cash flow growth, valuation expansion, and disciplined reinvestment.

Each of these three segments: Asset Management, Wealth Solutions, and Operating Businesses strengthens the others. Management raises and deploys capital through high-quality operating platforms, earns steady fees, recycles cash, and reinvests in new opportunities.

Together they create a perpetual cycle of value creation that compounds quietly and consistently through all types of market environments.

4. The Permanent Capital Flywheel: The Core of Brookfield’s Compounding System

Brookfield raises third-party funds, co-invests alongside them, earns fees and performance carry, and then recycles profits into new opportunities. The result is a self-sustaining flywheel of growth where more assets under management lead to more fees, more capital, and ultimately more investment capacity.

While many asset managers depend on short cycles of sentiment, Brookfield benefits from time. Its funds typically have ten-year lifespans and use long-dated, non-recourse debt, giving it flexibility to acquire when others retreat. That structure is how it capitalized after the 2008 financial crisis, and it is how it will capitalize again as the world rebuilds energy and data infrastructure.

Brookfield functions much like a modern Berkshire Hathaway focused on real assets, but with institutional scale and a fee structure that allows it to compound even in slower markets.

Outstanding Management and Alignment

If Brookfield’s structure is its engine, its culture is the fuel. The company’s success comes from an owner-operator mindset embedded at every level.

Bruce Flatt, who joined in 1990 and became CEO in 2002, owns roughly 3% of BN (that is a huge stake of a $116 billion market cap enterprise), a stake worth about $3.5 billion. Insiders collectively hold approximately $12 billion of stock. The company avoids dilution, keeps stock-based compensation minimal, and consistently buys back shares. Management acts like owners because they are owners. These few facts may be my favorite part of this business.

Flatt’s philosophy is timeless: buy great assets cheaply, improve them, finance prudently, and recycle capital into better opportunities. That discipline has guided Brookfield through every crisis in recent history. The spinout of BAM in 2022 clarified the company’s structure (more information here), and the earlier acquisition of Oaktree Capital added world-class credit and distressed-debt expertise (more information here). Today, BN stands as a diversified allocator across some of the most durable sectors of the global economy.

The leadership’s credibility is hard-earned. Distributable earnings per share have compounded at double-digit rates for more than two decades, supported by rising dividends and conservative leverage. What sets Brookfield apart is not only the results, but the culture of patience and rationality that produces them. Where others rush, Brookfield waits. Where others speculate, it invests with discipline. This is the exact type of management team I am satisfied with leaving my hard-earned money with.

The Engine of Compounding

Brookfield’s long-term value creation comes from four interconnected sources that continuously reinforce one another and drive steady growth across its ecosystem.

Fee-Related Earnings Growth
As global institutions and individual investors continue allocating more capital to alternative assets, Brookfield’s assets under management have grown at an average of ten to twelve percent annually. These fees are high-margin, recurring, and resilient through market cycles, forming the foundation of the company’s compounding model.

Carried Interest Realization
When Brookfield’s private funds sell mature assets, they earn carried interest, typically twenty percent of profits above a set hurdle rate. The firm currently has more than ten billion dollars in unrealized carried interest, representing profits already earned through strong performance but not yet recognized. This embedded value acts as a future earnings reserve that will be unlocked over time. This is a huge area of value creation for the business that goes unrecognized by the market sometime because the profits are to be realized and Wall Street lacks patience.

Distributions from Owned and Wealth Assets
Brookfield’s returns are strengthened by the steady income from its operating and wealth platforms. The company’s holdings in Brookfield Renewable and Brookfield Infrastructure generate consistent and growing distributions, while Brookfield Reinsurance within the Wealth Solutions segment provides a stream of long-term insurance float and annuity income. Together these cash flows support buybacks, reinvestment, and new fund launches, adding an additional layer of compounding to the model.

Capital Recycling and Buybacks
Brookfield regularly sells mature assets at premium valuations and reallocates capital into higher-yield opportunities or repurchase its own shares. This discipline enhances per-share intrinsic value, improves balance sheet flexibility, and reinforces the long-term compounding cycle.

Together, these four drivers allow Brookfield to compound intrinsic value at a mid-teens rate over time. Even during turbulent markets, the company continues to build value through stable fee income, recurring cash flows, and a long-term mindset that views volatility as opportunity.

Secular Tailwinds

Brookfield sits at the intersection of some of the most powerful long-term forces shaping the global economy. These structural shifts are creating an environment where capital, energy, and infrastructure are becoming more valuable, and Brookfield is positioned at the center of it all.

Alternative Assets Becoming Mainstream
Pension funds and institutions that once focused almost entirely on public markets are now allocating heavily to private alternatives. By 2030, these assets are expected to represent more than a quarter of global investable capital, and Brookfield is among the most trusted managers in the space. The company’s scale, reputation, and performance record have made it a go-to partner for sovereign wealth funds and large institutions seeking long-duration, inflation-protected returns.

The Infrastructure Supercycle
Aging power grids, transportation systems, and industrial networks require trillions of dollars in upgrades and expansion. At the same time, artificial intelligence and data centers are creating new energy and connectivity demands that will reshape the world’s infrastructure map. Brookfield’s renewable and infrastructure platforms are perfectly positioned to deliver the energy generation, transmission, and storage capacity needed to power this transformation.

AI-Driven Energy and Data Demand
The rise of artificial intelligence has unleashed an unprecedented appetite for data processing and energy consumption. Global data center capacity is expanding rapidly, and the grid must evolve to support this growth. Brookfield’s expertise in renewable generation, transmission infrastructure, and energy storage makes it a natural partner for hyperscale cloud and AI providers. The company is already investing in large-scale power and data projects with some of the world’s leading technology firms.

The Reshoring and Industrial Rebuild
As global supply chains shift and governments push for energy and manufacturing independence, developed economies are witnessing a wave of reshoring. This creates massive demand for logistics hubs, localized energy systems, and industrial real estate. Brookfield’s global footprint across infrastructure, utilities, and property development allows it to capture this multi-decade rebuild in the real economy.

Digital Infrastructure Expansion
Connectivity has become a critical utility. Fiber networks, wireless towers, and data transmission assets are now as essential as roads and power lines. Brookfield Infrastructure Partners has built a significant presence in this space, owning and operating digital networks across several continents. The continued rollout of 5G, fiber, and cloud connectivity will fuel another leg of steady growth for the company.

The Energy Transition
Brookfield Renewable is one of the largest clean energy producers in the world. Its diverse portfolio across solar, wind, hydro, and storage assets gives it a durable advantage as the global economy continues to decarbonize. Governments and corporations are investing heavily in renewable capacity, and Brookfield’s integrated expertise in construction, financing, and long-term operations ensures it remains at the forefront of this transition.

Private Credit and Insurance Capital
Through Oaktree and Brookfield Reinsurance, the company now manages more than two hundred and fifty billion dollars in credit and insurance assets. These pools of permanent capital provide a steady, scalable funding base that supports compounding through economic cycles. As traditional banks pull back from lending, private credit continues to grow, creating significant opportunities for Brookfield to deploy its balance sheet intelligently.

Global Wealth Creation
As global wealth expands and populations age, investors are searching for stable, yield-producing assets that can deliver consistent returns. Brookfield’s investment platforms provide those opportunities through tangible, cash-generating assets that serve as an alternative to public equities and bonds. The company’s Wealth Solutions platform also broadens access to private markets, extending its reach beyond institutions to the growing individual investor segment.

Structural Underinvestment in Real Assets
For more than a decade, capital spending in energy, utilities, and infrastructure lagged behind global demand. This has created a structural shortage of essential real assets. Brookfield’s patient capital, deep relationships, and operational expertise allow it to fill that gap, building and acquiring high-quality assets where others cannot.

A Shifting Inflation and Monetary Environment
Brookfield’s focus on real assets provides natural protection in an environment where inflation and interest rates remain structurally higher than in the past decade. Many of its contracts are linked to inflation indices, ensuring its cash flows grow in real terms over time.

Together, these tailwinds form a powerful backdrop for Brookfield’s next decade of growth. From the energy transition and digital infrastructure boom to the institutionalization of private wealth and the rise of AI-driven demand, every major secular trend points toward the kind of real, long-duration assets Brookfield owns and manages. It is precisely this alignment between macro forces and business structure that makes the company one of the most durable compounders in the world today.

Evidence: A Recent and Substantial Investment with the US Government

This week, Brookfield announced one of the most significant energy partnerships in recent U.S. history: an $80 billion nuclear infrastructure agreement with the federal government (Official press release: here) The deal marks a pivotal step by Washington to secure reliable energy capacity ahead of an expected surge in demand from artificial intelligence, data centers, and industrial electrification.

As the world prepares for an unprecedented strain on power grids driven by AI adoption, this partnership reflects a national effort to ensure energy resilience and independence. Brookfield’s deep expertise in developing and managing long-duration energy assets makes it a natural choice to lead such a massive initiative.

The announcement immediately caught my attention and prompted me to revisit Brookfield in detail. I have owned and followed this company for years, but this deal highlights just how critical Brookfield’s role in modern infrastructure has become. It is rare to see government policy, private capital, and long-term strategic necessity align so clearly. Brookfield’s scale, reputation, and operational excellence position it as one of the few entities capable of executing projects of this magnitude. The more I looked, the more this partnership seemed to capture the essence of why I consider BN one of the most durable compounders in global markets.

Risks

The main criticism of Brookfield is its complexity. The web of listed partnerships, private funds, and intercompany holdings can make it difficult to value. This contributes to a persistent conglomerate discount, but that lack of transparency is also what creates opportunity for those who understand it.

Leverage is another factor often misunderstood. Brookfield uses debt primarily at the asset level, structured as long-term and non-recourse. This approach limits risk to individual assets rather than the parent company. Periods of higher rates may slow deal activity but rarely threaten the firm’s solvency.

Carried interest realization can be uneven. In slow markets, performance fees are delayed, though they still accrue as future profits. Key-person risk is also real, with Bruce Flatt viewed as the cultural anchor of the organization. Fortunately, the next generation of leadership is already deeply embedded in the business.

Finally, operating globally across regulated industries exposes Brookfield to political and legal risks. So far, its conservative governance and reputation have protected it from major missteps.

Valuation and Return Outlook

Let’s talk numbers! When valuing BN, I focus on long-term value creation rather than short-term metrics. The combination of AUM growth, carried interest, and capital recycling provides a strong foundation for durable compounding.

Base Case

In my base case, I assume distributable earnings grow at roughly 11% annually, supported by steady AUM expansion, disciplined capital recycling, and the scaling of Brookfield’s Wealth Solutions platform. With modest buybacks reducing share count and a long-term valuation multiple of 18x DE, the model implies a 15% IRR over the next decade.

This scenario reflects continued execution but not perfection, steady growth across fee-bearing capital, incremental margin expansion, share repurchases, and consistent deployment into higher-yield assets. It assumes Brookfield maintains its disciplined approach while unlocking value from its embedded carry and insurance float.

At today’s valuation near ~$47 per share, the model suggests a 2036 price target of approximately $205, which aligns well with my long-term return goals. The outcome is driven more by the power of compounding, a steady climb built on reliable, recurring earnings and a management team that continues to execute with precision.

My expected modest re-rating toward 18× would match peers like Blackstone and KKR unlocking substantial value simply based on a reappraisal by the market.

Bull Case

If Brookfield compounds AUM closer to 14–15% annually and distributable earnings accelerate toward ~18% growth and commands a multiple of 20-22x, returns could exceed a 20% IRR over the next decade.

This scenario assumes stronger realization of carried interest, continued expansion of the Wealth Solutions and insurance platforms, and a meaningful multiple re-rating as investors recognize the durability of Brookfield’s fee-based model.

Bear Case

In a more conservative scenario, distributable earnings growth slows to 7–8% annually, weighed down by delayed carry realizations or softer fundraising cycles. Even under this setup, Brookfield’s durable fee-related income and permanent capital base provide a solid floor for returns.

Assuming valuation multiples command a 15× P/DE range, the model still supports an 8–10% IRR over the next decade, roughly in line with long-term equity market averages. That outcome reflects the strength of Brookfield’s business model: even in a slower growth environment, steady cash flows from its operating and wealth platforms and disciplined capital management protect intrinsic value.

So What?

My personal 10-year IRR hurdle is 15% so the base case is right where I feel comfortable adding more. As you can see, in my worst-case scenario, BN likely still beats index fund returns, a true “heads I win a lot, tail I still win scenario”.

Complexity Versus Conviction

Owning Brookfield requires patience and a willingness to embrace complexity. The business is sprawling, intricate, and not easily modeled. But that complexity is part of its edge. Markets often misprice what they do not fully understand, and Brookfield’s depth ensures that true intrinsic value compounds quietly beneath the surface.

When I first invested, I wrestled with the same doubts many investors have: can management continue delivering high returns across such a vast platform? Decades of execution have answered that question. The culture of alignment, discipline, and opportunity capture has persisted through every cycle.

Oh, and their track record has been like no other. They have returned a 19% IRR over 30 years (and above 25% over the last 20 years) in shareholder value. This a total return of over 27,000% outperforming juggernauts like LVMH, Walmart, Microsoft, and Warren Buffet’s Berkshire Hathaway. To put this into perspective, $100 invested in Brookfield 30 years ago would be worth $18,520 today – INCREDIBLE!

Final Takeaway

Brookfield is not a company to trade; it is a business to own. It represents something increasingly rare in modern markets: a management team deeply aligned with shareholders, a structure designed for compounding, and exposure to some of the most durable megatrends of our time.

The new nuclear partnership only reinforces the thesis. Brookfield is not merely investing in assets; it is shaping the backbone of the next era of global growth, powering AI, electrification, and a more sustainable energy future.

In my view, BN remains a quality compounder trading below intrinsic value. When I own Brookfield, I’m not just holding a stock; I’m partnering with one of the most capable allocators of capital in the world.

Disclaimer

This article is for informational purposes only and does not constitute financial advice. Always consult a qualified financial advisor before making any investment decisions.

Subscribe now

Retirement planning can feel like an overwhelming task, but choosing the right retirement account is one of the smartest moves (and one of the most important moves) you can make to secure your financial future. These accounts aren’t just about saving, they’re tax-advantaged tools that let your money grow over decades, taking advantage of the power of compounding. In this guide, we’ll break down the major retirement accounts available in 2025, what they are, and who should consider opening and investing in them. My goal is to keep it clear, practical, and actionable, so you can pick the right plan for your goals (not to buy a luxury purse!).

Let’s get started! Check out a recent LinkedIn post I made that gained some popularity online and to set the stage.

Why Retirement Accounts Matter

Retirement accounts are designed to help your investments grow faster through tax advantages, whether it’s tax-deferred growth or tax-free withdrawals. The earlier you start, the more time your money has to compound, turning small contributions into a sizable nest egg. Each account has unique rules, contribution limits, and benefits, so choosing the right one depends on your income, job, and long-term plans. Think of it like picking the right tool for a job and match the account to your situation, and you’ll be setting yourself up for success.

*I’m going to provide two explanations for each account:

• A simple version as if you were 12, so you can easily understand the basics, and

• A grown-up version with fancy terms like “tax-deferred” for when you want to sound smart at dinner parties.

1. 401(k): The Workplace Standard

Explain it to me like I’m 12: A 401(k) is like a special piggy bank for grown-ups to save money for when they retire, which is when they stop working full-time, usually when they’re older. It’s offered by some employers, so you can put part of your paycheck into this account before taxes are taken out. That means you pay less tax now, but you’ll pay taxes later when you take the money out in retirement, usually after age 59½. The money in the 401(k) can grow over time if you invest it in things like stocks or bonds, kind of like how a small plant can grow into a big tree. Sometimes, your boss might even add extra money to your 401(k) as a bonus, called a “match.” But if you take the money out too early, you might have to pay taxes and a penalty. It’s a smart way to save for the future!

Explain it to me like an adult: A 401(k) is an employer-sponsored retirement plan where you contribute a portion of your paycheck before taxes, lowering your taxable income. Investments grow tax-deferred, and you pay taxes only when you withdraw funds in retirement. Many employers offer matching contributions (for example 4% of your contributions up to a limit), this is a cheat code and essentially is free money. In 2025, the contribution limit is $24,000, plus an $8,000 catch-up for those 50 and older. Should you need to withdrawal funds sooner than the stated IRS limits, you will be hit with an immediate tax bill and a 10% early withdrawal penalty.

Key Features:

• Tax Benefits: Pre-tax contributions reduce your taxable income; withdrawals are taxed as ordinary income.

• Investment Options: Typically limited to mutual funds, ETFs, or target-date funds selected by your employer.

• Employer Match: Varies by company but can boost your savings significantly.

• Withdrawal Rules: Penalty-free withdrawals after age 59½; required minimum distributions (RMDs) start at age 73. In other words, you must withdrawal a certain amount and prohibited to hoard it only to pass it down after you pass away (what a great problem to have 😊).

Pros:

• Tax Advantages

• Employer Match

• High Annual Contribution Limits:

Cons:

• Limited Investment Options

• Penalties for Early Withdrawal

• Required Minimum Distributions

Who Should Open One: If your employer offers a 401(k), especially with a match, it’s a must full stop. It’s ideal for employees who want an easy way to save, particularly those in higher tax brackets who benefit from the tax deduction. If your plan has limited or high fee options, contribute enough to get the match, then explore other accounts.

Pro Tip: Always max out the employer match it’s essentially a guaranteed return. Choose low cost index funds or ETFs to minimize fees and maximize growth. Not to beat a dead horse, but this is a CHEAT CODE.

*Bonus: A 403(b) account is the 401(k)’s cousin and is the non-profit equivalent.

2. Traditional IRA: The Flexible Choice

Explain it to me like I’m 12: A Traditional IRA is like a special savings box for grown-ups to save money for when they’re older and not working anymore, like during retirement. You put money in this box, and the cool thing is, you don’t have to pay taxes on that money right away. Instead, you pay taxes later when you take the money out to use it, usually when you’re over 59½ years old. The money in the box can also grow over time if you invest it in things like stocks or bonds, kind of like planting a seed that grows into a bigger tree. But, if you take the money out too early, you might have to pay extra taxes or penalties.

Explain it to me like an Adult: A Traditional Individual Retirement Account (IRA) is a personal account you open yourself, independent of an employer. Contributions are tax-deductible, and investments grow tax deferred. In other words, you do not pay tax on the front end, but you pay taxes on the back end upon withdrawal. The 2025 contribution limit is $7,500, with a $1,000 catch up for those 50 and older.

Key Features:

• Tax Benefits: Contributions may be fully or partially deductible, based on your income and workplace plan. Withdrawals are taxed as ordinary income.

• Investment Options: A large menu to choose from - stocks, bonds, ETFs, mutual funds, or even alternative assets.

• Withdrawal Rules: Penalty-free after age 59½; RMDs start at age 73.

• Income Limits: Deductibility phases out for higher earners with workplace plans ($83,000–$103,000 for singles in 2025).

Pros:

• Tax-Deductible Contributions

• Flexible Investment Options

• Accessible for Most

Cons:

• Income Limits on Deductions

• Early Withdrawal Penalties

• Required Minimum Distributions (RMDs)

Who Should Open One: Perfect for those without a 401(k) (or those with a 401k that has maxed out the IRA contribution limit), like freelancers or small business owners, or anyone wanting more investment flexibility. It’s also great for high earners who can deduct contributions and expect a lower tax bracket in retirement.

Pro Tip: Open your IRA with a low cost brokerage (for more information on this check out the previously published article titled “Holler to Tide Investment Guide: Your Roadmap to the best Trading Platforms”) and invest in quality businesses with strong fundamentals for long-term growth (for more information on this check out the previously published article titled “From Holler to Tide: My Journey Into the Markets”).

3. Roth IRA: The Tax-Free Winner

Explain it to me like I’m 12: A Roth IRA is like a special savings jar for grown-ups to save money for retirement, when they’re older and not working full-time. You put money into this jar after you’ve already paid taxes on it. The awesome part? The money grows over time if you invest it in things like stocks or bonds, and when you take it out after age 59½, you don’t have to pay any taxes on the money or the growth—as long as you follow the rules! It’s like planting a seed now and picking tax-free fruit later. But, if you take the money out too early, you might owe taxes or a penalty on the growth (not the money you put in). It’s a great way to save for the future if you think taxes might be higher later on!

Explain it to me like I’m an Adult: A Roth IRA (my personal favorite) is like a Traditional IRA, but you contribute after-tax dollars, so qualified withdrawals in retirement are tax-free. In other words, you pay the tax on the front end and can withdrawal tax free on the back end. The 2025 contribution limit is $7,500, with a $1,000 catch-up for those 50 and older.

Key Features:

• Tax Benefits: No upfront deduction, but qualified withdrawals (after age 59½ and a five-year holding period) are tax-free, including earnings.

• Investment Options: Same as a Traditional IRA—stocks, ETFs, mutual funds, etc.

• Withdrawal Rules: Contributions can be withdrawn anytime without penalty (taxes are already paid). Earnings are penalty free after 59½; no RMDs during your lifetime.

• Income Limits: Eligibility phases out for higher earners ($156,000–$166,000 for singles in 2025).

Pros:

• Tax-Free Withdrawals

• No Required Minimum Distributions (RMDs)

• Flexible Withdrawals

Cons:

• No Upfront Tax Deduction

• Income Limits for Contributions

• Early Withdrawal Penalties on Earnings (but none if you withdrawal after the IRS age limit).

Who Should Open One: Ideal for younger investors, those in lower tax brackets, for parents opening a retirement account on behalf of a child or dependent, or anyone expecting higher taxes in retirement. It’s also great for flexibility, since contributions (not earnings) can be withdrawn penalty-free for emergencies.

Pro Tip: Start a Roth IRA early to maximize tax-free growth over decades. It’s a powerful tool for long-term wealth building.

Bonus: You CAN NOT contribute the IRS maximum to both a Traditional IRA AND a Roth IRA. You can have both of these accounts but the maximum contribution for 2025 is $7,500 and an additional $1,000 for catch up available to those 50 years and older. These amounts must be split between the two accounts.

4. SEP IRA: The Self-Employed Boost

Explain it to me like I’m 12: A SEP IRA, or Simplified Employee Pension IRA, is like a special retirement savings account for people who work for themselves or own a small business. Imagine it as a big piggy bank where you, or your boss if you work for a small company, can put money to save for when you’re older and not working anymore. The cool thing is that the money you put in isn’t taxed right away, so you pay less tax now, but you’ll pay taxes when you take it out later, usually after age 59½. The money can grow over time if you invest it in things like stocks or bonds, like a seed growing into a tree. A SEP IRA lets you save a lot more money each year compared to a regular IRA, which is great for self-employed people or small business owners. But, if you take the money out too early, you might owe taxes and a penalty. It’s a smart way to plan for retirement if you’re your own boss!

Explain it to me like I’m an Adult: A Simplified Employee Pension (SEP) IRA is designed for self-employed individuals or small business owners. It offers higher contribution limits up to $69,000 or 25% of net business income in 2025, whichever is less.

Key Features:

• Tax Benefits: Contributions are tax-deductible; investments grow tax-deferred. Withdrawals are taxed as ordinary income.

• Investment Options: Similar to a Traditional IRA - stocks, ETFs, etc.

• Withdrawal Rules: Penalty-free after age 59½; RMDs start at age 73.

Pros:

• High Contribution Limits

• Tax-Deductible Contributions

• Flexible Investment Options

Cons:

• No Catch-Up Contributions

• Contributions Required for Employees

• Early Withdrawal Penalties

Eligibility: For self-employed individuals or business owners with employees (who must also receive contributions).

Who Should Open One: Great for freelancers, gig workers, or small business owners with steady income who want to save more than a Traditional or Roth IRA allows.

Pro Tip: Contribute more in high income years to maximize tax deductions. Pair with a Roth IRA if eligible to diversify your tax strategy.

5. Solo 401(k): The Entrepreneur’s Edge

Explain it to me like I’m 12: A Solo 401(k) is like a super-powered retirement savings plan for people who work for themselves and don’t have any employees (except maybe their spouse). Picture it as a big piggy bank where you can save money for when you’re older and not working anymore. You can put money in as both the “worker” and the “boss,” which means you can save a lot more than with other plans. The money you put in isn’t taxed right away, so you pay less tax now, but you’ll pay taxes when you take it out later, usually after age 59½. You can invest the money in things like stocks or bonds, and it grows over time, like a seed turning into a tree. If you take the money out too early, you might owe taxes and a penalty. Some Solo 401(k)s even let you borrow from your savings if you need to. It’s a great way for self-employed people to save big for retirement!

Explain it to me like I’m an Adult: A Solo 401(k), or Individual 401(k), is for self-employed individuals or business owners with no employees (except a spouse). It combines employee and employer contributions, allowing up to $24,000 as an employee plus 25% of business income as the employer, for a total of $69,000 in 2025 ($77,000 if 50 or older).

Key Features:

• Tax Benefits: Pre-tax contributions reduce taxable income; growth is tax-deferred. Roth Solo 401(k) options allow tax-free withdrawals.

• Investment Options: Broad, like an IRA - stocks, ETFs, and more.

• Withdrawal Rules: Penalty-free after age 59½; RMDs start at age 73.

Pros:

• High Contribution Limits

• Dual Contribution Types

• Roth Option Available

Cons:

• Limited Eligibility

• Administrative Complexity

• Early Withdrawal Penalties

Eligibility: For self-employed individuals or business owners with no full-time employees (except a spouse).

Who Should Open One: Perfect for self-employed professionals or consultants with high income who want to save more than a SEP IRA allows.

Pro Tip: Use the employer contribution to max out savings in profitable years. Consider a Roth Solo 401(k) for tax-free growth if you expect higher taxes later.

6. Health Savings Account (HSA): The Retirement Sleeper

Explain it to me like I’m 12: HSA, or Health Savings Account, is like a special piggy bank for medical expenses. It’s for people who have a certain type of health insurance plan called a high-deductible health plan. You put money into the HSA, and that money isn’t taxed right away, which means you save on taxes now. You can use the money to pay for things like doctor visits, prescriptions, or even bandages—pretty much anything medical. If you don’t use the money, it stays in the account and can grow over time if you invest it, like a plant growing bigger. The best part? If you use the money for medical stuff, you never pay taxes on it. You can even save it for medical costs when you’re older, like in retirement. But if you use it for non-medical things before age 65, you’ll owe taxes and a penalty.

Explain it to me like I’m an Adult: An HSA is a tax-advantaged account for those with high-deductible health plans (HDHPs). It’s designed for medical expenses but can double as a retirement account, as funds can be invested and withdrawn penalty-free for any purpose after age 65. In 2025, contribution limits are $4,300 for individuals or $8,550 for families, plus a $1,000 catch up for those 55 and older.

Key Features:

• Tax Benefits: Triple tax advantage—contributions are deductible, growth is tax-free, and withdrawals for medical expenses are tax-free. After 65, non-medical withdrawals are taxed but penalty-free.

• Investment Options: Many HSAs allow investments in mutual funds, ETFs, or stocks.

• Withdrawal Rules: No penalties for medical expenses at any age; non-medical withdrawals before 65 face a 20% penalty.

Pros:

• Triple Tax Advantage!!

• Investment Flexibility

• Retirement Savings Potential

Cons:

• HDHP Requirement

• Penalties for Non-Medical Withdrawals

• Record Keeping Burden

Who Should Open One: Ideal for anyone with an HDHP who wants to save for healthcare costs or boost retirement savings. It’s especially valuable for healthy individuals who can invest contributions for long-term growth.

Pro Tip: Pay medical expenses out of pocket if possible, letting your HSA grow tax-free for retirement. Invest in low-cost ETFs or quality stocks for maximum returns.

How to Choose the Right Account

The best retirement account depends on your job, income, tax situation, and goals. Here’s a quick guide:

• Employed with a 401(k)? Start with it, especially if there’s a match. Max it out, then add a Traditional or Roth IRA.

• Self-employed? A SEP IRA or Solo 401(k) offers higher limits for aggressive savers.

• Young or low tax bracket? A Roth IRA or Roth Solo 401(k) locks in today’s tax rates for tax-free growth.

• Have an HDHP? An HSA is a must for its triple tax advantage and retirement flexibility.

• Want investment control? IRAs (Traditional or Roth) offer the most options for building a portfolio of quality businesses.

The key is to start early and invest consistently. Focus on low-cost, diversified investments like index funds or carefully chosen stocks with strong fundamentals, and let time work its magic.

Avoiding Common Mistakes

Retirement investing isn’t about chasing hot trends, it’s about discipline. Here are a few pitfalls to avoid:

• High-fee funds: Steer clear of expensive mutual funds in 401(k)s or IRAs. Low-cost ETFs or index funds keep more money working for you.

• Ignoring fees: High fees can erode decades of returns. Compare expense ratios and choose low-cost providers.

• Neglecting your accounts: Review your investments yearly to ensure they align with your goals.

• Chasing returns: Stick to businesses with strong fundamentals that you understand, avoiding speculative bets.

*For more information on this check out the previously published article titled “Holler to Tide Investment Guide: 5 Big Mistakes Investors Are Making in 2025”.

The Wrap-Up: Build Wealth with Discipline

Retirement accounts are your foundation for long-term wealth. Whether it’s a 401(k) for the employer match, a Roth IRA for tax-free growth, or an HSA for its unique tax benefits, each account offers a path to financial security. The secret? Start now, invest in quality assets, and stay patient. As Warren Buffet once said, “The stock market is a device for transferring money from the impatient to the patient.” Choose the right accounts, invest wisely, and let compounding do the heavy lifting.

Parting Words and Subscription Invite

If this guide helped clarify your retirement options, subscribe to the Holler to Tide Investment Guide on Substack, follow me at @hollertotide on X, and share it with friends. Got questions about these accounts or investing? Drop them in the comments, and I’ll tackle them in a detailed reply. Until next time, happy investing!

Disclaimer: This information is provided for general informational purposes only and does not constitute financial advice. You should consult with a qualified financial advisor or professional before making any investment or financial decisions.

At some point, I hopped on YouTube to see if any of my favorite investing voices had shared anything new—and sure enough, I came across a gem. The video is by Phil Town and titled “5 Big Mistakes Investors Are Making in 2025,” and it immediately struck a chord. With everything going on, I figured this week’s guide should be a quick and practical write-up based on the insights from that video—simple topics that are pure gold.

That video got me thinking—despite all the market ups and downs, from AI stocks shooting to the moon to interest rates staying stubbornly high, investors are still falling into the same old traps. Phil Town laid it out clearly, and it really hit home. Whether you’re just starting out or have years in the game, avoiding these five common mistakes could be the difference between building lasting wealth or watching your portfolio take a hit. So, in the spirit of keeping it simple and smart this week, let’s dig into the five biggest mistakes investors are making in 2025.

Who’s Phil Town, Anyway?

Before we jump in, let’s give some credit to the man behind the insight’s, one of my favorite investors - Phil Town. He’s a former Green Beret turned hedge fund manager and the author of bestsellers like Rule #1 and Payback Time. Phil’s investing philosophy is grounded in value investing, drawing from Warren Buffett and Charlie Munger’s philosophy. He preaches buying wonderful businesses at fair prices and holding them long term (sound familiar?). No day trading, no chasing fads -just solid, research-driven investment. His ability to break down complex financial concepts into real talk is what makes his content resonate with everyday investors. If you’re new to the game, his teachings are a great place to start.

Subscribe now

Mistake #1: Chasing the Hype Train with Overconfident Hubris
Overview: Each year brings its hot stocks - 2025 is no exception. Diving into the frenzy of meme stocks, AI plays, or social media darlings without research, fueled by an overconfident belief in your investing prowess, sets you up for disaster. That hubris can lead to buying high and losing big when the hype inevitably fades.
Why It’s a Problem: Short-term trends aren’t the same as long-term value. If you’re investing based on TikTok or Twitter (X) hype, and your overconfidence convinces you that you’ve got it all figured out, you’re not investing—you’re gambling.
Avoid It By: Ground yourself by focusing on businesses you understand, with solid earnings, durable competitive advantages, and predictable cash flows—rather than letting hubris drive your decisions.

Mistake #2: Ditching Fundamental Analysis Due to FOMO
Overview: In 2025, many investors are skipping the basics - like analyzing balance sheets, income statements, and free cash flow driven by FOMO (fear of missing out) on the latest market trends, relying instead on vibes and gut feelings.
Why It’s a Problem: Without understanding a company’s financial health, you’re flying blind. FOMO can push you into overvalued stocks, even if the company seems solid, leaving you vulnerable to sharp declines.
Avoid It By: Resist the FOMO and commit to learning financials, digging into 10-Ks, and doing proper valuation work. Phil Town advises using a checklist and investing like a business owner, not a speculator chasing the next big thing.

Mistake #3: Falling for Recency Bias
Overview: Recency bias is the tendency to overemphasize recent events or trends when making decisions, assuming they’ll continue into the future. In 2025, many investors are caught up in the latest market upswing, expecting the good times to roll on without considering historical cycles or downturns.
Why It’s a Problem: Markets are cyclical, not linear. Relying on recent performance ignores the bigger picture, leading to poor decisions - like buying at peak valuations right before a correction hits.
Avoid It By: Study historical market patterns and focus on long-term fundamentals. Phil Town suggests sticking to a disciplined checklist, evaluating companies based on their intrinsic value, not recent price action, to avoid being swayed by short-term trends.

Mistake #4: Over-leveraging Like It’s 2007

Overview: With margin accounts easier than ever to access, a lot of investors are borrowing to juice returns. Sounds smart - until the market dips. This reminds me of one of my favorite Warren Buffett quotes, “A rising tide floats all boats….. only when the tide goes out do you discover who's been swimming naked."

Why It’s a Problem: Leverage multiplies gains and losses. In a downturn, you could get margin-called and lose more than your initial investment.

Avoid It By: Staying debt-free in your portfolio or using margin sparingly and with a big safety cushion.

Mistake #5: Straying Outside Your Circle of Competence

Overview: In 2025, with new industries like AI, green tech, or biotech booming, many investors are tempted to jump into unfamiliar sectors they don’t fully understand, chasing potential gains without grasping the risks or fundamentals.

Why It’s a Problem: Investing beyond your circle of competence—industries or businesses you don’t know well—makes it hard to accurately assess value or risks. You’re more likely to misjudge opportunities and lose money on ventures you can’t properly evaluate.

Avoid It By: Stick to what you know. Focus on industries and companies you understand deeply, where you can confidently analyze financials and competitive advantages. Phil Town emphasizes investing like a business owner, only in areas where you have a clear edge.

The Wrap-Up: Phil Town’s Takeaway

Phil’s bottom line is simple: Investing isn’t hard, but it requires discipline. Avoiding these five mistakes could save you years of headaches and help you build real wealth. If you take nothing else from this guide, remember to think like an owner, stay patient, and never forget the power of compounding over time.

Want to hear it straight from the man himself? Here is the link to the full video:

Parting Words and Subscription Invite

If you found this helpful, please subscribe to the Holler to Tide Investment Guide on Substack and share it with friends who might enjoy it. Until next time, happy investing!

Disclaimer: This information is provided for general informational purposes only and does not constitute financial advice. You should consult with a qualified financial advisor or professional before making any investment or financial decisions.

The Fintech Revolution: Trading Platforms in Focus

The financial world is getting a tech-fueled makeover, and trading platforms are at the heart of it. Gone are the days of calling your broker or paying hefty fees per trade. Today’s platforms blend AI-driven insights, mobile-first designs, and commission-free trading to make investing accessible to all. The global online trading market was worth $9.6 billion in 2023 and is projected to grow at a 7.3% CAGR through 2030, driven by rising retail investor participation and tech innovation. But not all platforms are created equal. Some cater to beginners with minimalist apps, while others arm pros with tools that rival Wall Street trading floors. Choosing the wrong one could mean missing opportunities or drowning in complexity. Let’s explore how our five contenders stack up in this booming fintech landscape.

Online Trading Market Growth Projection:

1. Robinhood: The Disruptor’s Playbook

Overview: Launched in 2013, Robinhood shook up the brokerage world with commission-free trading and a mobile app so slick it feels like a game. Targeting younger investors, it’s the poster child for democratizing finance. I haven’t used Robinhood myself, but I know several peers who do and are passionate advocates for it.

Pros:

· Zero Commissions: Trade stocks, ETFs, and options without fees (options have small per-contract costs).

· Dead-Simple App: Intuitive design makes buying your first stock as easy as ordering takeout.

· Fractional Shares: Invest in pricy stocks like Apple with just $1, perfect for small budgets.

· No Minimums: Start with pocket change, ideal for newbies.

· Crypto Access: Trade Bitcoin, Ethereum, and other coins alongside stocks.

· “Robinhood Gold” subscription that unlocks additional features like higher APYs on uninvested cash and an exclusive “gold credit card” with a 3% cash back benefit.

Cons:

· Bare-Bones Research: Limited charting and education tools leave active traders wanting more.

· Spotty Support: Past outages and slow customer service have frustrated users during market chaos.

· Payment for Order Flow (PFOF): May result in slightly worse trade prices, a trade-off for “free” trading.

· Narrow Asset Range: No bonds, mutual funds, or futures—strictly stocks, ETFs, options, and crypto.

· Reliability Woes: High-profile outages during 2020–2021 meme stock frenzies raised red flags.

Best For: Beginners and casual investors who want simplicity and low costs but don’t need deep tools.

Robinhood User Growth:

2. Fidelity: The Long-Game Champion

Overview: Fidelity is a household name, known for its retirement accounts, top-tier research, and customer-first ethos. It’s built for investors playing the long game, from IRAs to wealth planning. My wife’s 401k is held with Fidelity, and although the retirement plan’s rules prevent me from trading individual stocks—not a limitation of the platform—I’m satisfied with its performance and have no complaints.

Pros:

· No Fees: Commission-free stocks, ETFs, and options, with no per-contract fees.

· Research Powerhouse: In-depth reports, advanced charting, and third-party insights from Morningstar and more.

· Broad Investments: Stocks, ETFs, mutual funds (many no-fee), bonds, and fractional shares.

· Stellar Support: 24/7 phone, chat, and in-person help at branches, a rarity in fintech.

· Retirement Expertise: Industry-leading IRAs and low-cost index funds for future-focused investors.

Cons:

· Clunky Interface: Desktop platform can overwhelm beginners compared to mobile-first rivals.

· Higher Margin Rates: Borrowing costs for margin trading lag behind low-cost competitors.

· Limited Crypto: Only Bitcoin and Ethereum trading, missing the broader crypto wave.

· Slower to Innovate: Lacks trendy features like social trading or gamified apps.

· Premium Services Cost: Managed accounts often require $25,000+ minimums.

Best For: Long-term investors and retirement planners who value research and reliability.

Fidelity Assets Under Management:

3. Charles Schwab: The All-in-One Giant

Overview: Charles Schwab, a fintech pioneer, supercharged its offerings by acquiring TD Ameritrade in 2020. They were the first to introduce 0 commission trades, which was revolutionary at the time. With the thinkorswim platform and a vast investment lineup, it’s a one-stop shop for traders and investors alike. When I began investing, I used this platform for all my accounts, but as my investment journey evolved, I switched to Interactive Brokers to access foreign exchanges for international stocks. If Charles Schwab offered international stocks, I’d transfer all my funds back, as Schwab remains my favorite all-around trading platform.

Pros:

· thinkorswim Power: A trader’s dream with customizable charts, options tools, and back testing for pros.

· Commission-Free: No fees for stocks, ETFs, or options, with competitive per-contract rates.

· Wide Asset Selection: Stocks, ETFs, mutual funds (thousands no-fee), bonds, futures, forex, and fractional shares.

· Educational Goldmine: Webinars, tutorials, and paper trading inherited from TD Ameritrade’s playbook.

· Robust Support: 24/7 help via phone, chat, or 400+ branches.

Cons:

· Merger Hiccups: Account transitions from TD Ameritrade have caused glitches and delays for some users.

· Beginner Overload: thinkorswim’s complexity can scare off newbies; the main platform isn’t as sleek as Robinhood’s.

· Fees for Niche Assets: Non-no-fee mutual funds and futures trades carry costs.

· Crypto Lag: Only crypto futures and coin trusts, not direct trading like Robinhood.

· Support Strains: Post-merger, some report longer wait times during busy periods.

· No access to foreign stock exchanges

Best For: Active traders using thinkorswim and investors seeking a versatile, all-in-one platform.

Schwab Client Accounts Growth:

4. Interactive Brokers: The Pro’s Paradise

Overview: Interactive Brokers (IBKR) is the go-to for professional traders, offering rock-bottom costs and access to global markets. It’s a beast for those who know their way around a trading desk. My accounts are held here, and I use their platform daily with no complaints whatsoever.

Pros:

· Dirt-Cheap Trades: Per-share pricing (e.g., $0.005/share) and low margin rates crush competitors.

· Global Reach: Trade stocks, options, futures, forex, and bonds in 150+ markets worldwide.

· Trader Workstation (TWS): Sophisticated platform with charting, algorithms, and automation for power users.

· Obscure Investments: Warrants, structured products, and hedge fund access for the adventurous. Low Entry: Start with $100 for most accounts, plus fractional shares.

Cons:

· Not for Newbies: TWS is a maze for beginners; the mobile app feels clunky.

· Inactivity Fees: $10/month for low-activity accounts under $100,000, a sting for casual investors.

· Weak Support: Limited phone help; relies on chat and tickets, which can feel impersonal.

· Overkill for Most: Global markets and advanced tools are excessive for basic investors.

· Slow Setup: Strict verification can delay account opening.

Best For: Professional traders and high-volume investors, especially those eyeing international markets.

Interactive Brokers Trading Volume:

5. E*TRADE: The Middle Ground Ace

Overview: Backed by Morgan Stanley, E*TRADE strikes a balance between beginner-friendly design and pro-level tools, making it a versatile pick for diverse investors.

Pros:

· Dual Platforms: Power E*TRADE delivers advanced charting and options tools; the standard app is newbie friendly.

· Commission-Free: No fees for stocks, ETFs, or options; competitive mutual fund pricing.

· Solid Research: Morningstar, Thomson Reuters, and proprietary insights fuel informed decisions.

· Retirement Options: Strong IRAs and robo-advisor services with low fees.

· No Minimums: Jump in with any amount, no barriers.

Cons:

· Margin Costs: Higher borrowing rates than IBKR or Robinhood for margin traders.

· Crypto Limits: Only Bitcoin and Ethereum futures, no direct crypto trading.

· Hidden Fees: Some mutual funds and bonds come with transaction costs.

· Platform Overlap: Multiple interfaces (web, mobile, Power E*TRADE) can confuse users.

· Support Mixed Bag: Post-Morgan Stanley, customer service response times vary.

Best For: Investors wanting a mix of beginner ease and active trading tools.

E*TRADE Account Growth:

Who’s Got the Edge?

The trading platform race is a microcosm of the fintech revolution. Robinhood leads for simplicity but lacks depth. Fidelity dominates research and retirement but feels dated. Charles Schwab’s thinkorswim and scale make it a juggernaut, though merger growing pains linger. Interactive Brokers is unmatched for pros but alienates beginners. E*TRADE bridges the gap but struggles to stand out.

The Verdict & Key Takeaways

Picking a trading platform is like choosing a car: it depends on your journey. After weighing the pros, cons, and fintech trends, my primary recommendation is Charles Schwab for most investors. It’s thinkorswim platform empowers active traders, while its vast investment options and research suit long-term players. The merger with TD Ameritrade has had hiccups, but Schwab’s scale, low costs, and trusted brand make it a cornerstone of the fintech revolution. For beginners, Robinhood’s simplicity shines, but its limits make it a steppingstone. Fidelity is a close second for retirement-focused investors, while Interactive Brokers is the pro’s pick. E*TRADE is a solid middle ground but is lacking in keeping up with the others.

Disclaimer: This information is for general informational purposes only and does not constitute financial advice. Consult a qualified financial advisor before making investment decisions.

The healthcare industry is ripe for disruption, and one company is spearheading the effort with a bold, consumer first approach: Hims & Hers Health, Inc. (NYSE: HIMS). By leveraging telehealth, direct-to-consumer (DTC) delivery, and a focus on stigmatized or underserved health categories, Hims & Hers is redefining how people access medical care and wellness products. From men’s hair loss and erectile dysfunction treatments to women’s mental health and skincare solutions, Hims & Hers is building a digital health platform that prioritizes affordability, accessibility, and personalization. With a rapidly growing subscriber base and a scalable, asset-light model, Hims & Hers is prepared to dominate the telehealth revolution, much like Uber is transforming mobility. This perspective is supported by recent analyst upgrades, including Goldman Sachs’ 2025 outlook, which praises Hims’ “unique positioning in a $1 trillion healthcare market.”

Hims & Hers’ Business

Founded in 2017, Hims & Hers is a telehealth platform that connects consumers with licensed healthcare providers for virtual consultations, offering treatments for conditions like hair loss, erectile dysfunction, mental health, dermatology, and sexual wellness. The company delivers prescription and over-the-counter medications directly to customers’ doors, often at a fraction of traditional pharmacy costs. Hims & Hers operates a subscription-based model, providing recurring revenue and fostering customer loyalty through personalized care plans and ongoing support.

Hims & Hers generates revenue through:

• Subscription Fees: Customers pay for recurring deliveries of medications, supplements, or wellness products tailored to their needs.

• Consultation Fees: Affordable virtual consultations with licensed providers, often covered by subscription plans.

• Product Sales: Direct sales of proprietary and third-party health and wellness products, including skincare, vitamins, and sexual health treatments.

• Pharmacy Services: Hims & Hers owns compounding pharmacies, allowing it to produce and distribute medications at lower costs.

• Advertising and Partnerships: Sponsored promotions and partnerships with health brands targeting its growing user base.

  Subscribe now

In 2024, Hims & Hers reported 2.2 million subscribers, a 45% year-over-year increase, with revenue reaching $1.476 billion (TTM). Its asset-light model, which avoids the high costs of physical clinics or proprietary drug development, drives impressive margins and scalability.

Hims Subscriber Growth:

Hims Revenue Growth:

Hims co-founder, CEO, and Chairman of the Board Andrew Dudum:

Andrew Dudum, the visionary founder and CEO of Hims & Hers Health, Inc., leverages his entrepreneurial background and tech expertise to spearhead a transformative telehealth platform that delivers accessible, stigma-free healthcare solutions. With a proven track record of building consumer-focused startups, Dudum's leadership is a cornerstone of Hims' success, making him one of the best aspects of Hims as an investment. As of May 5, 2025, he owns approximately 10.2 million shares, equating to an 11.1% stake valued at over $370 million. This significant insider ownership highlights his deep commitment to shareholders and unwavering confidence in Hims & Hers' potential to disrupt the $1 trillion healthcare market. Numerous buy-and-hold investors have chosen Hims & Hers primarily due to Andrew Dudum's leadership, widely regarded as one of the most promising and dynamic CEOs in today's corporate landscape.

Does HIMS have a MOAT?

In short, I believe they are building and widening a MOAT (competitive advantage) each quarter with their execution and investment. Hims is only 8 years old and very much still in the growth mode and MOAT building phase. Hims & Hers stands out in the telehealth landscape by creating a complete network that integrates trusted branding, leading technology, clinical excellence, and innovative products and services, as illustrated in the diagram below. This interconnected framework drives a powerful competitive advantage, enabling Hims to deliver personalized, data-driven healthcare solutions at scale.

Hims & Hers Competitive Advantage Diagram:

At the core of Hims’ strategy is its ability to attract more subscribers to the platform, with 2.2 million users in 2024, driven by a trusted brand that destigmatizes sensitive health issues like erectile dysfunction and mental health. This trust fosters loyalty, as seen in the platform’s 80% subscription retention rate. Hims leverages leading technology, utilizing AI and machine learning to analyze user data, offering data-driven personalized solutions and services. For instance, its algorithms tailor treatment plans based on individual health profiles, improving outcomes and customer satisfaction. The platform’s partnership with tools like MedMatch enhances its ability to provide additional structured data and deeper insights, ensuring providers have comprehensive information for better decision-making. Finally, Hims’ focus on clinical excellence ensures higher quality outcomes, with licensed providers conducting over 10 million consultations in 2024, supported by in-house pharmacies that guarantee affordability and quality. By combining these elements with innovative products and services like its recent entry into weight loss with compounded GLP-1 medications Hims creates a self-reinforcing cycle that competitors struggle to replicate, solidifying its position as a leader in telehealth.

The Telehealth Landscape: A Booming Opportunity

Telehealth is transforming healthcare by making medical services more accessible and cost-effective. The U.S. telehealth market was valued at $101.2 billion in 2023 and is projected to grow at a 24.3% CAGR through 2030. Companies like Teladoc and Amwell have paved the way, but their focus on broad, enterprise-driven solutions leaves room for nimble players like Hims & Hers, which targets specific, high-demand health categories with a DTC approach.

Competitors face significant challenges. Traditional healthcare providers, such as CVS Health or Walgreens, rely on brick-and-mortar pharmacies and in-person care, which are costly and less convenient. Meanwhile, other telehealth startups struggle to differentiate or achieve profitability due to high customer acquisition costs and regulatory hurdles. Hims & Hers stands out with its vertically integrated model controlling consultations, prescriptions, and delivery all the while addressing stigmatized conditions that drive customer loyalty.

Telehealth Market Growth Projection:

Hims’ Strategic Advantage: Consumer Focus and Scalability

Hims & Hers excels at demand aggregation, much like Uber in mobility. Its platform connects millions of users with healthcare providers and products, creating a powerful network effect: more subscribers attract more providers and partners, which in turn enhances service offerings and lowers costs. In 2024, Hims & Hers processed over 10 million consultations, with 80% of subscribers opting for recurring treatment plans. This high retention rate, combined with a low customer acquisition cost (CAC) of $40 compared to the industry average of $100, underscores its efficiency.

Hims & Hers leverages data and AI to personalize care. Its platform analyzes user health profiles, preferences, and treatment outcomes to recommend tailored solutions, improving efficacy and customer satisfaction. Dynamic pricing ensures affordability, with treatments like generic sildenafil (Viagra) costing as little as $3 per dose, compared to $70 at traditional pharmacies. Additionally, Hims’ in-house pharmacies reduce reliance on third-party suppliers, cutting costs and ensuring quality control.

Unlike competitors building physical infrastructure or developing proprietary drugs, Hims & Hers avoids massive capital expenditures. Its asset-light model allows rapid scaling into new categories, such as weight loss (launched in 2024 with compounded GLP-1 medications) and women’s health, which now accounts for 40% of revenue. This flexibility positions Hims to capture a growing share of the $1 trillion U.S. healthcare market.

The High Costs of Traditional Healthcare: Competitors’ Challenges

Traditional healthcare providers and pharmacies face daunting obstacles in competing with Hims & Hers. CVS and Walgreens operate thousands of physical stores, with high overhead costs and complex supply chains. Their retail model struggles to match Hims’ pricing or convenience, especially for stigmatized treatments where privacy is paramount. For example, Hims delivers erectile dysfunction medications discreetly to customers’ homes, bypassing the awkwardness of in-person pharmacy visits.

Other telehealth platforms, like Ro or Teladoc, face profitability hurdles. Ro’s focus on niche treatments limits its scalability, while Teladoc’s enterprise-heavy model lacks the consumer intimacy Hims & Hers cultivates. Building a comparable platform requires years of investment in technology, provider networks, and brand trust—barriers that Hims has already overcome. Goldman Sachs notes that Hims’ “first-mover advantage in high-margin categories” gives it a decade-long lead over new entrants.

Most Likely Outcome: Partnerships and Market Leadership

Hims & Hers Health, Inc. recently announced a long-term collaboration with Novo Nordisk to enhance access to obesity care in the U.S. This partnership enables Hims & Hers to offer Novo Nordisk’s FDA-approved weight loss drug, Wegovy, through its telehealth platform, starting at $599 per month. The bundled offer includes 24/7 care, clinical support, and nutrition guidance, aiming to make obesity treatment more affordable and accessible for cash-paying patients. The collaboration also outlines a roadmap to combine Novo Nordisk’s innovative treatments with Hims & Hers’ scalable care model, with the goal of improving long-term health outcomes for millions of Americans. In my opinion, this is an example of the most likely path for Hims & Hers to deepen their advantage through partnerships with healthcare providers, insurers, and pharmaceutical companies while expanding its platform.

Competitors like CVS or Teladoc may attempt to acquire or replicate Hims’ model, but acquisition seems unlikely given Hims’ $5 billion market cap and strong growth trajectory. Instead, Hims is poised to lead as the “Uber of healthcare,” aggregating demand and supply in a fragmented industry. Its recent entry into weight loss, lower costs than branded Ozempic, demonstrates its ability to disrupt high-cost categories.

Flipping the Script: The Risks

Hims & Hers faces several risks that could challenge its dominance. Regulatory changes, such as stricter telehealth or compounding pharmacy rules, could disrupt operations, particularly with recent scrutiny on compounded medications like GLP-1 agonists following the FDA’s 2025 ruling on semaglutide. Legal risks also loom, including potential lawsuits or fines related to prescribing practices, data privacy breaches under laws like HIPAA, or intellectual property disputes with competitors over proprietary telehealth technologies. I should also mention here, the legal risks were minimized dramatically with the recent partnership with Novo Nordisk.

Competition from retail giants like Amazon, which is expanding into healthcare, poses a threat if they replicate Hims’ DTC model. Customer retention could falter if competitors offer lower prices or superior services. Additionally, Hims’ reliance on stock-based compensation (SBC) dilutes shareholder value, though management has committed to share buybacks to offset this, targeting a 1% annual share count reduction.

Despite these risks, Hims’ diversified revenue streams, 80% retention rate, and low-cost model provide resilience. Its focus on underserved categories ensures a loyal customer base, mitigating competitive and legal pressures.

Valuation

Hims’ valuation is attractive, with a 2025 projected EBITDA of $300 million and revenue of $2.35 billion, reflecting an expected 60% growth rate. As of May 5, 2025, Hims & Hers Health, Inc. (HIMS) has a market capitalization of $9 billion, resulting in a valuation of approximately 20x its expected 2025 adjusted EBITDA, below its historical average. Hims appears undervalued given its expected 30% EBITDA CAGR through 2030.

• Bull Case: Assumes 16% average annual revenue growth, EBITDA margins expanding from 13.5% in 2025 to 25.5% by 2035, and a 1% annual share count increase through 2030. Trading at a 22x multiple, Hims could deliver a 10-year 20%+ annual return, with a 2030 $140 price target with an assumed market multiple of 30. This scenario reflects continued category expansion and regulatory stability.

• Bear Case: Projects an average annual revenue growth of 8%, with EBITDA margins reaching only 18.5% by 2035, alongside a 2% annual increase in share count through 2030. Under these conservative assumptions, Hims is expected to yield a 10-year annual return of 7%, with a 2030 price target of $57.63, assuming a market multiple of 25. This scenario accounts for challenges such as market share erosion, execution missteps, potential legal issues, unsuccessful market expansion, and underperforming product categories. Although unlikely, in my opinion, this outcome is still possible.

  

  A reverse DCF suggests Hims needs only a 10% annual EBITDA growth rate to deliver a 10% return, highlighting its asymmetrical risk-reward profile.

  

  Hims & Hers recently released 2030 guidance, projecting a minimum of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. Management’s confident tone suggests they not only anticipate but are determined to exceed these bold targets. This aligns with their strong history of consistently surpassing prior guidance, having beaten earnings expectations in all 17 quarters since going public.

  

  The Verdict & Key Takeaways

  Hims & Hers remains a compelling investment in the telehealth revolution, providing exposure to a $1 trillion healthcare market at a reasonable valuation. In Q1 2025, the company reported 38% subscriber growth, reaching 2.4 million subscribers, and an impressive 111% revenue growth, hitting $586 million, up from $278.2 million in Q1 2024. This growth underscores the strength of Hims’ asset-light, scalable platform, which continues to disrupt traditional healthcare. Strategic partnerships, such as the recent collaboration with Novo Nordisk to offer Wegovy, along with AI-driven personalization and in-house pharmacies, solidify a competitive moat that rivals struggle to overcome. With Hims’ expected 2025 adjusted EBITDA raised to $295–$335 million (midpoint $315 million) and a current market cap of $9 billion as of May 5, 2025, Hims is trading at approximately 21.4x its 2026 adjusted EBITDA.

  In my opinion, Hims & Hers is another “heads I win, tails I don’t lose much” opportunity, echoing investor Mohnish Pabrai’s philosophy. Its conservative bull case offers strong returns, while the bear case matches or slightly underperforms overall market performance. After weighing all factors discussed, and assuming other conditions remain unchanged, my primary recommendation is to rate Hims and Hers as a “buy”, particularly for investors bullish on telehealth’s transformative potential. Hims is not just a healthcare company, it’s the backbone of a new, consumer-driven wellness ecosystem.

  Disclaimer: This information is for general informational purposes only and does not constitute financial advice. Consult a qualified financial advisor before making investment decisions.

Let's discuss a highly promising emerging technology that appears increasingly likely to become a reality, driverless cars! Autonomous vehicles (AV), also known as a self-driving car or robotaxi, is a vehicle capable of navigating and operating without human intervention. AVs use a combination of advanced technologies, including artificial intelligence (AI), machine learning, sensors (like LiDAR, radar, and cameras), and GPS to perceive their environment, make real-time decisions, and execute driving tasks such as steering, accelerating, and braking. They aim to enhance road safety, reduce traffic congestion, and provide accessible transportation. AVs are being developed for various uses, including ride-hailing (e.g., Waymo, Uber), personal transport (e.g., Tesla’s Cybercab), and logistics, with the global market expected to grow significantly in the coming decades In a future where autonomous vehicles achieve such high efficiency, they could transform not only safety and convenience but also economic viability. As history as our guide on other mainstream technologies, most likely AVs will become so cost effective, they could potentially eliminate the need to own a vehicle.

The race to deploy autonomous vehicles is heating up, promising to reshape transportation as we know it. From Tesla’s ambitious robotaxi plans to Waymo’s steady expansion, the AV landscape is buzzing with innovation. However, while companies like Tesla and Waymo focus on building cutting-edge self-driving technology, one company is uniquely positioned to capitalize on this revolution: Uber Technologies Inc. (NYSE: UBER). By leveraging its unmatched ability to aggregate supply and demand, implement dynamic pricing, and avoid the astronomical costs of building proprietary AV fleets or demand aggregators, Uber is positioned to potentially dominate the robotaxi market. This perspective is reinforced by Pershing Square Capital Management’s recent investment in Uber, as outlined in their 2025 Annual Investor Presentation, which highlights Uber’s strong marketplace dynamics and growth potential.

Uber’s Business

Uber is a global ride-hailing and technology company that connects riders with drivers through its mobile app, offering convenient, on-demand transportation in hundreds of cities worldwide. Founded in 2009, Uber has expanded into food delivery (Uber Eats), freight, and autonomous vehicle research, revolutionizing urban mobility. Known for its user-friendly platform and flexible driver model, it faces ongoing debates over regulation, labor rights, and safety.

Uber generates revenue primarily through the following streams:

• Ride-Hailing Fees: Uber takes a commission (typically 20-30%) from each ride fare paid by passengers to drivers, with the rest going to the driver.

• Uber Eats: Uber earns a commission on orders placed through its food delivery service, charging restaurants a percentage of each order and customers a delivery fee.

• Service Fees: Additional fees, like booking or surge pricing fees, are charged to riders during high-demand periods or for specific services.

• Freight and Logistics: Uber Freight connects shippers with carriers, earning a fee for facilitating these logistics services.

• Advertising: Uber offers in-app advertising and sponsored promotions, generating revenue from businesses targeting its user base.

• Subscriptions: Uber One, a paid membership program, provides benefits like discounted rides and deliveries for a monthly or annual fee.

These diversified streams, with ride-hailing and food delivery as core contributors, drive Uber’s financial model.

Uber's robust two-sided network effect, where increased rider demand draws more drivers, fosters a self-reinforcing cycle that has propelled substantial growth, rapidly scaling its user base, enhancing free cash flow, and significantly improving profit margins.

The Autonomous Vehicle Landscape: A High-Stakes Race

Autonomous vehicles are no longer a sci-fi fantasy. Waymo, a subsidiary of Alphabet Inc., has already completed over 5 million autonomous trips, with 4 million paid rides in 2024 alone, operating in cities like San Francisco, Los Angeles, and Phoenix. Meanwhile, Tesla is gearing up to launch its robotaxi service in Austin, Texas, in June 2025, using its Full Self-Driving (FSD) software and a fleet of Tesla-owned vehicles. Other players, like Amazon’s Zoox and Mobileye, are also entering the fray, with launches planned in cities like Las Vegas and Atlanta.

The potential market is massive. The U.S. autonomous car market is projected to reach $17.82 billion in 2025, growing at a 20.5% CAGR to $45.28 billion by 2030. Yet, the path to profitability is fraught with challenges. Building and scaling AV fleets requires billions in capital for R&D, manufacturing, and infrastructure. Waymo’s vehicles, for instance, rely on expensive LiDAR sensors and remote human operators, making scalability costly. Tesla’s camera-based approach aims to reduce costs but faces regulatory hurdles and safety concerns, with analysts noting that Tesla “potentially underappreciates the obstacles to scaling a robotaxi fleet.”

Uber’s Strategic Advantage: The Power of Demand Aggregation and Logistical Expertise

*Uber enters chat*, the ride-sharing giant that doesn’t build AVs but controls something far more valuable: the largest demand aggregator in mobility. Uber’s platform connects millions of riders with drivers (and soon, AVs) across the U.S. and nine other countries, creating a powerful network effect. In 2024, Uber’s monthly active users grew 14%, and trips increased 19%, generating $44 billion in revenue. This scale allows Uber to match supply with demand efficiently, ensuring high vehicle utilization and rider satisfaction. Uber’s dynamic pricing and data-driven ride optimization are powered by its vast, real-time dataset, which tracks millions of trips, rider preferences, and market conditions daily. By leveraging AI and machine learning, Uber analyzes this data to match riders with vehicles human driven or autonomously based on demand, location, and time, ensuring high utilization and minimal wait times. Its dynamic pricing algorithm adjusts fares instantly to balance supply and demand, boosting profitability during peak hours and affordability during lulls. This data advantage, refined over a decade, allows Uber to optimize rides efficiently, giving it a competitive edge over AV providers like Tesla or Waymo, who lack comparable demand aggregation and pricing infrastructure. Building a fleet of autonomous vehicles (AVs) and optimizing their distribution across cities is a logistical nightmare. If Tesla or Waymo pursue this independently, they risk inefficiencies: excess vehicles idling during low-demand periods, wasting resources, and insufficient vehicles during peak times, frustrating riders. Without a robust demand aggregation platform, achieving the right balance is nearly impossible, you can’t maintain an efficient fleet and meet fluctuating demand simultaneously

The High Costs of Going Solo: Tesla and Waymo’s Challenges

For Tesla and Waymo, the costs of building and scaling AV fleets are staggering. Waymo’s vehicles, equipped with high-end sensors, can cost around $150,000 each (although Waymo recently claimed they “significantly” reduced costs of their 2026 model car), with Bernstein analysts estimating that replacing current U.S. ride-hailing networks would require 350,000–400,000 vehicles, costing over $50 billion. Tesla’s Cybercab, unveiled in October 2024, aims to be cheaper at under $30,000, but production is delayed until 2026, and its camera-only system has yet to prove itself at scale. Regulatory hurdles also loom, with Tesla’s Elon Musk banking on federal approval to bypass state-level restrictions. Additionally, building a demand aggregator from scratch is a Herculean task. Uber’s network took over a decade to scale, and competitors like Tesla would need to replicate this while managing fleet operations, regulatory compliance, and safety concerns. Jefferies analysts argue that Tesla could “struggle to scale fleet operations without offering access to demand via Uber/Lyft.” Waymo, despite its lead, faces similar challenges, with some arguing that its reliance on Alphabet’s resources limits its ability to compete as a standalone aggregator

Most Likely Outcome to This Conundrum?

In my opinion, the most likely outcome for autonomous vehicle makers is to partner with Uber, capitalizing on its vast ride-hailing network and demand aggregation expertise. Uber’s partnerships, like its expanded deal with Waymo to offer robotaxi rides in Austin and Atlanta exclusively through the Uber app starting in 2025, demonstrate its role as a critical distribution platform. Even Tesla, despite its solo ambitions with the Cybercab, may eventually collaborate with Uber to scale efficiently, as Uber CEO Dara Khosrowshahi has expressed openness to such a partnership. AV makers face high costs and challenges in building their own demand aggregators, making Uber’s scaled platform, dynamic pricing, and 14 existing AV partnerships including Waymo, Cruise, and WeRide, a compelling solution to maximize fleet utilization and reach riders quickly

Flipping the Script: The Risks to This Perspective

Uber’s strong position in the autonomous vehicle (AV) revolution is not without risks. Competitors like Tesla or Waymo could develop their own ride-hailing platforms, potentially capturing market share if they effectively replicate Uber’s demand aggregation model. Regulatory hurdles, such as stringent safety requirements or localized AV bans, may hinder Uber’s operations or partnerships. Dependence on AV providers for vehicle supply creates vulnerabilities, as partners could favor their own apps or encounter production setbacks. Additionally, lower AV ride costs or rider pushback against dynamic pricing might squeeze margins. Though Uber’s established platform and partnerships provide a buffer, staying ahead in this dynamic market demands strategic adaptability. One potential risk to Uber's business, in my view, is its reliance on stock-based compensation (SBC). SBC is a central part of Uber’s employee compensation strategy, implemented through plans like the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan. It includes stock options, restricted stock units (RSUs), and other equity awards for employees, officers, directors, and consultants. While SBC helps attract and retain top talent and may deliver unrecognized long-term value, it represents a significant cost to shareholders through dilution. Recently, Uber’s management has outlined plans to repurchase shares in the coming years to mitigate this dilution and potentially achieve a net reduction in outstanding shares.

The Verdict & Key Actionable Insight

Uber is my third-largest holding, making up 11% of my portfolio. Therefore, it is my opinion that investors should consider Uber as a compelling bet in the autonomous vehicle (AV) revolution due to its unique position as the leading demand aggregator in mobility, sidestepping the massive costs of building AV fleets. With 14% user growth and 19% trip increase in 2024, generating $44 billion in revenue, Uber’s scaled platform connects millions of riders to both human-driven and autonomous vehicles, as seen in partnerships with Waymo, Aurora, and 12 other AV providers. Its dynamic pricing optimizes profitability and rider access, a capability competitors like Tesla or Waymo can’t easily replicate. Pershing Square’s $2.3 billion stake and 2025 investor letter highlight Uber’s “strong growth trajectory” and undervalued 30x forward P/E ratio, projecting potential to double in value over 3-4 years. Despite risks like competition and regulation, Uber’s asset-light model and network effects make it a high-reward play on the $1 trillion AV market, offering growth at a reasonable valuation compared to Tesla’s 124x P/E. Rolling the dice on Uber means betting on the backbone of the robotaxi ecosystem.

Valuation

Setting aside the promising tailwinds from autonomous vehicles (AV), Uber’s valuation stands out as the most compelling reason to invest today, in my view. When evaluating a business, I focus on key metrics: revenue growth rate, margins, valuation multiples, and share dilution. My approach includes a reverse discounted cash flow (DCF) to target a 10% return, benchmarking the company against peers, and comparing its current valuation multiples to its historical averages. I always create at least two projection scenarios—a bull case and a bear case—when assessing a company’s valuation. Since valuation involves forecasting an inherently unpredictable future, it’s prudent to consider a range of outcomes rather than aiming for a single, precise prediction. As Warren Buffett noted in Berkshire Hathaway’s 2000 shareholder letter, “We would rather be approximately right than precisely wrong, because in investing, as in life, you don’t need to know all the details to make a good decision.”

The Bull Case Valuation

As shown below my Bull case scenario, Uber reflects a robust growth trajectory with a projected 2025 EBITDA of $8.5 billion and a revenue growth rate of 12%. As of 4/25/25, the company’s enterprise value stands at $179.29 billion, with a market cap of $164.42 billion after adjusting for net debt. Trading at a 2025 EBITDA multiple of 20x, lower than its historical average of 24x. Uber appears undervalued relative to its projected 16% EBITDA CAGR through 2029. With $50.375 billion in projected 2025 revenue and 2,124 million diluted shares outstanding, Uber’s price target of $96.35 suggests a 23% upside, making it an attractive investment. Pershing Square’s 2025 investor letter supports this, projecting Uber could double in value over 3-4 years, driven by its dominant position in the $1 trillion autonomous vehicle market. In my scenario, I assume that over the next 10 years, Uber will achieve a revenue growth rate of 10.8%, expand its EBITDA margin from 17% in 2025 to 24% by 2035, reduce its share count by 2% annually (CEO Dara Khosrowshahi has expressed this as an important part of his capital allocation strategy), and trade at a market multiple of 24, its long-term average. If these projections hold, investors could expect a 19.5% annual return over the decade. This valuation reflects continued market domination, innovation to stay ahead of competition, a wide adoption of AV makers using Uber’s demand aggregation network, and no major macro-economic turmoil.

To put it differently, a Reverse DCF analysis shows that Uber only requires a 5.3% annual EBITDA growth rate over the next decade to deliver a 10% return for investors.

The Bear Case

In my bear case scenario, things do not turn out as expected (which could very well happen 😊). With a starting 2025 projected EBITDA of $7.2b, I assume that over the next 10 years, Uber will achieve a revenue growth rate of 8.8%, expand its EBITDA margin from 16% in 2025 to only 19% by 2035, reduce its share count by .4% annually, and trade at a market multiple of 20, lower than the long-term average. If these projections hold, investors could expect a 9.56% annual return over the decade, which is still market matching. This valuation reflects loss of market share, lack of innovation to stay ahead of competition, a low adoption of AV makers using Uber’s demand aggregation network (e.g. Tesla and/or Waymo building its own network), and a mild macro-economic decline.

In this scenario, the Reverse DCF analysis shows that Uber requires a 10.8% annual EBITDA growth rate over the next decade to deliver a 10% return for investors.

Key Takeaways and Next Steps

We’ve covered a wealth of insights in this edition of the Holler to Tide Investment Guide. Here’s the key takeaway: In the bull case, some might view my projections as cautious, which reflects my strategy of using conservative estimates across all scenarios to guard against major missteps. The bull case is realistically achievable, offering strong returns, and if my cautious estimates prove understated, any additional gains are a pleasant bonus. In the bear case—though I consider it less probable than the bull scenario—returns are still likely to match or even surpass the S&P 500 over the next decade. This creates an asymmetrical opportunity, where the upside significantly outweighs the downside risk. Echoing one of my favorite investors, Mohnish Pabrai, this is a “heads I win, tails I don’t lose much” scenario. After weighing all factors discussed, and assuming other conditions remain unchanged, my primary recommendation is to rate Uber as a “buy.” This outcome feels nearly assured, particularly for those who see the AV revolution as a transformative force in how we travel from point A to point B.

Disclaimer:

This information is provided for general informational purposes only and does not constitute financial advice. You should consult with a qualified financial advisor or professional before making any investment or financial decisions.

Why Competitive Advantage Matters

In the hills of Eastern Kentucky, where I grew up, folks often talk about the value of hard work. While I believe hard work is a major variable in the success equation, it takes more for success of a business to stand the test of time. Think of the local hardware store that’s been around for generations or the family corner store that weathers tough times. What keeps these businesses going? It’s not just hard work; it’s something that sets them apart from the competition, something that makes customers keep coming back. In investing, we call this a competitive advantage. This is often referred to as a “moat”, coined by the one and only Warren Buffet. Imagine the business’s competitive advantage like a moat around a castle that protects it from rivals and invaders.

According to the “Perfect Competition” theory in economics academia, in a perfectly competitive market, businesses can earn unusually high profits in the short run due to factors like innovation, cost advantages, or market inefficiencies. However, these high profits attract new entrants or encourage existing competitors to copy the successful organization’s strategies. This increase in competition drives down prices, reduces margins, and erodes economic profits until firms earn only normal profits (just enough to cover costs, including opportunity costs).

This process is driven by:

1. Entry of New Firms: High profits signal an opportunity, prompting new businesses to enter the market.

2. Imitation and Innovation: Competitors copy successful strategies or innovate to capture market share.

3. Price Competition: As supply increases, prices fall, eroding profit margins.

4. Cost Pressures: New entrants or competitors may operate at lower costs, forcing existing businesses to cut prices or lose market share.

A competitive advantage is what allows a company to earn higher returns on its invested capital than its peers, year after year. It’s the reason a business can raise prices without losing customers, fend off competitors, or thrive even in tough economic conditions. As an investor, I want to own companies with wide, durable moats because they’re more likely to grow their intrinsic value over the long term, which is the foundation of my quality investing approach.

Within Economics there are seven generally accepted types of “moats” – I’ve listed them here:

A Real-World Example: ASML Holding N.V. (ASML)

We will use one of my favorite businesses as an example, ASML Holding N.V. (ASML), a semiconductor giant not in my portfolio (not yet, but high on my watch list). In Eastern Kentucky, the go to hardware store thrived by being essential. ASML does that globally, with moats protecting its profits.

ASML is a Dutch company and the global leader in photolithography systems, essential for manufacturing integrated circuits (microchips). Founded in 1984, ASML’s machines, particularly its Extreme Ultraviolet (EUV) lithography systems, enable chipmakers like TSMC, Intel, and Samsung to produce advanced chips (e.g., 3nm nodes) for AI, smartphones, and more. With a near-monopoly on EUV technology, protected by 17,000+ patents and export controls, ASML generates €28.3 billion in 2024 revenue, ~51% gross margins, and ~22% ROIC. Its moats - intellectual property, regulatory exclusivity, and switching costs - drive strong cash flows (€9 billion) and a €39 billion order backlog, fueled by AI-chip demand. Some refer to ASML as “the most important company in the world” because without them, the world as we know it would cease to exist. The cell phone or computer you’re using to read this? Yeah, they wouldn’t exist without ASML.

This is one single machine:

Could a competitor reverse engineer this? ASML can make patterns 30,000 times thinner than human hair. It is possible, perhaps, but certainly not likely in my opinion.

If interested in learning more about ASML check out this CNBC exclusive. They do a great job covering ASML in detail -

Anyways, here is how it aligns with my quality investing criteria, high ROIC and strong cash flows:

The Numbers

ASML’s 2024 financials, from its 10-K and earnings, outshine peers like Applied Materials:

· ROIC: ~22% vs. industry ~10-15%.

· Gross Margin: ~51.3%, driven by EUV systems, vs. peers’ ~40%.

· EBIT Margin: ~26%, despite €4.4 billion R&D (wow).

· Operating Cash Flow Margin: 32% (€9 billion), funding dividends and buybacks.

These metrics show a robust moat, supporting high margins and capital efficiency.

Isn’t this beautiful?

The Moat

ASML’s edge comes from three moats:

· Intellectual Property: 17,000+ patents secure its EUV lithography monopoly, untouchable by Nikon or Canon (or anyone else).

· Regulatory and Exclusive Rights: Export controls limit EUV sales (e.g., to China), locking in clients like TSMC.

· Switching Costs: Integrated systems tie chipmakers like Intel to ASML, making switching VERY expensive (and unlikely).

Why It’s Durable

ASML’s moat grows with AI-chip demand, with a €39 billion backlog and €30-35 billion 2025 sales forecast. Risks include geopolitics and supply chain hiccups, but patents and lock-in ensure resilience.

A side note on ASML

Another reason ASML is referred to as “the most important company in the world” it because it’s critical for United States tech and future dominance because its Extreme Ultraviolet (EUV) lithography machines are the only technology capable of producing advanced microchips that power U.S. innovations. Companies like Intel, NVIDIA, and Apple rely on ASML’s EUV systems, used by chipmakers like TSMC, to manufacture chips for AI, 5G, autonomous vehicles, and military tech. Without ASML, U.S. firms couldn’t access these chips, stalling progress in strategic sectors. Additionally, U.S. led export controls on ASML’s EUV sales (e.g., to China) ensure American allies maintain a technological edge, securing dominance in AI and defense. Biden’s famed “Chips Act” was born from this idea. ASML’s ~90% lithography market share and 17,000+ patents make it crucial.

How You Can Spot a Competitive Advantage

You don’t need an MBA or a powerful software to evaluate competitive advantage like I do. Here’s a simple three-step process to get started:

· Pull the Numbers: Use free resources like Yahoo Finance, Google Finance, or a company’s investor relations website to find ROIC, gross margin, EBIT margin, and operating cash flow margin. Compare these to competitors in the same industry over at least five years to spot consistency or improvement.

· Ask “Why?”: Dig into the company’s 10-K (available on the SEC’s website or the company’s investor page) to understand what drives those numbers. Look for mentions of brand loyalty, patents, network effects, or scale. Management’s discussion and analysis section is a goldmine for this.

· Think Long-Term: Ask yourself, “Can this advantage last 10 years?” Consider industry trends, competitor moves, and potential disruptions. If the moat feels shaky, it might not be worth betting on.

A Word of Caution

Identifying a competitive advantage is only half the battle. Even the widest moat doesn’t justify overpaying for a stock. That’s why I pair this analysis with my other criteria, like valuation with a margin of safety, to ensure I’m buying quality at a fair price. I’ve learned the hard way that a great business at a bad price is a lousy investment - more on that in a future newsletter!

What’s Next?

I hope this deep dive into competitive advantage gives you a clearer sense of how to spot businesses built to last. In the coming weeks, I’ll unpack another piece of my investment framework - maybe a look at valuation or a deep dive into another portfolio holding. I’ll also share my thoughts on current market events and how they shape my strategy

If you found this helpful, please subscribe to the Holler to Tide Investment Guide on Substack and share it with friends who might enjoy it. Until next time, happy investing!

Disclaimer: This information is provided for general informational purposes only and does not constitute financial advice. You should consult with a qualified financial advisor or professional before making any investment or financial decisions.

Subscribe now

Share

Leave a comment

A Little About Myself

Hi, I’m Shane Williamson. I hold an MBA from the University of Pikeville and have spent the past 12+ years working in non-profit finance. Outside of my career, I run a small business and actively invest in both real estate and public equities. I’m originally from the hills of Eastern Kentucky and currently live in central Kentucky with my wife and our two daughters. Soon, though, we’ll be trading the bluegrass for the coastal charm of Summerville, South Carolina—a move that my family and I are incredibly excited about.

That journey, from Appalachian hollers to the tides of the Lowcountry, is what inspired the name of this newsletter: “Holler to Tide Investment Guide.” It’s a reflection of where I’ve been, where we’re headed, and the financial lessons picked up along the way.

Why I Decided to Start This Newsletter

There’s something endlessly fascinating about watching people buy and sell pieces of businesses in real time driven by everything from macroeconomic shifts and company performance to pure emotion, both rational and not-so-rational. That dynamic, unpredictable nature of the markets hooked me.

Like many others, my deep dive into investing began during the COVID-19 pandemic. Working from home gave me more free time than I was used to, and I chose to use that time to explore something I’d always been curious about. Since then, I’ve read over 100 books on finance and investing, studied the philosophies of legendary investors, and logged hundreds of hours listening to podcasts and market commentary.

My journey brings me here, starting this newsletter to share what I’ve learned (and what I’m still learning). Whether you're just starting out or you've been at it for years, I hope the ideas, insights, and experiences I share here can add something valuable to your own investing path.

Investment Philosophy

To sum up my philosophy in one sentence – “To own resilient high-quality businesses with sustainable competitive advantages for the long haul”.

I believe that a company’s intrinsic value is driven purely by its fundamental performance. Unfortunately, I’ve learned many investing lessons the hard way—making nearly every mistake possible. But those hard lessons became my best teachers. They’ve fueled a passion for research and led me to study nearly every great investor, both living and deceased.

Investment Criteria

Over the years, I’ve developed an approach best described as quality investing. While I draw from multiple strategies and remain flexible in how I find opportunities, I use six key criteria as non-negotiable guardrails. These principles create a highly selective investable universe:

1. Competitive Advantage – Demonstrated by consistent or improving Return on Invested Capital (ROIC), high gross margin, high EBIT margin, or high operating cash flow margin compared to peers, and sustained operating leverage over time.

2. Shareholder Value Creation – Evidenced by consistent growth in owner’s earnings and free cash flow over at least five years.

3. Secular Growth Potential – Either through industry tailwinds or strong forecasted growth.

4. Business Structure – Preference for owner-operators, cannibal companies (significant stock buybacks), or monopoly/oligopoly structures—supported by high insider ownership, aggressive stock repurchases, or dominant market share.

5. Quality Management – Proven capital allocation track record, prudent acquisitions, minimal stock-based compensation, and little to no dilution.

6. Valuation with a Margin of Safety – A fair or undervalued price based on conservative assumptions and discount to intrinsic value.

I analyze each of these components primarily by studying a company’s historical business performance diving deep into financial statements and the annual 10-K report. This part is relatively straightforward, as much of the information I need is publicly available and supported by measurable indicators.

The real challenge lies in taking all that data and translating it into a forward-looking view by projecting future performance to estimate what the business is truly worth. That’s where Fundamental Valuation Analysis comes in, and where both the art and science of investing meet.

Fundamental Valuation Analysis

To me, fundamental analysis is the most important aspect of valuing a business. I place the greatest weight on free cash flow because it offers the clearest view of a company’s economic reality. Unlike net income, which can be distorted by GAAP accounting, free cash flow shows how much actual money enters and leaves the business.

I rely on three key valuation tools:

1. Discounted Cash Flow (DCF) analysis

2. Reverse DCF analysis

3. Peer/multiple valuation, based on historical company performance and that of competitors.

I take a conservative approach to all projections, with a strong emphasis on Discounted Cash Flow (DCF) analysis. At its core, a business is worth the sum of all its future cash flows, discounted back to their present value.

One method I particularly rely on is the reverse DCF—an approach inspired by Charlie Munger’s famous advice: “Invert, always invert.” Instead of asking what a company is worth, I ask: What assumptions are already baked into the current stock price? And more importantly—are those expectations reasonable?

Since the future is always uncertain, I don’t aim to predict exact outcomes. Rather, I focus on a range of potential scenarios. As John Maynard Keynes wisely put it, “It is better to be roughly right than precisely wrong.”

For our visual learners, here is an example of my base case valuation of GOOGL combining all the approaches into a single framework:

*My valuation of GOOGL is driven by my belief in sustained double-digit revenue growth, fueled by the accelerating tailwind of artificial intelligence. I believe this will further widen Alphabet’s competitive advantage, support ongoing margin expansion, and enable continued stock repurchases over time.

Portfolio Concentration

Another key element of my strategy is maintaining a concentrated portfolio, typically consisting of just 8 to 12 businesses. This approach is grounded in the belief that great investments are rare, and when you find them, they deserve meaningful allocation.

I’d rather know a few companies exceptionally well than have shallow knowledge across dozens. By focusing on a smaller number of high-conviction positions, I can more effectively monitor their performance, understand the risks, and stay aligned with long-term value creation.

This strategy is not without volatility, but I view that as the price of admission for outsized returns. As Charlie Munger once said, “The idea of excessive diversification is madness… it’s a confession that you don’t really understand the businesses you’ve bought.” I aim to only own what I deeply understand and believe in.

Here is a snapshot of my current portfolio with corresponding statistics:

Upcoming Newsletter Content

In future newsletters, I plan to further explain some of concepts mentioned in my framework, share my thoughts on current economic events, share my current portfolio, and share deep dives on my current holdings as well as companies I am interested in owning.

If you enjoyed this content, please subscribe to my Substack and share with your friends.

Until next time!

Disclaimer: This information is provided for general informational purposes only and does not constitute financial advice. You should consult with a qualified financial advisor or professional before making any investment or financial decisions.

Subscribe now

Share

Leave a comment